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ABSTRACT 
 
Heart transplantation is the final treatment option for end-stage heart failure. In the United States, 
70 pediatric patients die annually on the waitlist while 800 well-functioning organs get discarded. 
Concern for potential size-mismatch is one source of allograft waste and high waitlist mortality. 
Clinicians use the donor-recipient body weight (DRBW) ratio, a standalone metric, to evaluate 
allograft size-match. However, this body weight metric is far removed from cardiac anatomy and 
neglects an individual’s anatomical variations. This thesis body of work developed a novel virtual 
heart transplant fit assessment tool and investigated the tool’s clinical utility to help clinicians safely 
expand patient donor pools. 
 The tool allowed surgeons to take an allograft reconstruction and fuse it to a patient’s CT 
or MR medical image for virtual fit assessment. The allograft is either a reconstruction of the donor’s 
actual heart (from CT or MR images) or an analogue from a health heart library. The analogue 
allograft geometry is identified from gross donor parameters using a regression model build herein. 
The need for the regression model is donor images may not exist or they may not become available 
within the time-window clinicians have to make a provisional acceptance of an offer. 
 The tool’s assessment suggested > 20% of upper DRBW listings could have been 
increased at Phoenix Children’s Hospital (PCH). Upper DRBW listings in the UNOS national 
database was statistically smaller than at PCH (p-values: < 0.001). Delayed sternal closure and 
surgeon perceived complication variables had an association (p-value: 0.000016) with 9 of the 11 
cases that surgeons had perceived fit-related complications had delayed closures 
(p-value: 0.034809). 
 A tool to assess allograft size-match has been developed. Findings warrant future 
preclinical and clinical prospective studies to further assess the tool’s clinical utility. 
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CHAPTER 1 
 
INTRODUCTION 
 
The heart transplant (HTx) is the final treatment option for end-stage congestive heart failure. A 
clinically-concerning problem for patients needing a HTx in the United States of America (USA) is 
the current donor-shortage. Recent publications found that approximately 1 in 10 adults die while 
waiting for a HTx [1–4]. The waitlist mortality rate is higher in pediatrics due to the limited number 
of appropriately sized organs, i.e., allografts. Mechanical treatment options for heart failure are 
traditionally stop-gap measures for either (1) bridge-to-recovery, (2) bridge-to-destination, or (3) 
bridge-to-transplant. Furthermore, mechanical treatment options may not be compatible with 
pediatric patients and even smaller adult sizes due to overall implantable device volume. The 
unfortunate reality in this donor-shortage is 70 pediatric patients die annually while 800 healthy, 
well-functioning cardiac allografts get discarded [5,6]. The donor-recipient body weight (DRBW) 
ratio is the clinical standard to evaluate allograft size-match but neglects anatomical aberrations 
and patient-to-patient differences that are within the norm. Concerns of potential size-mismatch is 
one source of allograft waste and waitlist mortality. 
 This dissertation presents the development and validation of a virtual HTx fit assessment 
tool to assess allograft fits. This tool relies on a library of healthy hearts and a regression model to 
predict an allograft’s total cardiac volume (TCV). Specifically, the development and validation of 
the library and regression model will be presented. The clinical utility of the tool will be investigated 
in a series of initial, retrospective, clinical studies. 
 The hypothesis of this research is volumetric medical images, i.e., computed tomography 
(CT) or magnetic resonance (MR) images, can be leveraged to provide additional clinical 
information related to HTx allograft size-matching of an offered donor. A novel virtual HTx fit 
assessment tool will be developed and validated to help leverage medical images for fit 
assessment. It is further hypothesized an early investigation into the tool’s clinical utility will produce 
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trends that suggest the tool can help safely expand patients’ donor pools and therefore improve 
allograft size-matching. 
 The author’s, i.e., Plasencia’s, pivotal contributions to the fields of biomedical engineering 
and medicine will be: 
 
1. a quantitative understanding of the biological signal relationships between the healthy 
TCV and various gross subject parameters within the pediatric and young adult population,  
 
2. the development and validation of a regression model that predicts normal, healthy heart 
TCVs while accounting for pediatric and young adult developmental growth and body type, 
 
3. the demonstration and the initial validation into the tool’s relevance in allograft size-
matching, and  
 
4. an initial investigation into whether clinicians can perceive allograft fit-related 
complications when fusing reconstructions onto a medical image. 
 
The author hopes this work further contributes to medicine by initiating other groups to investigate 
the strengths and short comings of the novel tool presented herein. The author hopes these groups 
will develop and validate their own improved virtual fit assessment methods for the clinical 
environment in which HTx and other areas of solid-organ transplant are considered. 
Chapters 2 and 3 are background and significance chapters. Chapter 2 introduces 
fundamental biological scaling relationships from the field of allometry that the allograft TCV 
prediction modeling process exploited. Chapter 3 introduces an overview of HTx and waitlist 
statistics and procedures. Furthermore, chapter 3 discusses current allograft size-matching 
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methods and its limitation to aggressively expand patient donor pools so clinicians can procure an 
allograft in-time for their patient.  
Chapters 4, and 5 cover tool development and prediction model validation. Chapter 4 
develops a library of normal, healthy hearts with patient parameters and TCV reconstructions 
included. Chapter 5 uses (1) the library, (2) linear regression techniques, and (3) concepts from the 
field of allometry to develop and validate an allograft TCV prediction model. The validation 
procedure in chapter 5 looks at the testing error of the developed prediction model but not the 
clinical utility. 
Chapter 6 covers early retrospective study validation of the tool’s clinical utility in 2 main 
outcome analysis studies. The first study investigates if the tool can alter surgeon perception to 
accept allografts that are traditionally considered oversized and therefore aid clinicians to expand 
donor pools. The second study investigates if the tool allows clinicians to perceive fits that are safe 
and fits that are not safe. The chapter concludes with the presentation of an additional, unique case 
study in which donor images were available for virtual assessment. 
Finally, chapter 7 covers the capital successes, limitations, future works, and conclusions 
of this novel tool. This includes an analysis of both the assumptions that had to be made in this 
body of work and the comprises needed to be made because (1) this is human research and (2) 
this is a retrospective, chart review study. 
The work presented herein are covered by the Phoenix Children’s Hospital (PCH) 
institutional review board (IRB) protocols #16-131 and #17-031. The additional case study was 
previously presented by the author as a case study and therefore was determined by the PCH IRB 
to be non-human research. 
Lastly, the author wants to bring to the reader’s attention that it is commonplace for the 
clinical environment to report body weight in a unit of “kilogram”, i.e., “kg”. The author recognizes 
“pound” is a unit of weight and “kg” is a unit of mass from different scientific unit systems. Multiplying 
“kg” by the gravitational acceleration constant produces a weight value. The author has taken it 
upon himself to intentionally not distinguish between body weight and body mass herein, unless 
stated otherwise, to ease confusion by using the established clinical terminology and reporting 
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practices. The common clinical practices related to this body of work are (1) “weight” (Wt) is often 
reported in kgs and (2) the DRBW ratio interchangeably relates donor and recipient body masses 
(using kgs) and body weights (using lbs). Clinicians can interchangeably use either kgs or lbs for 
the DRBW ratio – assuming the numerator and denominator keep the same unit – because of the 
linear relationship between the two units. 
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CHAPTER 2 
 
PULLING FROM GENERALIZED KNOWLEDGE IN THE FIELD OF ALLOMETRY 
 
The novel virtual HTx fit assessment tool developed within this body of work requires a regression 
model to predict allograft TCV from gross donor parameters. The prediction model is required 
because measuring an allograft TCV will, in general, be impractical for the majority of clinical 
scenarios. To develop the regression model, chapter 2 will cover the field of allometry and consider 
if the knowledge from this field can potentially be implemented to predict allograft TCVs. The field 
of allometry is a subset of biology in which biologist mathematically study biological scaling 
relationships [7]. 
The review within this chapter will (1) provide an overview of the field of allometry and (2) 
introduce the reader to the power-law functions the field deploys in size scaling analysis. In the first 
half of this chapter the reader will be introduced to the initial contributions Galileo Galilei had on the 
field of allometry, understand the mathematical strength and simplicity of the power-law functions 
in biological scaling, and be able to identify isometric versus allometric scaling relationships. In the 
second half of this chapter, a simple, retrospective analysis on previous respiratory and 
cardiovascular empirical results will be performed to demonstrate the relevance of the power-law 
functions in studying the cardiovascular system. Additionally, the author will postulate what scaling 
relationship between TCV and body mass is to be expected. The consequences of the postulated 
scaling relationship will be discussed in the following chapter 3. At the end of chapter 2 the reader 
should, at a minimum, understand why the author considered it worthwhile to investigate if the 
power-law functions could be used to predict an allograft’s TCV. 
 
2.1 Introduction to the Square-Cube Law and the Field of Allometry 
 
Dialogues Concerning Two New Sciences (Galileo Galilei in 1638) is traditionally attributed as the 
original publication that described a physical phenomenon that is now known as the square-cube 
  6 
law [8]. Galileo observed that the ratio of volumes of two similar geometries will always be greater 
than the ratio between their corresponding surfaces. Galileo’s “greater than” observation assumes 
the larger object is placed in the numerator position. This observation introduces, in an indirect 
manner, that a volume of an object increases at a faster rate than its corresponding surface. It is 
now understood this phenomenon is a consequence of volume having its characteristic unit, i.e., 
length, cubed while area has its characteristic unit squared. In other words, this a consequence of 
volume and area being reported in m3 and m2, respectively.  
The phenomena described by the square-cube law is by no means isolated to volumes 
and areas. It could be another spatial relationship such as volume and length, or it can be a 
completely different characteristic unit relationship like time is with velocity and acceleration. The 
early geometric ratio shape analysis Galileo performed is now often analyzed by using power-law 
functions to scale both geometric and non-geometric relationships. 
The simplicity and berth of the power-law functions to scale quantities have been the pillars 
for the adoption of this mathematical tool in many fields of modern science, engineering, and 
manufacturing [8–19]. Applying power-law functions to anatomical, physiological, and other 
biological relationships is fundamental to the field of allometry [7,16,20,21]. Within biology and 
medicine, this scaling methodology has been used in various studies and applications that include 
but are not limited to the investigation of biological size limits, prediction of size-based biological 
needs, understanding of size-based toxin and drug clear rates, scaling of pharmaceutical trial study 
dosages from animal to human, and reduction of adult drug dosages for pediatrics [7,22–30]. 
 The generic power-law function, Equation 2.1, scales the relationship between the two 
quantities “x” and “y” in which “a” is the proportional constant and “b” is the scaling exponent: 
 
𝑦 = 𝑎 ∗ 𝑥𝑏 (Equation 2.1) 
 
The proportional constant, “a”, quantitatively describes “how” the two quantities are different in 
Equation 2.1. This proportional constant is independent of size scaling. As its name implies, the 
scaling exponent, “b”, contains the scaling information but does not describe “how” the quantities 
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are different outside of scaling. To better visualize the meaning of the proportion constant and 
scaling exponent, the reader can think about a basic geometric shape like the sphere. 
The governing equation for the volume of a sphere is 𝑉𝑜𝑙𝑢𝑚𝑒 =
4
3
∗ 𝜋 ∗ 𝑟𝑎𝑑𝑖𝑢𝑠3. 
Immediately it should be obvious that this geometrically-descriptive equation is a power-law 
function (i.e., Equation 2.1) in which 𝑎 =
4
3
∗ 𝜋 and 𝑏 = 3. If the reader visualizes the volume and 
radius of a sphere as two different quantities, i.e., two different objects, that are dependent on one 
another then the reader can view the constant “a” as a quantitative way to describe “how” these 
two “geometries” relate. The descriptive nature of “a” can be better appreciated when comparing 
the sphere’s volumetric equation to the equations for (1) a cube’s volume, (2) a regular 
tetrahedron’s volume, (3) a regular octahedron’s volume, or (4) even between the volume and 
surface area equations of a sphere with radius as the input. This “how” just happens to be a scalar 
value description. It is because “a” describes “how” these two quantities relate (independent of size) 
that this variable is referred to as the “proportional constant”. This “how” description by the variable 
“a” holds for non-geometric relationships. The scalar value of constant “b” in this example is 3 in 
which we are scaling the radius, i.e., a length, “x”, to the sphere’s volume, “y”. This scaling value is 
expected because a volume increases by a power of 3 while the radius increases by a power of 1. 
At initial glance Equation 2.1 may not appear simple; power-law functions appear to be 
particularly problematic when there is more than one input quantity. However, Equation 1 can be 
simplified when it is linearized by applying a log-log transform as seen in Equation 2.2: 
 
𝑦 = 𝑎 ∗ 𝑥𝑏 ↔ 𝑙𝑛(𝑦) = 𝑙𝑛(𝑎) + 𝑏 ∗ 𝑙𝑛(𝑥) (Equation 2.2) 
 
Similarly, a power function with two input quantities can be simplified when it is log-log transformed 
as seen in Equation 2.3: 
 
𝑦 = 𝑎 ∗ 𝑥1
𝑏1 ∗ 𝑥2
𝑏2 ↔ 𝑙𝑛(𝑦) = 𝑙𝑛(𝑎) + 𝑏1 ∗ 𝑙𝑛(𝑥1) + 𝑏2 ∗ 𝑙𝑛(𝑥2) (Equation 2.3) 
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It should be noted with Equation 2.3 that the proportional constants between “𝑦” and the inputs “𝑥1” 
and “𝑥2” are combined into a single proportional constant variable “a”. The scaling exponent 
variables are not combined. 
Power-laws are a mathematically powerful class of functions because, as Equations 2.2 
and 2.3 demonstrate, the nonlinear relationships can quickly be simplified when applying a log-log 
transform to linearize the relationships. Once the power-law relationship is log-log transform, then 
the proportional constant serves as the intercept (i.e., in the form of 𝑙𝑛(𝑎)) and the scaling 
exponents serve as slopes that scale the relationships linearly. It is while a power-law function is 
linearized one could then apply generalized linear regression techniques to fit empirical data and 
therefore determine the proportional and scaling exponent coefficients. Using log based e, i.e., 
natural log, in the log-log transform is preferable because it allows one to take the exp() function to 
the left- and right-hand-sides of the fitted model to easily reverse the forward transform. In other 
words, applying the exp() function to the left- and right-hand-sides of the fitted model is to take the 
backward transform. Reporting the fitted model after the backwards transform is applied allows the 
input(s) and output to be trivial because these variables no longer need to be log transformed 
before being inputted into the developed model. 
Studies within the field of allometry will often fit empirical data of a given power-law function 
to either interpret the biological significance or make biological predictions [7]. A fundamental 
interpretation a biologist can make from the quantitative scaling exponent metric is whether a 
scaling relationship is isometric or allometric. Referencing the Equation 2.1 power function, an 
isometric scaling relationship is said to exist when the empirical (?̂?) and theoretical (𝑏) scaling 
exponents are equivalent; otherwise the relationship is allometric. The theoretical scaling exponent 
is based on the powers of the characteristic units. For example, if the inputs “x” and “y” in 
Equation 2.1 are an area (Area=Length2) and a volume (Volume=Length3), respectively, then an 
isometric relationship postulates ?̂? ≈ 𝑏 ≝ 3 2⁄ = 1.5. 
The power-law function relationships analyzed heretofore made comparisons based on 
two or more quantities with the same characteristic unit. It is preferable, in general, for the quantities 
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being compared to have a commonality in their relationship which is to say they share a 
characteristic unit. Sharing a characteristic unit eases the interpretation of the scaling between the 
quantities and allows one to either postulate relationships before empirical data is collected or to 
postulate relationships that cannot be measured. However, the power-law functions do not require 
the inputs and outputs to have the same characteristic unit. One can either (1) mathematically 
relate the different characteristic units based on the use of appropriate constants or (2) fit the 
appropriate power-law function between the inputs and output without relating the different 
characteristic units [7].  
Mathematically relating different characteristic units, i.e., option (1), might be preferable to 
option (2) for two important reasons. First, option (1) may help to simplify the interpretation of the 
empirical data. Second, option (1) may help to postulate relationships in which one of the quantities 
has yet to be measured or cannot be measured. For example, let us assume one wants to know 
the scaling relationship between the radius of a sphere, “x”, and the volume of a sphere, “y”, but 
rather then collecting the sphere’s volume, the sphere’s mass was collected instead. If the density 
of the sphere can be assumed to be a uniform constant then there will be a linear relationship 
between volume and mass. Quantitatively the scaling exponent of a linear relationship is unity, i.e., 
1. Given the scaling exponent is 1 and volume has its characteristic unit (i.e., length) to the power 
of 3 then an appropriate power can be found to mathematically describe the scaling exponent of 
mass as a length; i.e., 𝑏 ≝ 1 = 𝐿𝑣𝑜𝑙 𝐿𝑚𝑎𝑠𝑠⁄ = 3 𝐿𝑚𝑎𝑠𝑠⁄  → 𝐿𝑚𝑎𝑠𝑠 = 3 with “𝐿” being the characteristic 
power.  This result implies, in effect, that the scaling of this sphere’s mass can mathematically be 
described as the characteristic unit, i.e., length, to the power of 3.  
The particularly usefulness of this mathematical observation for the field of allometry, i.e., 
option (1), is often seen when one is comparing a geometric scaling relationship to body mass – 
an important and easily obtainable biometric. Substituting mass for volume allows one to quickly 
postulate if there is an isometric or allometric scaling relationship between mass and the geometric 
quantity [7]. This concept will be implemented shortly to postulate the scaling exponent relationship 
between TCV and body mass. 
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2.2 Cardiac Relevant Allometry relationships within Mammalians 
 
Allometry has been an important field of study in biology to postulate and explain the scaling of 
biological structural sizes and physiological processes. Aerobic metabolism scaling relationships 
can explain many of the scaling relationships seen in mammalian cardiovascular and respiratory 
systems. 
The current chapter section will now retrospectively analyze historical aerobic metabolic 
data to support the consideration of using a power-law function to predict allograft TCV in this body 
of work. Relevant, historical data to be used in this analysis are scaling exponent values that were 
compiled in Schmidt-Nielsen’s textbook, “Scaling: Why is animal size so important?”, and are 
provided in Table 2.1 [7]. Cardiac stroke volume was not available in Schmidt-Nielsen’s textbook, 
therefore, it was acquired from West et al.’s journal publication [31]. 
Mammals consume oxygen to perform aerobic metabolism – the major metabolic process 
mammals can sustain long-term to release the energy needed for cellular function [32–34]. The 
scaling exponent value between oxygen consumption and mammalian body mass is 0.76. Given 
the lungs and heart have key functions in transporting oxygen for aerobic metabolism it could be 
postulated that the scaling relationships of these biological systems should relate to the scaling of 
oxygen consumption. 
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Empirical Scaling Relationships for Metabolism 
Respiratory Unit ?̂? 
Lung Volume ml 1.06 
Tidal Volume ml 1.04 
Breath Rate 1/min -0.26 
Ventilation Rate ml / min 0.80 
Cardiovascular 
  
Heart Mass kg 0.98 
Stroke Volume ml 1.03 
Heart Rate 1/min -0.25 
Cardiac Output ml / min 0.81 
Metabolism 
  
Oxygen Consumption ml / min 0.76 
 
Table 2.1: The presented scaling relationships are with respect to body mass. The proportional 
constant does not drive scaling relationships and therefore has been excluded. Compiled data is 
from Schmidt-Nielsen’s textbook, “Scaling: Why is animal size so important?” and West et al.’s 
publication [7,31]. 
 
The amount of oxygen delivered to the body for aerobic metabolism is driven by the 
ventilation of the lungs and the cardiac output of the heart. Assuming the efficiency of oxygen 
consumption is good but not 100%, then one could postulate the scaling exponents for ventilation 
and cardiac output might be slightly larger than that of oxygen consumption. It is well known and 
logical that chemical reactions, in general, will never have a 100% yield efficiency [35]. The 
empirical ventilation and cardiac output rates presented in Table 2.1 (0.80 and 0.81, respectively), 
in fact, do have a slightly greater exponent scaling value. The field of allometry can further analyze 
the anatomical and physiological scaling relationships of the respiratory and cardiovascular 
systems by considering their classical governing equations. 
The classical governing equations for ventilation of the lungs and cardiac output of the 
heart are as follows [33,34]: 
 
𝑉𝑒𝑛𝑡𝑖𝑙𝑎𝑡𝑖𝑜𝑛 ≝ 𝑇𝑖𝑑𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 ∗ 𝐵𝑟𝑒𝑎𝑡ℎ 𝑅𝑎𝑡𝑒 (Equation 2.4) 
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𝐶𝑎𝑟𝑑𝑖𝑎𝑐 𝑂𝑢𝑡𝑝𝑢𝑡 ≝ 𝑆𝑡𝑟𝑜𝑘𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 ∗ 𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒  (Equation 2.5) 
 
Given we are only interested in scaling relationships, proportional constants will not be considered, 
i.e., they were excluded in Table 2.1. The justification for excluding the proportional constants is 
they do not contain scaling information. In implementing the above assumption, the provided 
empirical exponential scaling factors from Table 2.1 can now be plugged into Equations 2.4 and 
2.5 to investigate if the scaling relationships hold. The scaling relationships are: 
 
𝑀𝑎𝑠𝑠0.80 ≅  𝑀𝑎𝑠𝑠1.04 ∗ 𝑀𝑎𝑠𝑠−0.26 
0.80 ∗ log(𝑀𝑎𝑠𝑠) ≅  1.04 ∗ log(𝑀𝑎𝑠𝑠) −  0.26 ∗ log(𝑀𝑎𝑠𝑠) 
0.80 ≅  0.78, 
 
for the respiratory system and: 
 
𝑀𝑎𝑠𝑠0.81 ≅  𝑀𝑎𝑠𝑠1.03 ∗ 𝑀𝑎𝑠𝑠−0.25 
0.81 ∗ log(𝑀𝑎𝑠𝑠) ≅  1.03 ∗ log(𝑀𝑎𝑠𝑠) −  0.25 ∗ log(𝑀𝑎𝑠𝑠) 
0.81 ≅  0.78, 
 
for the circulatory system. The scaling relationships are determined to be approximately equivalent 
and mathematically imply that tidal volume, breath rate, stroke volume, and heart rate must be 
balanced for a mammal to sustain an adequate oxygen consumption rate for aerobic metabolism. 
These mathematical cardiovascular and respiratory relationships with oxygen consumption are 
expected because (1) these biological systems are responsible for oxygen delivery and (2) aerobic 
metabolism is the only metabolic process a mammal can sustain long-term for cellular function 
[33,34]. 
 The mathematical implications suggest cardiovascular and other organ systems scale to 
meet the biological needs of healthy subjects. In general, this analysis of aerobic metabolism 
supports the stance that concepts from the field of allometry can describe how organ systems scale 
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mathematically by using power-law functions. These results provided the author with enough 
evidence that the power-law functions should be considered as a potential method to predict 
allograft TCV. 
 
2.3 Developmental Growth and Overweight Effects on Scaling Relationships 
 
A limitation with the field of allometry is that the majority of historical studies do not consider 
developmental growth. Many of the well-established metabolic and cardiovascular relationships in 
the field of allometry are developed using either data from various adult mammal species or data 
from within a single, adult mammalian species [7,23,24,36]. In fact, the analysis in the previous 
chapter section used only adult mammalian derived data. 
The works of de Simone et al. and Bide et al. strongly suggest, in general, that the well-
established adult scaling relationships that are typically referenced from the field of allometry do 
not capture developmental growth [23,37]. The work of de Simone et al. specifically demonstrated 
human cardiac scaling relationships between adults and pediatrics do not hold [37]. These findings 
emphasized the importance that particular caution should be taken when using historical scaling 
relationships from the field of allometry to compare adults and youth.  
A second limitation with the field of allometry is that the majority of historical studies do not 
consider overweight. However, relatively recent clinical publications have been implementing the 
power-law functions to either compare or normalize the scaling exponent values of cardiac metrics 
between healthy and overweight individuals [37–41]. 
The implications of these key limitations are (1) children do not scale downwards as small 
adults and (2) body type (e.g., overweight) affect the scaling relationships. To effectively predict 
allograft TCV of realistic donors for a children’s transplant center, which will include pediatric 
donors, a model needs to exist that considers both developmental growth and body type. Capturing 
a wide range of subject time points in the developmental process and a wide range of body types 
to fit to a power-law function (or any other type of model framework) will likely be necessary to 
realistically model the allograft TCV. 
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2.4 What is the Postulated Scaling Exponent of the Mammalian Heart? 
 
Before ending this chapter, it will be useful to postulate what the scaling exponent is between the 
TCV and body mass of the adult mammal. The scaling exponent will need to be postulated 
because, although the scaling relationship between total cardiac mass (TCM) and body mass is 
well-established for the adult mammal, i.e., ?̂? = 0.98 ≅ 1, the author is unaware of a published 
scaling relationship between TCV and body mass in adult mammals [7]. Having a postulation of 
what the scaling exponent value is for adult mammals will be useful to present a potential limitation 
of the DRBW ratio as a standalone clinical metric for allograft size-fit assessments in chapter 3. 
This potential limitation will be one argument to support the need for a better allograft size-matching 
method in pediatric transplants at a minimum.  
There are three requirements to postulate what the scaling exponent between TCV and 
body mass might be. The postulation argument is based on an earlier example from this current 
chapter in which the density of a sphere was assumed constant. First, various adult mammalian 
studies have shown that body weight and TCM have a 1:1 scaling, i.e., body weight and TCM scale 
isometrically as ?̂? = 0.98 ≅ 1 implies [7,20,21,27]. Second, it is a given that cardiac tissue has a 
constant density [42–45]. Third, it must be assumed that the blood volume within the TCV scales 
isometrically with TCM. If these three arguments hold then it would mathematically imply there is a 
1:1:1 scaling of body weight, TCM, and TCV. Recent literature found a linear, i.e., isometric, 
relationship between TCV and left ventricular volume in healthy hearts [46]. If it can be assumed 
the remaining three cardiac chambers also scale isometrically with TCV then this publication further 
supports the postulation that TCV and body mass scale isometrically. This postulation that TCV 
and body mass scale isometrically will suggest in chapter 3 that there might be clinical implications 
of using adult DRBW ratio criteria in pediatrics. 
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CHAPTER 3 
 
BACKGROUND AND SIGNIFICANCE FOR PROPOSED VIRTUAL FIT ASSESSMENT TOOL 
 
Phoenix Children’s Hospital clinicians initiated the collaboration that led to the development of the 
novel virtual HTx fit assessment tool presented herein. The clinicians seeking a better methodology 
to assess donor allograft fits into heterotaxy patients needing transplant. Heterotaxy is a particularly 
challenging group of congenital heart disease patients to find an appropriate donor fit for because 
many of the import anatomical structures are removed from their typical placement area, e.g., 
mirrored across the coronal plane. Although heterotaxy patients have extreme anatomical 
aberrations, the clinical standard remains the use of the DRBW ratio as a standalone metric to 
assess if a donor allograft will fit a patient. The metric assumes that a donor and patient have similar 
anatomical configurations, and weight comparisons are indicative of allograft size matching. The 
metric’s first assumption makes the identification of an appropriately sized donor allograft 
particularly challenging for the heterotaxy population. Pediatric HTx fit assessments are 
challenging, in general, because a large subset are structural congenital heart disease cases. 
Donor organ shortages in the USA add additional complications to this clinical situation since 
doctors do not want to unnecessarily decline a donor offer for concern they may not be able to 
procure another organ for their patient.  
Chapter 3 will (1) provide an overview of the current clinical challenges in procuring a donor 
allograft and (2) introduce a potential solution that will be developed to address current clinical 
allograft size-matching limitations. In the first half of this chapter the reader will be introduced to the 
current donor allograft shortage in the USA, the reader will understand key size-related 
considerations clinicians need to consider for fit assessment, and the reader will understand the 
limitations of size-fit assessment tools currently available. In the second half of this chapter the 
reader will be introduced to the author’s proposed solution to the clinical limitations in the current 
allograft size-matching methodologies. The chapter will conclude with what, if any, considerations 
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need to be made so the proposed solution can be implemented for any of the 4 distinct types of 
HTx procedures. 
 
3.1 Heart Transplant Allocation and the Allograft Shortage 
 
Heart transplantation is the preferred treatment option in late-stage heart failure; although, donor 
organs (allografts) remain limited [6,47]. Pediatric patients listed for HTx (i.e., potential allograft 
recipients) have the highest waitlist mortality rate for any patient population needing a solid-organ 
donor [6]. However, half of all cardiac allografts in the USA are left unused in which 36% of the 
unused allografts were well-functioning allografts, i.e., 18% of all available cardiac allografts are 
discarded even though they are well-functioning o›rgans [5]. In practical terms, this 18% 
corresponds to 800 well-functioning allografts being discarded while 70 pediatric patients die on 
the waitlist annually in the USA [5,6]. Under the current allograft allocation policies, the USA 
pediatric waitlist mortality is largest for the youngest of patients, as is shown with the compiled data 
in Table 3.1 from Almond et al. [6]. 
 
Waitlist Mortality for Pediatric Weight Groups 
Weight Group The Percentage of 
Waitlisted Pediatrics 
within a Weight 
Group that go to 
Mortality: 
The Percentage of All 
Waitlist Pediatric 
Mortalities 
Represented by 
Weight Group: 
The Frequency of 
Pediatric Waitlist 
Mortalities within a 
Weight Group: 
≤ 5kg 24% 25% 175 
≤ 20kg 20% 64% 370 
> 20kg 12% 36% 160 
> 65kg 11% 5% 10 
Total   530 
 
Table 3.1: From Almond et al.’s publication, it was approximated that 24% of the smallest pediatric 
patients die on the waitlist while accounting for 25% of all pediatric waitlist mortalities. Although 
Almond et al. reported 533 pediatric mortalities, over a 7.5-year period, starting in 1999, the results 
in the current table were approximated to be 530 from a bar graph. Almond et al.’s results account 
for approximately 70 pediatric mortalities while on the waitlist annually. 
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The approximate 25 deaths in a group of 100 of the youngest children (by weight in 
Table 3.1) versus the approximate 10 deaths in a group of 100 for the largest of children 
demonstrates age-specific waitlist mortality discrepancies [6]. The discrepancy that the youngest 
of patients die on the waitlist is due to the current shortage of size appropriate allografts [6]. The 
mortality rate of 10 in 100 for the largest children is comparable to the adult population and therefore 
makes this mortality rate “acceptable” given the current overall donor shortage [1–4]. It is worth 
noting that critiques of the current nationwide donor shortage in the USA fault the opt-in policy while 
(1) Americans are in favor of organ donation and (2) opt-out European countries have larger donor 
rates [48]. Ultimately, the waitlist mortality rate in the young pediatric population is unacceptably 
high in the USA [6,49]. 
 Allograft allocation within the USA is performed by the United Network of Organ Sharing 
(UNOS) organization (information can be found on their website: www.unos.org) [50]. UNOS has 
broken the USA into 11 distinct territories for donor allocation [50]. A patient needs to be listed in 
the UNOS database to receive a donor offer by the organization. To be listed in the database, a 
patient’s clinical team must provide clinically pertinent donor requirements and patient information. 
Required data includes the patient’s severity of congestive heart failure (starting with the sickest 
the levels are 1A, 1B, and 2) and donor requirements (e.g., acceptable weight range, blood type, 
etc.). Higher status patients get priority over lower status patients and longer listed patients get 
priority to more recently listed patients in being offered a donor. While listed, patient status may 
change to a 7A listing because they are either too sick or appear to be getting well enough to justify 
delaying a transplant in the immediate future. The intent of the 7A status is to pause the patient’s 
position on the waitlist while the clinical team waits to determine if, and when it is clinically 
appropriate to move forward with a transplant.  
At donor availability, an allograft will be sequentially offered with priority going to the patient 
with the highest status and duration on the waitlist in which the donor matches both the listed 
patient’s clinical requirements and UNOS territory. If no centers accept the allograft for their patient, 
and if time permits it, then the allograft may be offered outside the donor’s territory w ith the 
understanding there will likely be an extended “cold ischemic time”. “Cold ischemic time” is a 
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clinically important time measurement recognizing that a harvested allograft, before transplantation 
is complete, is slowly dying while being transported. “Ischemic” refers to the lack of blood flow to 
the organ which causes tissue deterioration of the allograft. “Cold” refers to the organ being 
preserved on ice to minimize tissue deterioration during transportation.  This time duration begins 
once the donor’s aorta is cut and continues until the allograft is attached to the recipient’s aorta. 
Failure to find a recipient for an allograft is frustrating for transplant teams because an unused 
organ is a wasted organ during the current nationwide donor shortage. Finding allografts for the 
very young pediatric patients are particularly challenging because many donors are outside their 
UNOS listed acceptance range. 
To address poor pediatric outcomes UNOS implemented the current, 3-tier, “sicker first” 
policy, in 1999, in which pediatric patients (< 18 years) received priority allocation of adolescent 
allografts [6,51]. The policy that pediatric allografts are first offered to pediatric patients was more 
of a concern for allograft coronary artery disease associated with older donor hearts then that of 
the donor shortage [6,51]. The same policy reprioritized all patients < 6 months of age from top tier 
priority for receiving an allograft to middle tier [51]. As previously shown, Almond et al. 
demonstrated this policy yields an unacceptably high waitlist mortality rate for pediatric patients 
with body weights ≤ 10kg and still unfavorable rates for patients ≤ 20kg [6]. The UNOS policy likely 
favors older pediatric patients because these patients get priority over adults in receiving pediatric 
allografts and, unlike younger children, are more likely to be able to accept adult allografts while 
infants are forced to share allografts with older pediatric patients.  
Clinicians of pediatric patients – especially when locating allografts for the very young – 
must expand their patient’s typical donor criteria to increase the likelihood of procuring an allograft 
in time given the current UNOS policies. Typical methods clinicians use to expand their recipient’s 
donor pool are as follows: (1) ABO-incompatible transplantations in the very young and (2) 
expanding listed DRBW ratio criterion [6,52]. 
ABO-compatible transplantations are generally required otherwise aggressive allograft 
rejection will occur due to an immune system response. The clinical practice of accepting ABO-
incompatible allografts for infants is based on observations that the immune systems of the very 
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young are not yet fully developed and are unlikely to cause aggressive allograft rejection later in 
life if the transplant is done early enough [52]. Performing ABO-incompatible transplants allows the 
donor pools of infants to be safely expanded. 
The DRBW ratio criterion is the standalone metric HTx centers use to assess if a donor 
allograft will safely fit. Expanding the lower and upper DRBW ratio criteria is seen as another 
method to expand a patient’s donor pool. Through experience, in general, clinicians will cautiously 
expand the metric criteria range to expand their patient’s donor pool, as is suggested in literature 
[53–56]. However, the DRBW ratio ranges are limited in considering unique patient aberrations 
typically seen in structural congenital heart disease. This limitation of the DRBW ratio metric makes 
it particularly challenging for clinicians to safely expand the donor pool of congenital heart disease 
patients based on weight. This body of work attempts to reduce allograft waste (e.g., the annual 
discarding of approximately 800 well-functioning hearts) and to reduce waitlist mortality through the 
development a novel tool that helps clinicians safely expand their patients’ DRBW ratios. 
 
3.2 The Clinical Standard for Allograft Size Matching and Concerns for Mismatch 
 
The current standard of care for HTx centers to determine if an offered allograft will appropriately 
fit a patient is to use the DRBW ratio as a standalone metric [46]. The offered donor’s weight is the 
value placed in the numerator position and the recipient’s weight is placed in the denominator 
position. In general, a DRBW ratio matching 1 is considered preferable [57–59].  
 The lower and upper weight range centers are potentially willing to accept for their patient, 
is required to list their patient onto the UNOS database. The listing standard of care is for clinicians 
to use the DRBW ratio methodology as a tool to identify the weight listing range they are potentially 
willing to accept. To ensure a patient is provided with allograft offers that are size appropriate while 
not unnecessarily limiting their donor pool, centers will set a lower and upper DRBW ratio criteria 
range they are willing to consider. Due to the donor shortage, many centers are progressive in 
allograft procurement for their patients by widening the DRBW range criteria they list their patients 
for and then, within reason, are willing to accept size mismatched donor offers [59–64]. Pediatric 
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centers are generally more aggressive with the lower and upper DRBW ratio ranges they are willing 
to set due appropriate size allografts being grossly limited for their patient population [59,61]. 
Typically, centers will only accept offers that approach the outer boundaries of the listed DRBW 
ratio criteria when there is concern that another, more appropriate donor offer will not be made 
available before the patient reaches a level of deterioration that is irreversible. 
The DRBW ratio criteria that patients are listed for are center specific and can occasionally 
be age-specific. Conventional centers will, in general, set the criterion range in pediatric patients 
from 0.75 to 1.50 and increase the criterion range from 0.75 to 3.00 for infants that are ≤18 months 
old [46]. A key clinically contributing factor to the increased DRBW ratio range in infants is the donor 
allograft shortage in which approximately 25% of listed infants will die on the waitlist [6,59,61]. A 
select group of centers (including PCH) have historically expanded the DRBW ratio range from 
0.70 to 4.00 in extreme cases. Although clinicians expand the DRBW ratio range to help ensure 
they procure an allograft for their patient, clinical complications arising from cardiac allograft size 
mismatches are a concern. 
First, undersized allografts affect the cardiac output the allograft can perform (i.e., 
𝐶𝑎𝑟𝑑𝑖𝑎𝑐 𝑂𝑢𝑡𝑝𝑢𝑡 = 𝑆𝑡𝑟𝑜𝑘𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 ∗ 𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒). Cardiac output (flow rate) is the systemic volume 
of blood the heart can move over a given period of time. Flow rate needs are proportional to an 
individual’s body size, i.e., adults have a larger cardiac output need then infants [37]. A heart being 
able to meet an individual’s cardiac output needs, relative to size, is an important requirement of a 
well-functioning organ, as is demonstrated with hemodynamic monitoring systems reporting a 
patient’s cardiac index [65].  
An undersized allograft would need to increase its heart rate to provide an appropriate 
circulatory flow rate. Hosenpud et al. published empirical results supporting increased heart rate is 
a likely consequence of allograft undersized mismatch [57]. This increased heart rate would add 
stress to the allograft that could potentially have negative clinical consequences [66]. An 
excessively undersized allograft could potentially be incapable to meet a patient’s cardiac output 
needs. In fact, clinical practice is to avoid undersized allografts (preferring slightly oversized 
allografts) for patients with elevated pulmonary vascular resistance due to concern for 
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hemodynamic insufficiency and the potential development of right ventricular failure [58,63,66]. The 
concern for right ventricular failure development in the undersized allograft is a potential 
consequence of the long-term lung hemodynamic resistant load the inferior muscle must contend 
with to drive the pulmonary circulation. 
Second, oversized allografts are likely to compress the surrounding anatomical structures 
and themselves [59,67]. Furthermore, there is concern that an oversized allograft will over-perfuse 
the patient [59,67]. The various types of compression effects clinicians are weary of in accepting 
an oversized allograft include lung compression, lung collapse, descending aorta compression, and 
pulmonary vein compression [59,61,67]. An allograft “self-compressing” itself is one concern that 
can compromise circulatory function [67]. To avoid “self-compression” the surgeon will slowly 
reduce the sternum chest spreader while intensely monitoring the pressure of the right atrium in 
the operating room. In situations of sudden, excess right atrial pressure (or other clinical indications 
of oversized compression effects) during attempted chest closure, the chest will remain open and 
closure will be completed at a later date – opening one or both pleural cavities have also been 
performed when needed [59,67]. Sudden over-perfusion is a potential complication of transplanting 
an oversized allograft in which a sudden increase of blood flow to the brain can cause neurological 
symptoms. The neurological symptoms of oversized allograft mismatch include coma, convulsions, 
and headaches but these issues normally resolve after several day [59,67].  Although oversized 
allografts might be well-tolerated, as is suggested with the expanded DRBW ratios HTx centers will 
accepted, excessively oversized allografts are a clinical concern for HTx recipients. 
 
3.3 Limitations of the DRBW Ratio Method and other Previously Proposed Solutions 
 
The DRBW ratio metric used in allograft size matching in HTx assumes that, in general, similar 
body weights correspond to similar patient and donor TCVs and that the offered allograft is capable 
of sustaining appropriate hemodynamics long-term [57,58,66,68]. Although the DRBW ratio metric 
is the current standard of care, there are inconstancies on whether this ratio predicts patient fit-
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related outcomes well [69–72] or poorly [53,55,56,59,61,62,73,74], or fit-related outcomes depends 
on patient size [66,75]. 
The conventional pediatric DRBW ratio criteria that centers typically list for may be derived 
from adult HTx studies and may explain why pediatric studies are suggesting that DRBW ratio 
ranges can be expanded [46,49,54,56,61,67,74,76]. Referring back to chapter 2, it was postulated 
that TCV and body have a linear, isometric scaling relationship (i.e., ?̂? ≈ 1) in the adult population. 
This postulated adult scaling relationship was found by the author – to be presented in chapter 4 – 
to not hold when pediatric developmental growth was involved (i.e., ?̂? ≈ 0.84). As discussed in 
chapter 2, there are ample examples for empirical scaling exponent relationships found in adult 
mammals to change when developmental growth is involved – including between adult and 
pediatric developmental growth in human cardiac anatomy and physiology 
[7,21,23,24,27,37,40,77–80]. Applying adult-derived DRBW ratio boundary limits to pediatrics 
imposes the adult scaling relationship (likely an isometric scaling relationship) onto pediatric 
patients during allograft size-matching. 
The decrease in the scaling exponent between the adult postulated value and the 
measured value of the pediatric population mathematically suggest adult DRBW ratio criteria are 
limiting pediatric donor pools. The mathematical argument that adult criteria are limiting the donor 
pool for pediatric patients is based on the clinical assumption that the upper and lower donor-
recipient TCV ratio are needed to be held constant between these age groups and not the DRBW 
ratio for a safe allograft fit. The smaller scaling exponent in pediatrics mathematically implies a 
larger weight range is needed so the TCV ratio matches the adult population.  
 To demonstrate this statement, let us consider the historical DRBW cut-off range of ±20% 
that was often suggested (corresponds to a DRBW ratio range of 0.80 to 1.20) [55,59]. Based on 
(1) the postulated adult scaling exponents and (2) the mathematical properties of exponents, the 
corresponding lower and upper TCV ratio ranges for the adult can be calculated from the historic 
DRBW ratios as follows: 
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𝐿𝑜𝑤𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜 = 𝐿𝑜𝑤𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜1 = 0.801 = 0.80 
 
and 
 
𝑈𝑝𝑝𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜 = 𝑈𝑝𝑝𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜1 = 1.201 = 1.20 
 
Now, using our previously listed assumption that the lower and upper TCV ratios safe ranges are 
the same constants for both adult and pediatric populations, let us find the corresponding lower 
and upper DRBW ratio criteria for pediatrics (using the pediatric scaling exponent): 
 
𝐿𝑜𝑤𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜 = 0.80 = 𝐿𝑜𝑤𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜0.84 
→ 
𝐿𝑜𝑤𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜0.84 0.84⁄ = 𝐿𝑜𝑤𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜1 0.84⁄ = 0.801 0.84⁄ = 0.77 
 
and 
 
𝑈𝑝𝑝𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜 = 1.20 = 𝑈𝑝𝑝𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜0.84 
→ 
𝑈𝑝𝑝𝑒𝑟 𝐷𝑅𝐵𝑊 𝑅𝑎𝑡𝑖𝑜0.84 0.84⁄ = 𝑈𝑝𝑝𝑒𝑟 𝑇𝐶𝑉 𝑅𝑎𝑡𝑖𝑜1 0.84⁄ = 1.201 0.84⁄ = 1.24 
 
The mathematical results suggest a wider DRBW ratio range is possible in pediatrics if matching 
the TCV ratio range is the clinically relevant factor. Although this increased weight range is minimal 
it becomes more pertinent if one is trying to match a TCV ratio of 3.00 - this corresponds to a DRBW 
ratio of 3.57 in pediatrics. Applying adult DRBW ratio criteria fails to consider developmental growth 
and this mathematical exercise suggest adult criteria may potentially be limiting pediatric donor 
pools unnecessarily. 
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Abnormal body weight (e.g., obesity and excess fluid overload) may further negate the 
clinical relevance of the DRBW ratio metric [46,66,67,81,82]. Excess fluid overload is common in 
waitlisted patients as a complication of end-stage congestive heart failure [46,66]. To overcome 
abnormal body weight limitations, recent publications have suggested potential applications of 
echocardiography-derived estimates to predict cardiac fit [46,81,83]. Some centers have suggested 
height is a more appropriate then weight is in the DRBW ratio metric because the height 
measurement is not generally susceptible to edema or subcutaneous fat [46,81,83,84].  
Pathology and progression of disease further complicate allograft size-matching based on 
the DRBW ratio as a standalone metric. For example, size-matching allografts for patients with 
congenital heart disease is nontrivial [67,85]. Some clinicians and clinical research groups suggest 
patients with enlarged hearts, e.g., dilated cardiomyopathy, can tolerate an allograft with a DRBW 
>> 1, i.e., well-oversized allograft [46,54,59,67,81,83]. In fact, PCH will take linear measurements 
of chest x-ray and compute the cardiothoracic ratio for patients with cardiomyopathy to potentially 
further expand their patients’ DRBW listing ranges, and thus further expand their patients’ listed 
donor pools. 
 
3.4 Proposal of a Virtual Heart Transplant Fit Assessment Tool 
 
The previous chapter section discussed that although the DRBW ratio is the clinical standard to 
predict if an allograft will fit within a patient, it is an indirect size matching metric that is far removed 
from the cardiac anatomy and susceptible to abnormal weight. Furthermore, it is standard for 
clinicians to expand the lower and upper DRBW ratio criteria they are willing to accept to ensure 
allograft procurement for their patient. However, by expanding the DRBW ratio, clinicians are 
reducing the safety margins of this metric when there are already established limitations with this 
method.  
To address concerns of expanding donor pools by expanding DRBW ratio criteria, some 
groups have looked for solutions outside of weight comparisons. Recently proposed solutions to 
assess donor-recipient allograft match were presented in the previous chapter section but these 
  25 
solutions have their own set of limitations. Height has been suggested to address the abnormal 
weight limitation but it is still far removed from the cardiac anatomy. While echocardiography-
derived and x-ray-derived fit assessment methods are more direct, they may be limited in 
accounting for both donor and/or patient cardiac and thoracic cavity aberrations. 
Considerations of a congenital heart disease patient’s unique three-dimensional (3D) 
cardiothoracic space will need to be taken into account to safely expand a patient’s donor pool. 
Congenital heart disease patients are cases with surgically complex thoracic environments that 
account for approximately 50% of infant and child HTx cases and 25% of adolescent HTx cases 
[72,85–90]. If a novel tool is to be successfully developed to safely expanding donor pools based 
on size matching in the pediatric HTx center then it will need to consider patient-specific anatomical 
aberrations of the cardiothoracic-space. 
Fitting ventricular assist devices and artificial hearts based on patient size is an area of 
medicine analogous to cardiac allograft sizing matching. There has been a recent push to safely 
assess mechanical device fit by performing computer fit assessments, i.e., virtual implant 
assessments [91–93]. A virtual implant assessment is performed by strategically fusing a medical 
device’s geometry onto a patient’s medical image. These case studies have shown instances 
where large mechanical circulatory support devices fit in undersized patients failing to meet 
standard fit criteria assessments [91–93]. The potential benefit of a virtual implant assessment is a 
patient’s structural aberrations can be accounted for when fusing a computer geometry of an 
implant device onto the patient’s medical image. These case studies indicate there are pediatric 
subpopulations that may in fact have the thoracic morphology capable of supporting a larger donor 
heart. The work herein leverages the virtual implant assessment techniques for allograft size fit 
assessment. 
This study hypothesizes that current computer technology can be leveraged to better 
assess a donor’s fit within a patient’s anatomy by computationally simulating a transplant surgery 
in the computer, i.e., a virtual transplant. It is speculated that virtually fitting, i.e., fusing, an allograft 
onto a pre-operative recipient medical image dataset to assess for potential fit-related 
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complications will, in general, address the limitations of the DRBW and echocardiography-derived 
methods.  
The virtual assessment will involve taking either a donor’s cardiac reconstruction or a 
cardiac reconstruction from a healthy patient with a matching TCV. These reconstructions are of 
the TCV in which blood volume and tissue that is deep to the myocardial exterior surface are 
included. A surgeon will then be able to mimic a surgery by translating and rotating the allograft 
geometry into place – hence the term “virtual surgery”. The surgeon will be able to move the 
allograft until they determine either (1) a fit is safely possible or (2) a fit is not safely possible. 
Although it might be considered preferable to use a donor’s allograft reconstruction for 
virtual HTx fit assessment, a regression model to predict allograft TCV and a library of healthy heart 
reconstructions will need to be developed for virtual fit assessments to be clinically feasible. A 
regression model to predict allograft TCV from gross donor metrics and library of healthy heart 
geometries will be needed for the following reasons: (1) donors will rarely have CT or MR medical 
images available and (2) time constraints, e.g., image transfer, reconstruction, and virtual fit 
assessment times. It is therefore hypothesized that a regression model to predict allograft TCVs 
can be developed from non-invasive donor parameters readily available to a recipient’s HTx center 
and validated. 
Once the novel tool is developed, driven by a developed regression model, a fit 
assessment could potentially be achieved within the allotted time a center usually has for deciding 
to accept an allograft offer or not. In real-time the clinical team will be able to virtually assess an 
offered allograft’s fit in a patient’s complex, congenital thoracic environment. A clinician would be 
able to visualize the fit and decide to accept an allograft that may have traditionally been considered 
too large. This allows the clinician to expand their patient’s donor pool in real-time. Finally, it is 
hypothesized virtual fit assessments will be demonstrated to help safely expand the patient’s donor 
pool. 
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3.5 Types of Heart Transplants 
 
Chapter 3 will now be concluded with a technical overview of the different types of HTx procedures 
that a surgeon can perform. The purpose of the overview is to discuss how the technical differences 
of each surgical procedure might affect how the final virtual assessment is developed and/or 
implemented. There are 4 distinct HTx procedures clinically available. These distinct procedures 
are classified into one of two transplant types: (1) heterotopic heart transplant (HHT) and (2) 
orthotopic heart transplant (OHT). The OHT class encompass 3 of the 4 district types of HTx in 
which the diseased, native heart is removed. The HHT class is unique because the diseased, native 
heart remains and therefore a patient will have two functional hearts - although the native heart has 
limited functionality. All 4 types of HTx are unique at the procedural level because of the variations 
in how the allograft can be anastomosed to the patient. 
 As a reminder, a virtual fit assessment is performed by taking a healthy allograft geometry 
and fusing it onto a patient’s medical image for assessment. The assessment espies any overlap 
of the allograft with surrounding anatomical structures to suggest if there are clinical concerns for 
compression effects. 
 HHT is largely an outdated technique in which the donor heart is attached to the failing 
native heart [94–96]. In general, only when a patient is offered an excessively undersized allograft 
and/or the patient has high pulmonary resistance a clinical team in the USA might consider 
performing a HHT in the current medical era [94–96]. The typical procedure is to anastomose the 
right atriums and the ascending aortas of the donor and recipient together [94–96]. The result is a 
HHT recipient has two functioning hearts – although one is a failing heart. There are cases in which 
HHT can be used to let the disease heart recover but mechanical support appears to be preferable 
for such circumstances in the current era [95–98]. The current virtual assessment tool has potential 
to be used to assess HHT fits by assessing how the donor heart would fit within the patient’s right 
plural cavity. The surgeon performing the virtual fit would need to carefully rotate the allograft 
geometry so the right atriums are near one another. Approximate placement of the allograft’s right 
atrium to the recipient’s right atrium is required for the structures to be anastomosed. However, 
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there is yet to be a HHT procedure performed at PCH and therefore it will not be investigated 
herein. 
 An important observation of HHT procedures is the clinical feasibility to fit a second, 
although smaller, heart into a patient’s chest cavity. This largely outdated clinical practice therefore 
suggest there are circumstances in which an oversized allograft can safely fit a patient. Since the 
HHT procedure can fit a secondary heart into a patient’s cavity, it is further justification that a virtual 
assessment tool can be developed to assess oversized allograft fit – as developed herein.  
 OHT is now the gold standard in end-stage heart failure treatment after the development 
of immune suppressant mediations [94–96]. Suppressants help to prevent or at least minimize 
allograft rejection Before suppressants were available HHT was preferred because at least the 
native heart could potentially be preserved if the donor allograft was rejected [95,96]. In general, 
OHTs are a class of procedures in which the vast majority of the patient’s heart is removed. Only 
a small patch or set of patches of the native heart are kept to anastomose the donor heart to the 
patient [94,99]. The invasiveness of OHT transplants make them a permeant surgical modification. 
The current OHT transplants are broken up into 3 types: total, bicaval, and biatiral transplants 
[94,99,100]. 
 First, total OHT is a procedure in which 6 anastomoses are to be made at the superior 
vena cava, inferior vena cava, pulmonary artery, aorta, and at 2 patches encompassing either the 
left or right pulmonary veins’ inlets to the heart [94,99]. This procedure preserves both atrium and 
thus helps to protect both the mechanical and electrophysiology of the donor heart [99–102]. 
Although this procedure has preferred outcomes (when done correctly), it is technically challenging 
with a particular concern of correctly attaching the pulmonary veins to the donor heart without 
bleeding [94,99,102,103]. Attaching already small vessels, e.g., pulmonary veins, can potentially 
further complicate the procedure in the smallest of children. The technical challenges of pulmonary 
vein attachment make the remaining 2 OHT methods preferable because they are associated with 
much more clinically manageable complications. 
 Second, bicaval OHT is a procedure in which 5 anastomoses are made [94,99]. The 
anastomosis of the bicaval procedure are similar to the total OHT except there are no pulmonary 
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vein anastomosis. Instead of attaching the pulmonary veins to the donor allograft a single patch 
comprised of the back of the recipient’s left atrium (which contains the pulmonary vein) is 
anastomosed to the allograft. Bicaval OHT is clinically preferable as it is a trade-off between 
minimizing post-operative mechanical and electrophysiology complications by preserving the right 
atrium and the relative ease for the surgeon to safely implement the anastomoses [94,99,100,104]. 
Finally, biatrial OHT is a procedure in which 3 anastomoses are to be made at the 
pulmonary artery, aorta, and a single patch of the posterior atrium wall (containing both the left and 
right chambers) that encompasses the vena cava and pulmonary veins [94,99]. This procedure is 
associated with post-operative complications that include mechanical, electrophysiology, and 
thrombosis issues [99,104]. However, anastomosing 3 large structures is technically simplistic, 
making it the easiest OHT to surgically implement, in general. In fact, even though biatrial OHT is 
associated with higher risk for post-operative complications, it is the preferred transplant in (1) 
infants and the smallest of children and (2) for highly complex structural congenital heart disease 
cases [90]. The few, large anastomoses sites greatly ease the surgeon’s ability to safely suture the 
allograft to the patient. 
In all three OHT procedures the donor heart is manipulated such that the allograft can be 
anastomosed to the patient. The total OHT leaves the donor heart with minimal manipulation and 
therefore more effectively parallels the virtual fit assessment procedure because the allograft TCV 
(with no geometric manipulation) is fused to the recipient medical image. While bicaval and biatrial 
techniques involve relatively more complex modification to the donor allograft then a total OHT, all 
three procedures leave only small patches of the patient’s native heart to anastomose to the 
allograft. 
To gauge if there was enough clinically perceived value in modeling the virtual allograft 
geometries for all 3 types of OHT, the author talked to cardiologists and cardiovascular surgeons 
at PCH. Although there was high interest in developing a tool to assess HTx fits with the allograft 
intact, there was no interest in manipulating the allograft geometry for any of the 3 types of OHT. 
In fact, there a very strong and resounding negative response from the clinical community to 
investigate fits in which slight modifications were made to the allograft geometry. Dr. Tara 
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Karamlou, a cardiothoracic surgeon, summed up the reason for the clinical disinterest in assessing 
virtual fits based on specific OHT procedures as follows, “[…] the anastomoses for OHT are non-
space-occupying lesions”. She continued to refer to the anastomosis cuffs cited in literature as 
“patches” to further convey the anastomosis sites had little to no effect on final transplanted heart 
volume. For the author, Dr. Karamlou’s use of the word “patch” was a powerfully descriptive 
explanation that the anastomose cuff had perceived negligible effect on the final transplanted 
volume and therefore the author has retained the term herein.  
As demonstrated by Dr. Karamlou’s feedback on how to perform the virtual HTx fit 
assessments, the clinical perception is the anastomoses required in OHT result in a zero-net TCV 
gain/loss for the donor allograft. Given the current clinical disinterest in assessing donor volumetric 
changes due to procedural anastomoses, this area of consideration was not considered as part of 
the work herein. If future virtual HTx fit assessments start to either consider (1) flow, thrombus, 
and/or compression complication effects through fluid-surface interaction simulations or (2) if it 
becomes possible to simulate electrophysiology changes as the allograft adapts and ages post-
HTx, then simulating procedures based on OHT type should be investigated. 
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CHAPTER 4 
 
DEVELOPMENT OF THE HEALTHY HEART LIBRARY 
 
The design concept of the novel virtual HTx fit assessment tool required a dataset of normal, 
healthy heart computer geometries, i.e., reconstructions, with the associated noninvasive, gross 
parameters included. The dataset was referred to as the “healthy heart library” or informally as the 
“library”. The library was used for 2 distinct tasks in developing and analyzing the novel tool. First, 
the library was used to develop a regression model that predicts a donor’s allograft TCV from gross 
donor parameters, i.e., predictors. Second, the TCV reconstructions were used to assess if an 
offered allograft would fit by performing a geometry-driven virtual fit assessment. The geometry-
driven assessment was achieved by using a library reconstruction that matched the donor’s 
predicted allograft TCV. 
Chapter 4 covers the development and the demographics of the healthy heart library. The 
library development, e.g., data collection, was performed via a retrospective, chart review. The 
chart review isolated patients with normal, healthy cardiac anatomies and physiologies that were 
available in CT or MR images. TCV reconstructions were generated from the acquired medical 
images and then had their volumes measured. CT and MR measured TCV (mTCV) values were 
statistically analyzed to help ensure minimized or eliminated bias between the modality 
measurements. The lack of a mTCV modality bias would justify combining both the CT and the MR 
data into the allograft TCV prediction model and, in general, the tool’s overall development process. 
The allometric scaling relationships between TCV and gross geometric predictors within the library 
were analyzed to appreciate both the data and the modeling process undertaken in chapter 5. For 
this body of work, the creation of the healthy heart library dataset constituted as Aim 1. 
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4.1 Methods and Materials of the Healthy Heart Library 
 
The IRB approved a chart review for 100 (minimum 50) normal, healthy heart subjects with 
retrospective CT or MR images. Pulled subject data was de-identified. The subject data was used 
to develop the allograft TCV prediction model and the TCV reconstructions. 
The requested subject sample size range was selected to meet the typical statistician 
recommendations for developing a parametric, linear regression model. The typical 
recommendations for parametric, linear regression modeling are that (1) there is at least 10-20 data 
points per potential predictor parameter and (2) there is no less than 50 data points in total [105]. 
From a practical point-of-view, the sample size cutoff was kept to 100 subjects because there was 
a concern there would be a limited number of healthy heart patients available in the hospital’s chart 
system. 
The healthy cardiac subject parameters were either pulled during the chart review, 
calculated from the pulled parameters, or reconstructed and measured from the pulled medical 
images. The data and their units (or classification levels) that were included into the healthy heart 
library were listed in Table 4.1. Body surface area (BSA) was calculated using the Mosteller 
equation [106]. Body mass index (BMI) was calculated using the specific relative body weight 
indexing equation that was originally coined to that same clinical term, i.e., “BMI” [107]. The mTCV 
and the gross parameters (i.e., Sex Age, Ht, Wt, BSA, and BMI) were specifically included within 
the library to serve as the model’s criterion variable and as potential model predictors, respectively. 
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Table 4.1: The list of chart data pulled from healthy heart subjects were presented in the current 
Figure. BSA and BMI were calculated from Ht and Wt. TCV was reconstructed and measured from 
cardiac medical images. 
 
Identification of normal, healthy heart subjects were performed by reviewing radiologist 
reports. Subjects reported as having no greater than mild dilation or obstruction of the greater 
vessels or coronaries were considered to be included in the library. Greater vessel and coronary 
anomalies deemed to not affect either the cardiac anatomy (including size) or physiology were 
included within the library as normal. Subjects with pathologies or have undergone treatments 
known to potentially affect cardiac anatomy, size, and pathology were automatically excluded. A 
cardiologist involved in the study confirmed the normal, healthy heart findings before including the 
subject into the dataset. Subjects that were diagnosed with anemia or had undergone some classes 
of chemotherapy drugs were typical examples where the cardiologist had automatically excluded 
the individual from the health heart library. 
Healthy Heart Library Data 
 
Chart Data: Classification or Units 
Cardiac Medical Images  CT/MR 
Sex Male/Female 
Age months 
Height cm 
Weight kg 
  
Calculated:  
Body Surface Area m2 
Body Mass Index kg/m2 
  
Reconstruction:  
Total Cardiac Volume Geometry - 
  
Measured:  
Total Cardiac Volume mL 
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Reconstructions of subject healthy hearts were generated from CT or MR cardiac image 
volumes. When possible, the image volumes at cardiac peak diastole were used because the 
ventricular muscles would be relaxed, i.e., the ventricles would be at or near their volumetric largest. 
Only the TCVs were reconstructed for this body of work. The reconstructions were produced in the 
following sequential order: (1) images were segmented in Mimics Innovation Suite software 
(Materialise, Leuven, Belgium), (2) initial reconstructions were post-processed in Geomagic Studio 
software (3D Systems, South Carolina), and (3) the completed reconstructions were fused to the 
subject’s images within Mimics for quality assurance. The myocardium and anatomical structures 
deep to the myocardium exterior surface (including blood volumes) were defined as part of the 
TCV. Figure 4.1 shows a reconstruction of a subject’s TCV with the reconstruction’s contour fused 
onto the medical image. The mTCV values were acquired from the reconstructed geometries using 
Mimics. 
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Healthy Heart Reconstruction Showing TCV Boundary 
 
Figure 4.1: Visualization of a healthy TCV reconstruction (red). TCV contour lines were fused onto 
the subject’s orthogonal medical image viewing planes (A, B, and C) to illustrate the TCV boarder 
– the reconstruction included blood volumes (image (E)) and anatomical structures deep to the 
myocardium exterior surface. The 3D TCV geometry were illustrated with (F) and without (D) 
reconstructed blood volumes independently reconstructed. The transparent setting of the TCV in 
image (F) demonstrated the thick and thin exterior muscular walls of the left and right ventricles. 
 
The mTCV values were statistically tested to ensure there was no significant difference 
between the CT and MR measurements. Failing to detect a statistical difference was perceived to 
suggest the modality measurements were equivalent and provide justification for combining the 
mTCVs within the healthy heart library. Suggesting that the mTCVs were equivalent would support 
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the allograft prediction model, the recipient images, and donor allograft geometry do not need to 
account for modality. The statistical test was performed with a one-way ANOVA 
(alpha = 0.05, H0 = 0) in the commercial software JMP (SAS Institute Inc., Cary, North Carolina); 
the null hypothesis was the modalities had equivalent mTCVs. 
The allometric scaling signals for the library’s geometric predictors were analyzed to 
appreciate the upcoming TCV modeling process and more generally the TCV signals related to 
developmental growth. Specifically, the geometric signals analyzed were between TCV and the 
geometric-specific gross donor parameters (Ht, Wt, BSA, and BMI). The allometric signal analysis 
consisted of first natural log transforming both the TCV and gross parameters and then performing 
a series of 4 univariable, linear regression fits. The allometric signal fitting process was repeated 
twice in which (1) all 97 data points were used and (2) Cook’s distance (4 𝑁⁄ ; were “𝑁” was library 
size) removed influential outliers [108,109]. 
 
4.2 Results of the Healthy Heart Library 
 
A total of 97 healthy heart subjects were identified and included in the healthy heart library dataset. 
There was a bias towards the male sex (64%) in the library dataset. Library demographics were 
presented in Table 4.2. Figures 4.2 illustrated the healthy heart library subjects’ mTCVs verses 
their corresponding Sex, Age, Ht, Wt, BSA, and BMI parameters. Figure 4.3 was a BMI color-coded 
version of Figure 4.2 and included to illustrate the interaction effect between BMI, i.e., body type, 
and the corresponding predictors on TCV. 
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Demographics of the Healthy Heart Library (N=97) 
Demographic characteristics Results 
Heart Volume (mL) 535 ± 259 (36 - 1340) 
Male 62 
Female 35 
CT 50 
MR 47 
Age (months) 155 ± 70 (3 - 358) 
Height (cm) 147 ± 31 (42 - 186) 
Weight (kg) 53 ± 29 (2.8 - 139) 
BSA (m^2) 1.46 ± 0.54 (0.18 - 2.59) 
BMI (kg/m^2) 22.8 ± 7.2 (13.5 - 46.5) 
Data are reported as mean ± standard deviation (range) or N  
 
Table 4.2: Normal cardiac subject demographics used to train and test the predictive models in 
chapter 5. Although imaging modality was not a predictor in the regression model, the mTCVs were 
derived from the CT and MR images and therefore the modality demographics were included. 
Figure 4.4 and corresponding ANOVA test (presented shortly) showed CT and MR measurements 
were equivalent and therefore justified the combining of both modalities’ mTCVs and 
reconstructions for use in the virtual HTx fit assessment tool. 
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Plot of Healthy Heart Library Demographics (N=97) 
 
Figure 4.2: Healthy heart parameters plotted against mTCV for all 97 subjects. Visual inspection 
suggested nonlinear and possibly linear trends were present in the data between subject gross 
parameters and TCV. The nonlinear trends suggested the data will need to be transformed for 
linear regression techniques to be implemented in chapter 5’s linear TCV modeling process. The 
data trends suggested growth patterns can be leveraged in an allograft TCV prediction model. 
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Color-Coded Plot of Healthy Heart Library Demographics (N=97)
 
Figure 4.3: A BMI color-coded plot of Figure 4.2 suggested body type, i.e., obesity, along with 
developmental growth, can be leveraged in TCV modeling process. Visual inspection suggested 
there were influential outliers in the data, e.g., a morbidly obese individual (marked red). 
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Subject demographic percentages were grouped by age: 6% (infants and toddlers, 0-2yrs), 
29% (children, 2-12), 60% (adolescents, 12-21), and 5% (adult, 21+) [110]. Breaking the age group 
into groups by year for 0 to 21 years old, i.e., 22 groups, resulted in each of the age groups 
representing, in general, between 1% and 5% of the library’s total data population. The adolescent 
age groups spanning 12 to 17 were the exceptions in which each of the age groups represented 
between 6% and 11% of the total data population. 95% of the subjects were of the adolescent age 
or younger at the time of their image scan. The oldest individual in the library was 29 years old at 
the time of their image scan. 
Subject demographic percentages grouped by body type, i.e., BMI, were: 43% (𝐵𝑀𝐼 <
20 𝑘𝑔 𝑚3⁄ ), 25% (20 𝑘𝑔 𝑚3⁄ ≤ 𝐵𝑀𝐼 < 25 𝑘𝑔 𝑚3⁄ ), 14% (25 𝑘𝑔 𝑚3⁄ ≤ 𝐵𝑀𝐼 < 30 𝑘𝑔 𝑚3⁄ ), and 18% 
(30 𝑘𝑔 𝑚3⁄  ≤ 𝐵𝑀𝐼). BMI 𝑚𝑒𝑎𝑛 ± 𝑆𝑡. 𝐷𝑒𝑣. by age group were: 16 ± 1 𝑘𝑔 𝑚3⁄  (infants and toddlers, 
0-2yrs), 18 ± 5 𝑘𝑔 𝑚3⁄  (children, 2-12), 25 ± 7 𝑘𝑔 𝑚3⁄  (adolescents, 12-21), and 30 ± 7 𝑘𝑔 𝑚3⁄  
(adult, 21+) [110]. Figure 4.4 illustrated the relationship between Age and BMI. 
 
Figure 4.4: Visual graph inspection suggested subject BMI was generally independent of subject 
Age. The exception appeared to be for subjects < 100 months of Age in which their BMI was held 
relatively constant. 
 
Image modality demographics had a near negligible bias towards the CT modality (52%) 
in the healthy heart library. The ANOVA test failed to reject the null hypothesis that the mTCVs 
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were statistically the same between image modalities (p-value = 0.5156, Cohen’s distance effect 
size = 0.1328). This ANOVA result suggested the CT and MR mTCVs were equivalent in the 
practical sense. Figure 4.5 visually illustrated the ANOVA results in a box-and-whisker plot. 
 
Figure 4.5: mTCVs for the different modalities. The small box-and-whisker plot horizontal lines (red) 
indicate the lower whisker, 25th-quartile, 50th-quartile, 75th-quartile, and upper whisker for CT and 
MR. The 25th-quartile, 50th-quartile, 75th-quartile values were (314mL, 513mL, and 674mL) for CT 
and (356mL, 539mL, and 685mL) for MR, respectively. The large horizontal line (grey) indicated 
the grand mean of 535ml, i.e., the mean for the N = 97 samples. 
 
Allometric scaling signals between geometric-specific parameters and TCV were estimated 
and presented in Tables 4.3 and 4.4. The estimated coefficients and standard errors (SEs) were 
determined with (Table 4.4) and without (Table 4.3) influential outliers removed. In general, minimal 
changes in estimated coefficients and SEs were observed, with BMI being the exception. The 
scaling exponents were compiled in Table 4.5 and generally showed the estimated, i.e., empirical, 
values were slightly less than the postulated, i.e., theoretical, values. 
The Pearson’s correlations for the TCV and the continuous predictors in the library were 
presented in Table 4.6. The correlation between TCV and BMI was a particularly weak (0.67). The 
correlation between TCV and Ht, Wt, and BSA were stronger (> 0.84). 
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Allometric Scaling Signals of Geometric Metrics with TCV: With Influential Outliers 
Structural Framework (R software notation) 
TCV ~ 1 + Variable 
Modeled log-log Transform Equation 
ln(TCV) = 𝖆 + 𝖇 ∗ ln(Variable) 
or 
TCV = 𝐞𝖆 ∗ Variable𝖇 
Coefficients Value SE t-value p-value 
𝖆𝐇𝐭 -5.07466 0.3922915 -12.93594 0 
𝖇𝐇𝐭 2.258016 0.0789381 28.60488 0 
     
𝖆𝐖𝐭 2.9793897 0.10269996 29.01062 0 
𝖇𝐖𝐭 0.8306572 0.02660205 31.22531 0 
     
𝖆𝐁𝐒𝐀 5.777092 0.01933058 298.85762 0 
𝖇𝐁𝐒𝐀 1.246316 0.03473741 35.87819 0 
     
𝖆𝐁𝐌𝐈 1.993526 0.5139927 3.878511 2.00E-04 
𝖇𝐁𝐌𝐈 1.343744 0.1661563 8.087231 0.00E+00 
     
 
Table 4.3: The 4 allometric scaling coefficients, i.e., 𝖇 values, between TCV and Ht, Wt, BSA, and 
BMI were calculated from the library (N = 97). As a mathematical consequence of how the 
univariable regression was fitted (the input variables were natural log transformed before fitting) 
the 𝓪 coefficient in the generic allometric equation was 𝓪 ≜ 𝐞𝖆, i.e., 𝖆 = 𝒍𝒏(𝓪) ≠ 𝓪. 
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Allometric Scaling Signals of Geometric Metrics with TCV: Without Influential Outliers 
Structural Framework (R software notation) 
TCV ~ 1 + Variable 
Modeled log-log Transform Equation 
ln(TCV) = 𝖆 + 𝖇 ∗ ln(Variable) 
or 
TCV = 𝐞𝖆 ∗ Variable𝖇 
Coefficients Value SE t-value p-value 
𝖆𝐇𝐭 -5.506137 0.3931865 -14.00388 0 
𝖇𝐇𝐭 2.341282 0.0789146 29.66854 0 
     
𝖆𝐖𝐭 3.097235 0.11614581 26.66678 0 
𝖇𝐖𝐭 0.8045534 0.02984497 26.95776 0 
     
𝖆𝐁𝐒𝐀 5.782347 0.01818777 317.925 0 
𝖇𝐁𝐒𝐀 1.249588 0.03331858 37.5042 0 
     
𝖆𝐁𝐌𝐈 2.846198 0.3803801 7.48251 0.00E+00 
𝖇𝐁𝐌𝐈 1.095032 0.1224039 8.946055 0.00E+00 
     
 
Table 4.4: The 4 allometric scaling coefficients, i.e., 𝖇 values, between TCV and Ht, Wt, BSA, and 
BMI were calculated from the library (N = 97). Influential outliers were identified and removed using 
Cook’s distance (> 4/N). As with Table 4.3, the backwards transform was 𝓪 ≜ 𝐞𝖆, i.e., 𝖆 = 𝒍𝒏(𝓪) ≠
𝓪. 
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Allometric Exponent Scaling Signals of Geometric Metrics with TCV 
Coefficients Postulated 
Relationship 
Value 
With Influential Outliers Without Influential Outliers 
Value SE Value SE 
𝖇𝐇𝐭 3.0 2.26 0.08 2.34 0.08 
𝖇𝐖𝐭 1.0 0.83 0.03 0.80 0.03 
𝖇𝐁𝐒𝐀 1.5 1.25 0.03 1.25 0.03 
𝖇𝐁𝐌𝐈 3.0 1.34 0.17 1.10 0.12 
      
 
Table 4.5: The presented 4 allometric scaling exponent values, 𝖇, and their SEs were compiled 
from Tables 4.5 and 4.5. Wt and BSA’s lower SEs suggested these models’ coefficient estimates 
were relatively robust. The BMI and Ht SEs were large and mildly large to suggest these models’ 
coefficient estimates were of relatively poor and slightly decreased robustness, respectively; 
Table 4.6’s correlation values further supported this finding. 
 
Healthy Heart Library Pearson’s Correlations 
 TCV Age Ht Wt BSA BMI 
TCV 1.000 0.763 0.846 0.901 0.920 0.670 
Age  1.000 0.861 0.789 0.858 0.563 
Ht   1.000 0.803 0.912 0.467 
Wt    1.000 0.975 0.869 
BSA     1.000 0.772 
BMI      1.000 
 
Table 4.6: Pearson’s correlations for predictors were presented (N = 97). Sex and imaging modality 
were binary variables and therefore were excluded. Ht, Wt, and BSA had relatively strong 
correlation with TCV while the Age and BMI correlations with TCV were weaker. 
 
4.3 Discussion of the Healthy Heart Library 
 
The normal, healthy heart library was built to develop a novel virtual HTx fit assessment tool. 
Although the tool was originally geared towards the general HTx assessment; given:  
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1. the higher waitlist mortality rate in the youngest of patients, 
  
2. the tool’s concept was conceived to expand donor pools for patients with major 
cardiothoracic anatomy and physiology aberrations (largely in the CHD patient population), 
and 
 
3. the clinical collaborators were pediatric cardiologist from a pediatric hospital, 
 
the focus of the tool’s development was geared towards pediatric HTxs. Specifically, for this thesis, 
it was perceived as being an unnecessary burden to include a larger adult, healthy heart population 
given the younger pediatric HTx population was most likely to benefit from the tool. The challenge 
in adding a larger adult healthy heart population and including adult transplant cases was (1) new 
collaborations would have needed to be made and (2) this would have expanded this work to a 
multicenter study. Keeping this work as a single center study resulted in only 5% of the healthy 
heart library being comprised of adults, i.e., 21+ years of age, with the oldest individual in the 
dataset being 29 years old. 
 Assessment of the Age, Ht, Wt, BMI, and BSA parameter results, as was shown in 
Table 4.2 and Figures 4.3 and 4.4, demonstrated the library encompassed a wide range of 
developmental growth, body types (e.g., overweight), and sizes present in the pediatric population. 
Requiring the library to encompass a large pediatric population range, which included a young adult 
population, helped to ensure the allograft TCV model makes interpolated predictions while avoiding 
extrapolated predictions. For example, including the available adult population in the library helped 
prevent extrapolated allograft TCV predictions in older pediatric donors (chapter 5). Unrealistic 
predictions can result when the model is made to extrapolate a prediction outside the training 
dataset range [108]. Less robust regression models, including models suffering from 
multicollinearity, are particularly at risk for extrapolating unrealistic predictions because their 
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estimated coefficients are unstable due to having large SEs - even when the extrapolation is mild 
[108,109].  
The Sex demographic was biased towards male (64%) in the healthy heart library. In 
general, a data bias is not ideal from a regression modeling point-of-view (chapter 5). The male 
bias was similar in a practical sense to both the general pediatric HTx (56%) and the CHD pediatric 
HTx (61%) population biases [6,111,112]. Furthermore, no other health heart individuals were 
available at our collaborating institute within the IRB approved 15-year data window to increase the 
library’s female population. Going outside this approved time duration to include more females 
would have changed this body of work to a prospective study – this would have increased the 
overall approval and execution challenges. Additionally, adding only prospective females to correct 
the male bias is not ideal from a statistical point-of-view because it could introduce nuisance factors 
(e.g., imaging protocol changes, types of healthy patients that were imaged, etc.). Given no other 
health heart individuals were available within the 15-year time-window and the male bias conformed 
reasonably well with the other important HTx populations, the Sex bias was considered no further 
and the library was moved forward in the tool’s development process. 
 The one-way ANOVA results suggested the mTCV values were constant between 
modalities (p-value = 0.5156, Cohen’s D effect size = 0.1328). The large p-value (>>> 0.05) 
suggested there was no statistically-significance difference between the CT and MR 
measurements. Specifically, from a statistical point-of-view, the null hypothesis that the mTCVs 
sample populations were the same was not rejected because the p-value was large. Furthermore, 
the effect size was small and corresponds to the CT and MR populations sharing a distribution 
overlap that was > 85%  [113]. It is worth noting that even if the p-value was small, the small effect 
size, i.e., the large overlap between the two modality populations, and the small difference between 
the modality means, i.e., 34mL, would suggest the statistical-significance was meaningless in a 
practical sense. These results justify the CT and MR measurements were practically the same. The 
ANOVA test results support the stance that the CT and MR data can be combined in the healthy 
heart library without further consideration with what modality the data came from. 
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 The estimated allometric proportional constants and scaling exponents between TCV and 
Ht, Wt, and BSA were relatively consistent with (Table 4.4) and without (Table 4.3) influential 
outliers removed. The consistency between the estimated coefficients was expected because their 
SEs were small, even when the influential outliers were kept. BMI was unusual for the 4 geometric 
parameters being fitted because the SEs were relatively large and resulted in a relatively large 
fluctuation between the coefficient estimates. The Pearson’s coefficients in Table 4.6 demonstrated 
Ht, Wt, and BSA all correlated well with TCV, i.e., all 3 correlations were > 0.84 with Ht having the 
lowest correlation of the 3. BMI had a relatively poor correlation of 0.67. The relative variations in 
the SE for BMI were most probably a direct consequence of the correlation results, as 
demonstrated in Table 4.5. Age had a correlation of 0.76 and suggested the SE of a univariable fit 
with TCV might be between the BMI and the Ht, Wt, and BSA SEs. The unusual BMI SE and 
correlation results preluded an upcoming discussion in this section that BMI was not an indicator 
of developmental growth.  
 The scaling exponents were more closely analyzed in Table 4.5 and compared to their 
postulated, i.e., theoretical, scaling exponents with respect to TCV developmental growth. The key 
observation was the scaling exponents for Ht, Wt, and BSA had relatively minor deviations from 
their postulated values; the deviations were all hypoallometric in nature. BMI had a strong deviation 
from its postulated scaling exponent; the deviation was hypoallometric in nature. The correlation 
and amount of deviation from the postulated scaling exponents suggested Ht, Wt, and BSA 
described a major allometric scaling factor in developmental heart size, i.e., developmental growth, 
but not BMI. 
Increase in Ht and BSA as an indication for pediatric growth was trivial. Increase in Wt as 
an indication for pediatric growth was less trivial because of body types, e.g., obesity. For example, 
in looking at the extreme ranges for Age and Wt in the healthy heart library we would never expect 
to have a 3-month-old weighing 139kgs or a 29-year-old weighing 3kgs. Matching these extreme 
and opposing Age and Wt ranges was perceived as clinically impossible for normal, healthy 
individuals and therefore supported Wt reflects developmental growth more than body type in the 
pediatric population. Similarly, the extreme TCV sizes differences between infants and adults 
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further supported Age helped to reflect developmental growth. It was trivial Age does not capture 
developmental growth between adults as growth generally stops after adolescents. Furthermore, 
the strong Pearson’s correlations between Ht, Wt, and BSA developmental growth with TCV growth 
had a strong causality because as an infant develops into an adult it was expected the heart will 
need to grow much larger to produce sufficient cardiac output. The fact that the resting infant heart 
rate decreases from approximately 140 to 70 beats per minute in the adult further supports the 
heart must grow to produce sufficient cardiac output as the individual grows [114,115]. 
BMI was recognized as a metric of body type (e.g., overweight) and generally independent 
of Age, as visual inspection of Figure 4.4 suggested. The previous discussion that the TCV range 
in the library was more a reflection of developmental growth and the poor Pearson’s coefficient 
reported between TCV and BMI further appears to have supported the BMI parameter does not 
reflect developmental growth. The only Age-related trend visually seen with BMI was that children 
and infants hold a constant (or near constant) BMI value, as was shown in Figure 4.4. This trend 
with Age and BMI might suggest infants and children “eat-to-grow” and after early developmental 
growth ends then poor, excessive eating habits (and lack of exercise) can result in overweight and 
obesity. This trend in children and infants having a small, relatively consistent body type, i.e., small 
BMI, might explain why the Pearson’s coefficient was not closer to 0. The results suggested BMI 
does not indicate developmental growth but rather body type. A regression model might include 
BMI to help account for the effects, i.e., nuisance factors, of body type hidden within developmental 
growth (or possibly Wt with another developmental growth parameter).  
From the TCV point-of-view, the TCV range (36 to 1340mLs) in the healthy heart library 
was large. Age, Ht, Wt, and BSA generally increased with respect to TCV. The strong Pearson’s 
correlations between Age, Ht, Wt, and BSA and TCV (Table 4.6) supported the inference that the 
major factor contributing to heart size was developmental growth. The results highly suggested the 
allograft TCV prediction model developed in chapter 5 would largely be driven by one or more of 
the developmental growth components, i.e., Age, Ht, Wt, and BSA. The weaker correlation between 
Age and TCV suggested Age would not be the only developmental growth predictor if it were 
present in the final model. Finding Age had a weaker correlation with developmental growth is trivial 
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once it is recognized the oldest of the healthy heart subjects had likely stop growing, i.e., had 
finished going through puberty, for a period of time. Furthermore, the author was not aware of a 
causality for BMI being a driving force in developmental growth patterns but rather it was perceived 
as an indication for accounting for patient body type. The weak but measureable correlation 
between BMI and TCV suggested allograft TCV predictions might need to account for body type 
by adjusting the predicted TCV. As an analogues to BMI adjusting for body type, Sex was 
investigated in chapter 5 because the final model might need to adjust allograft TCVs based on 
whether the donor was male or female. 
The univariable fits between TCV and the geometric predictors suggested allometric 
scaling were present in the data and suggested the final allograft prediction model would derive 
from these field of allometry concepts. In analyzing the geometric signal patterns, an interesting 
pattern in the scaling exponent (Table 4.5) was observed. In dividing the empirical scaling 
exponents (with influential outliers included) by the corresponding theoretical scaling exponents 
the signals’ ratios were: 0.75 (Ht), 0.83 (Wt), 0.83 (BSA), and 0.44 (BMI). When the influential 
outliers were removed, the signals’ ratios were: 0.78 (Ht), 0.80 (Wt), 0.83 (BSA), and 0.37 (BMI). It 
appears that parameters related to TCV developmental growth (i.e., Ht, Wt, and BSA) have an 
empirical to theoretical signaling ratio of approximately 0.80. BMI did not show this trend. Although 
this empirical-theoretical signal ratio pattern of 4/5ths in TCV developmental could be happenstance, 
it was an unexpected trend outside the scope of this body of work. Future work might want to 
investigate if there is a causality for this biological signal and if it holds for other developmental 
growth signals. 
Limitations of the healthy heart library, with regards to the novel virtual HTx tool’s 
development, fell into two major categories. The limitation categories were: (1) the patients that 
were used as “healthy” subjects in the healthy heart library and (2) the collaborating hospital’s 
clinical imaging practices. 
First, the library was comprised of perceived normal, healthy heart patients. Given this was 
a retrospective study the “healthy” subjects were patients that received medical imaging because 
of a perceived clinical concern. Subjects ranged from trauma patients (in which cardiac anomalies 
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were not expected), to cancer patients (medications excluded a subset of these patients), to even 
cardiac patients (with minor cardiac aberrations). As the methods indicate, extreme retrospective 
subject vetting isolated only 97 subjects that could be used in the library out of thousands of patients 
that had CT or MR scans over a 15-year period of time. Close inspection of the 97 subjects was 
performed during data collection to help ensure the TCVs were normal, well-functioning organs. 
Second, this retrospective study was dependent on what field-of-view images were 
archived and what imaging protocols were implemented. Only the archived images were available 
for TCV reconstruction because the original, i.e., raw, data was deleted to make room for new 
scans on the imaging systems. Furthermore, technicians would often truncate the apex of the heart 
while setting the final FOV to be archived because it was of no clinical value for the specific clinical 
case. The author was made aware of this archiving truncation practice, in which only the clinically 
relevant FOV is kept, through informal discussions with the scanner technicians. 
Peak-diastole images, i.e., images acquired approximately at the 80% R-R interval of the 
electrocardiogram signal, were perceived as preferable because the ventricles would be at their 
largest volumes. Time-specific cardiac acquisitions are achieved through cardiac-gating, i.e., image 
acquisition was triggered by the electrocardiogram signal. Imaging the ventricles at their largest 
was perceived as important because the ventricles (blood volume and muscle mass) contribute a 
significant portion on the overall TCV. An additional benefit of imaging the heart at the 80% R-R 
interval was it corresponds to the longest, most static time-point in the cardiac cycle. Imaging the 
heart when it is at its most static time-point in the cardiac cycle helps to reduce risk of motion 
artifacts.  
Hospital scan protocols and practices appeared to become more selective with what time-
points were imaged over the 15-year period. In regard to the CT images, it was observed that 
obtaining images at the 80% R-R interval became more and more difficult as scan dates became 
more resent in the hospital’s acquisition timeline. This appears to be due to a clinical shift from 
implementing retrospective to prospective CT acquisition protocols over the years. A logical 
causality in this observed trend might be radiologist wanting to implement prospective studies to 
reduce patient radiation exposure [116]. Many of the more recent prospective studies focused at 
  51 
or around the 40% R-R interval, i.e., peak systole. MR imaging did generally keep retrospective 
scanning protocols in place with cardiac MR scans typically captured images at the 0%, 20%, 40%, 
60%, and 80% R-R intervals. The lack of a shift away from MR retrospective scan protocols while 
there was a shift of the CT protocols helps to further support procedural changes were likely driven 
by patient radiation exposure concerns associated with CT scans. 
Another issue with cardiac-gating was this method was not always implemented – this was 
often seen in trauma and lung-related cases. The consequences of not using cardiac-gating were 
(1) time-point specific cardiac images could not be acquired and (2) images would be slightly blurry 
around the TCV boundary due to motion artifact.  
Due to the low healthy heart sample size, both images that were acquired outside the 80% 
interval and without cardiac-gating were included so an allograft TCV prediction model could be 
developed. However, the 80% R-R interval images or at least the cardiac-gated images were used 
when available. 
Clinical MR CT scan quality for anatomical reconstructions were often limited by poor out-
of-plane spatial resolution, driven by trade-offs addressing the poor temporal resolution of the MR 
modality [116,117]. Specifically, the source of poor spatial resolution was radiology tried to reduce 
scan times by reducing the number of slices they acquire within the heart’s FOV [116,117]. 
Radiologist make the out-of-plane spatial resolution trade-off such that important anatomical and 
functional data is able to be acquired within the typical time-window clinicians clinically have with 
the patient. Many of the MR cardiac images had poor out-of-plane spatial resolution but good in-
plane resolution. CT scanners have phenomenal temporal resolution and therefore it was rare to 
find CT scans with poor spatial resolution [116]. The ANOVA test, comparing CT and MR 
measurements and illustrated in Figure 4.5, helped justify the resolution differences did not affect 
the TCV measurements. 
The health heart library was carefully pulled together to balance the realistic heart data that 
was available for this thesis body of work while acquiring the data needed to develop the novel 
virtual heart transplant fit assessment tool. Statistical analysis of the library justified the combination 
of CT and MR data and suggested the allograft prediction modeling process would be successful 
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if it included for field of allometry concepts. The library data had a large distribution of subjects to 
help ensure the developed model avoids both mild extrapolations and extrapolations. Although the 
library is of a low, moderate size, the data sample size met statistician recommendations to build 
the parametric, linear allograft TCV prediction model. 
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CHAPTER 5 
 
DEVELOPMENT OF THE INITIAL AND IMPROVED ALLOGRAFT TCV PREDICTION MODELS 
 
A regression model to predict normal, healthy allograft TCVs was developed as a part of the novel, 
virtual HTx fit assessment tool. This predictive model was developed in recognition that most donor 
CT or MR images would not exist or, if they do exist, they would not likely be readily available to 
the recipient’s institution. Performing a virtual fit assessment with existing donor images is 
technically challenging because the donor images need to (1) be electronically transferred through 
a secured system, (2) have the donor TCV reconstructed, and (3) have the virtual assessment 
performed within the 1-hour time-window clinicians typically have to make a provisional 
acceptance. 
The developed predictive model allows a clinical team to identify a TCV reconstruction in 
the healthy heart library (with a similar volume) to serve as an analogue for the actual allograft’s 
geometry during the virtual fit assessment. For clinical utility, the model was developed to only 
consider gross donor metrics that were readily available at allograft offer with current clinical 
practices. To make use of the model, the novel tool needed to assume that (1) the donor cardiac 
allografts were normal, healthy, and well-functioning hearts and (2) TCVs of equivalent sizes had 
similar anatomical geometries. The predictive model allowed the tool to perform an assessment 
within 10 minutes while assessments driven by donor images required up to 30 minutes after 
images were transferred. Even with donor image assessments taking 30 minutes, it was recognized 
that transferring the donor CT or MR images between centers would be the major source for the 
time-related limitations because it is an unusual request. The perceived time-related data transfer 
bottlenecks included no current mechanisms set up to ease either the CT or MR acquisition of a 
deceased individual nor the expeditious transfer of the acquired data. The inclusion of the predictive 
model simplified the assessment process and increased the practicality of implementing the tool in 
the current clinical environment. 
  54 
Chapter 5 covers the development and the validation of the allograft TCV prediction model. 
The model was developed from the health heart library dataset. The first half of chapter 5 covers 
the development and validation of the initial model, i.e., Model-A. The second half of chapter 5 
covers improvements to the initial modeling process. These improvements produced the final 
model, i.e. Model-B, that were used in the virtual HTx fit assessment tool. Using Model-B’s 
structural framework, the chapter includes the development of a more conservative third model, 
i.e., Model-B*. This conservative model was developed to limit, i.e., offset, the likelihood of allograft 
TCV under-predictions. Biasing Model-B to avoid under-predictions by favoring over-predictions 
was undertaken to avoid foreseeable complications when the tool is used to maximize the allograft 
a clinical team is willing to accept. For this body of work, the development and validation of the 
allograft TCV prediction model constituted as Aim 2. 
 
5.1 Methods and Materials of the Allograft TCV prediction Model 
 
All subjects in the healthy heart library (N = 97) were used to develop and validate the final allograft 
TCV prediction model from gross donor parameters. The modeling process considered and 
implemented only parametric, linear regression techniques - partly due to the limited population 
size of the healthy heart library [118]. Six gross parameters, listed in Table 5.1, were initially 
considered to be potential predictor variables in the prediction model. In chapter 4, an ANOVA test 
compared the CT and MR mTCV values (p-value = 0.5156, Cohen’s D effect size = 0.1328). The 
ANOVA test results helped to justify that the current modeling process in chapter 5 did not need to 
account for modality type. 
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Table 5.1: The list of healthy heart library data that was pulled from patient charts and used to 
develop the allograft TCV prediction model. BSA and BMI were calculated from the pulled data. 
 
 The modeling process, i.e., model development and validation, consisted of 7 major steps 
as shown in Figure 5.1. Given (1) modeling steps 2 to 6 were repetitive in nature and (2) an 
exhaustive modeling search to identify top structural frameworks was implemented, it was sensible 
to semi-automate the modeling process. A model’s “structural framework” refers herein to a 
mathematical equation comprised of a unique combination of predictor main effect and interaction 
terms while the coefficient values were left undetermined. The modeling process was semi-
automated in a series of R language (R Core Team, Vienna, Austria) computer scripts [118,119]. 
R was chosen for its vast collection of open-source statistical packages that have been generated 
by a currently active statistical community. Implementing the available package functions helped to 
reduce the coding efforts of the author. The breaks between the series of in-house computer scripts 
allowed the author to evaluate and, if appropriate, implement minor modifications without rerunning 
the entire modeling process. Not needing to rerun the script from the beginning helped to reduce 
the modeling process’s time duration because the exhaustive search was a computationally 
expensive procedure. The final allograft TCV prediction model was identified in step 7. 
 
Considered Regression Modeling Variables 
 
Predictor Variables: Classification or Units 
Sex Male/Female 
Age months 
Height (Ht) cm 
Weight (Wt) kg 
Body Surface Area (BSA) m2 
Body Mass Index (BMI) kg/m2 
  
Criterion Variable: 
 
Total Cardiac Volume (TCV) mL 
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The Key Steps of the Initial Modeling Process 
 
Figure 5.1: Diagram of the key steps used in the development of Model A. Cross-validation was 
implemented twice – midway through the modeling process and at the end. 
 
Several statistical metrics were repeatedly evaluated throughout the modeling procedure. 
The mean absolute error (MAE), mean absolute percent error (MAPE), mean error (ME), mean 
percent error (MPE), mean square error (MSE), and root mean square error (RMSE) were a 
particularly important set of 6 statistical metrics used throughout this body of work. These 6 metrics 
quantitatively highlight unique attributes of the prediction error, i.e., residual. Consequently, this 
grouping of 6 metrics was henceforth referred to as the “statistical modeling metrics” within this 
thesis. It is noteworthy to highlight the importance in distinguishing errors derived from training and 
testing data (discussed later); therefore, “training statistical model metrics” and “testing statistical 
model metrics” were phrases used herein to further differentiate the type of “statistical modeling 
metrics” being analyzed. The corrected Akaike Information Criterion (AICc), symmetric mean 
absolute percent error (sMAPE), and symmetric mean percent error (sMPE) were additional metrics 
reviewed in the modeling process. These 3-additional quantities are statistical modeling metrics in 
their own rights but this thesis reserves this “statistical modeling metrics” terminology for the 6-
aforementioned metrics. The reasoning for separating the 3-additional metrics was the AICc metric 
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is of unique importance and the remaining 2 metrics were not routinely referred to during the 
modeling process. All statistical metric formulas used herein were presented in Table 5.2. 
 
The Formulas used to Quantify the Statistical Metrics 
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Table 5.2: The modeling metric formulas were combined within the current table. Notice the 
formulas within the right column were slight modifications of the corresponding equations in the left 
column. The formula variables were used as follows: 𝑦𝑖 (actual TCV value), ?̂?𝑖 (predicted TCV 
value), 𝑁 (sample size, e.g., 𝑁 = 97, unless Cook’s distance suggested otherwise or k-fold cross-
validation was being implemented), 𝑘𝑗 (number of terms within a unique structural framework), and 
?̂?𝑗 (estimated maximum likelihood). In general, the indices “𝑖” and “𝑗” corresponded to a specific 
data point and to a specific statistical model, respectively. During the 100 k-fold cross-validation 
runs, “𝑖” represented a data point within a specific fold. 
 
Step one, the models were fitted using non-transformed, i.e., original-value, and 
transformed (henceforth isometric* and “allometric*) training datasets. The transforms were 2 
methodical attempts to linearize the original data such that applying linear regression techniques 
would allow for field of allometry concepts to be implemented in the substructure of the models’ 
structural frameworks. The isometric* and allometric* refer to the values being transformed such 
that specific field of allometry concepts could be considered. The use of isometric* data and 
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allometric* data does not signify the transforms made the datasets isometric or allometric in nature 
(as this would be self-defeating for the modeling process). These 3 non-transformed and 
transformed datasets were referred herein as the 3 “datatypes”. Considering these 3 different 
datatypes in the modeling process was one of the fundamental causations for modeling steps 2 to 
6 to be repetitive in nature.  
The “isometric” data herein was previously transformed such that a linear regression 
modeling process would generally fit the data well if isometric scaling assumptions held between 
the predictors and the TCV. The predictor variables were transformed by applying appropriate 
powers to scale the variables’ characteristic units to that of volume. For example, to match height 
(m) and BSA (m2) to the volume’s characteristic unit (i.e., m3), their values were transformed by 
taking the powers of 3 and 1.5, respectively. In other words, power-law functions were carefully 
crafted such that the independent variables would be transformed to force an investigation of the 
isometric assumption. Furthermore, the density of the entire, i.e., whole, human body can generally 
be accepted as a constant that is near equivalent to soft tissue in an individual with a normal, 
healthy body weight [120,121]. The body density constant implies the body weight’s characteristic 
unit is equivalent to volume; therefore, in this work, weight was taken to the power of 1 to force an 
investigation of the isometric assumption. The 1:1:1 scaling of body weight, TCM, and TCV and the 
field of allometry concepts, both presented in chapter 2, further support scaling weight by the power 
of 1. The Age and Sex predictors were not transformed (yet still considered in the model) because 
they were non-geometric variables. The set of transforms applied to investigate an isometric scaling 
relationship were henceforth combined together and were referred to as the “cubed transform” – 
“cubed” is referring to the characteristic unit of volume. 
The “allometric” data herein does not require an isometric scaling for a linear regression to 
fit the data well; however, isometric scaling relationships could be discovered in the process. 
Allometric scaling was considered in the modeling process by log transforming the data. The log 
transforms used log based e, i.e., natural log. Unlike the cube transform, the natural log transforms 
were not specifically tailored to geometric scaling relationships between a predictor and the 
characteristic unit of TCV; therefore, Age was log transformed. Although Sex could also be log 
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transformed, it is a nominal, categorical variable that, if transformed, would (1) not add to the 
modeling process, (2) complicate the interpretation of the model, and (3) be problematic because 
it is commonplace to use the dummy-variable “0”. Specifically, the resultant of log transforming “0”, 
i.e., 𝑙𝑜𝑔(0), is undefined (and its right-sided limit goes to negative infinity). Therefore, Sex was not 
transformed but it was considered in the model. Henceforth, the set of transforms applied to 
investigate a generalized allometric scaling relationship were combined together and were referred 
to as the “log-log transform” – “log-log” is referring to both the dependent and independent variables 
being log transformed. 
Step two, multicollinearity between predictor variables were tested for and appropriately 
addressed in an iterative process for each of the 3 datatypes. The variance inflation factor (VIF) 
was used to test for collinearity. Iteratively the predictor with the largest VIF value was 
systematically removed and the remaining predictors reanalyzing until the largest VIF value 
achieved a threshold < 10. A VIF of 1 indicates no collinearity between two variables while a value 
greater than or equal to 5 or 10 generally indicates strong collinearity [108,109,118]. Removing 
predictors until the VIF condition was met, helped to ensure the coefficient estimates were robust 
and generally meaningful with respect to the dependent variable [108,109,118]. As will be seen 
later with the improved modeling process, the iterative removal of the largest VIF first is not a set 
procedural requirement for addressing collinearity issues.  
A generalized, i.e., reference, modeling procedure was included herein, where no 
collinearity corrections were implemented. This reference model was included to demonstrate the 
importance of addressing collinearity issues in the modeling process. Although high collinearity 
does not necessarily degrade the predictive performance of a modeling process (especially when 
training errors are being analyzed to assess the performance), it is well known that collinearity 
issues reduce the robustness of the produced models [108,109,118]. Specifically, skipping the VIF 
procedure put the reference modeling process at risk by allowing the exhaustive search procedure, 
i.e., step 3, to consider models with collinearity issues for candidacy in the group of “top models”. 
Step three, to identify the potential structural frameworks for the final allograft TCV 
prediction model, an exhaustive search was performed. The exhaustive search was implement 
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using the R “glmulti” package [122,123]. Main effects (predictors) and pair-wise interactions 
(multiplication of two predictors) were considered terms within the structural frameworks. Three-
way and larger interactions were not considered due to (1) a limitation in the “glmulti” code and (2) 
the computational cost required to include larger interactions [122]. The AICc metric was used, 
instead of the classical R2 and adjusted-R2 metrics, to quickly compare the exhaustive search 
structural framework performances in which the number of included terms varied for each model’s 
structural framework [118,122–124]. For comparative purposes, the AICc metric requires training 
datasets of the same size or, even better, the same dataset; therefore, all 97 healthy heart library 
data points were used in each of the exhaustive search fits [108,118,125,126]. Structural 
frameworks with lower AICc values were generally perceived to be better predictive models [124].  
Using the lowest AICc value as a reference, AICc differences for all the exhaustive search 
results were determined. Literature suggest that AICc difference criteria of > 10, > 4, and ≤ 2 have 
negligible, some, and substantial chance that the two models being compared have similar 
performances; however, choosing the final threshold criterion one uses is somewhat subjective 
[124]. An AICc difference threshold of ≤ 2 is a typical, i.e., historical, guideline to help reduce the 
number of model structural frameworks needed to be considered in the modeling process 
[122,124–128]. Using this historical guideline, models with AICc differences of ≤ 2 were moved 
along in the modeling process. The small AICc difference criterion provided strong evidence that 
the models moved along in the modeling process had relatively equivalent prediction performances 
and therefore a close investigation of their testing statistical metrics was required to tease out the 
“best” model. 
Step four, the potential models underwent a k-fold (k = 10) cross-validation process to 
identify, e.g., help validate, well performing structural frameworks that were not sensitive to specific 
training and testing datasets [118]. Cross-validation procedures validate models by systematically 
separating the data into a series of training and testing data subsets at random to estimate both 
the model’s coefficient(s) and the testing error several times. Estimating the testing error several 
times further allows for the testing error variance to be estimated. Ultimately, this process helps to 
ensure the model is robust to both the training and testing datasets that are used. Cross-validation 
  61 
procedures are particularly useful in validating model structural frameworks when the data available 
for both the training and testing datasets are of limited size [118]. The healthy heart library (N = 97) 
was of moderate, i.e., limited, size and therefore supported the need for implementing a cross-
validation procedure. 
The k-fold procedure was run 100 times to remove bias in a single k-fold procedure. 
Running a 10-fold procedure 100 times corresponded to developing and testing the model 1000 
times. The 100 runs were achieved in the semi-automatic script by using 100 unique seeds to 
randomly generate the k-fold subsets. These seeds allow for the same “random” subsets to be 
algorithmically regenerated to ultimately ease result comparisons between the different models. 
Furthermore, these 1000 folds produced 1000 testing statistical model metric results that were 
averaged to remove the aforementioned fold bias. The averaged testing statistical model metric 
results were then used to identify up to the top 10 potential model structural frameworks per 
datatype (up to 30 models in total) that were to move forward in the modeling process. In addition 
to averaging the 1000-fold testing statistical model metric results, their minimum, 1st-quartile (1st-
Qt), 2nd-quartile (2nd-Qt ; i.e., median), 3rd-quartile (3rd-Qt), maximum, and standard deviation (St. 
Dev.) were also determined. It is worth noting this same k-fold cross-validation procedure was 
repeated a second time, in step 7, to select the final, “best” model. 
Step five, heteroscedasticity in the top models were tested for and corrected when needed. 
Visual inspections of Figures 4.2 and 4.3 initially suggested heteroscedasticity in the library training 
dataset. Residual graphical visualizations and a heteroscedasticity test, i.e., the Breursch-Pagan 
test, were used to confirm heteroscedasticity [129,130].  
Two methods to correct for heteroscedasticity were considered. The first method used the 
“varclass” functions in the R “nlme” package [129,131]. The “varclass” function uses sub-functions 
to reweight the coefficient estimates by applying mathematical assumptions to the data’s variance. 
For example, the “varExp” sub-function generates weights that correct for heteroscedasticity by 
assuming the variance has an exponential fit between a dependent and independent variable 
paring. The various sub-functions were considered for each of the independent and dependent 
variable pairings in an iterative fashion. Heteroscedasticity was indirectly suggested when applying 
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“varclass” functions improved the AICc and the training statistical model metric results. The second 
method used Cook’s distance criterion (4/N) to identify and remove influential outliers from the 
training dataset [108,109]. It is worth nothing the 4/N Cook’s distance cutoff is often presented in 
literature as 2 √𝑁⁄ . The AICc and the training statistical model metric results produced by both 
methods were analyzed to determine which, if any, corrections were needed to reduce 
heteroscedasticity issues in the modeling process. 
Step six, the near final estimated coefficient p-values were assessed to ensure all model 
terms were statistically-significant. Estimated coefficients with p-values of ≥ 0.05 and ≥ 0.025 were 
considered to be automatically and potentially insignificant, respectively. Statistically-insignificant 
coefficients can likely be removed from the model because they should have negligible effect on 
the remaining estimated coefficient values and the overall prediction error (excluding the prediction 
issues associated with an overfitted model) [108,109,118]. If coefficient values were candidates for 
removal, in an iterative fashion, the model was re-estimated with the largest p-value coefficient 
term removed and the training statistical metric values recalculated. Remaining coefficient 
estimates, SEs, and training statistical metric values were monitored throughout the insignificant 
coefficient removal process to ensure minimal changes were observed, i.e., to ensure no negative 
impact was observed in a term’s removal. This iterative process was repeated until all coefficients 
with p-values ≥ 0.025 were removed without negatively affecting the model. Given the previously 
implemented modeling steps, the author was advised that large coefficient estimate p-values 
(≥ 0.05) should not be expected in step 6. A large coefficient p-value would likely have signified a 
serious issue in the design and/or implementation of the modeling protocol herein and therefore 
would need to be investigated and corrected.  
It is worth mentioning that both steps 5 and 6 used all N = 97 data points to quantify the 
errors and, in general, used these same data points to train these same potential models (removal 
of influential outliers by using Cook’s distance was the exception). No data holdout to calculate the 
testing error was performed. Given the reported errors in these 2 steps were comprised entirely or 
largely of training errors (with influential outliers included) the errors in these steps were referred to 
as training errors herein. Analyzing the training errors in steps 5 and 6 was considered acceptable 
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because (1) it simplified the heteroscedasticity and the insignificant coefficient correction processes 
and (2) no model selection (outside of model permutations) was performed in these steps. In 
particular, the modeling process was studiously crafted to ensure actual model structural framework 
selection steps were driven solely by testing error metrics in steps 4 and 7. 
Step seven, the approximately top 10 models from each of the 3 datatypes (30 in total) 
were to be 10-fold cross-validated a second time. Additionally, each of the models were fitted one 
last time using all N = 97 data points in the final training dataset (excluding the influential outliers 
the Cook’s distance procedure removed). The testing statistical model metric results from the 10-
fold cross-validation were used to identify the final, “best” performing allograft TCV prediction 
model. The reported testing predicted TCV (pTCV) results were determined by averaging the 100 
10-fold cross-validation runs. The design of step 7 allowed for the ‘best’ model to be selected from 
testing errors (by implementing a second k-fold cross-validation) and for the ‘best’ model to help 
reduce future allograft TCV prediction testing error overestimates (by estimating the final 
coefficients will all 97 data points).  
The usage of “best” model, in step 7, was used to indicate (1) the modeling process was 
somewhat subjective, (2) the modeling process was dependent on model requirements and 
assumptions, and (3) the very label of best can be misleading between extremely similar performing 
models. The subjective nature refers to both the designer’s selection of statistical modeling metrics 
to be analyzed and the designer’s overall preference for one metric over another. A large variety of 
statistical metrics were included herein to ensure various error attributes were considered in the 
modeling process and to avoid biasing a specific error attribute. Furthermore, the designer 
requirements and assumptions herein were carefully considered based on concepts and/or 
practices from the fields of allometry, statistics, and medicine. Finally, the issue of labeling a model 
as “best” out of a set of similar performing models (without the quotations) is training and testing 
dataset variations might fluctuate in ranking performance order. However, the cross-validation 
procedures implemented in steps 4 and 7 helped to minimize the ranking order fluctuation issues 
between the training and testing samplings used at structural framework selection. The initial 
  64 
modeling protocol presented herein was ultimately designed to help ensure a strong, final allograft 
TCV prediction model was developed – this initial model was referred herein as Model A. 
 
5.2 Results of the Allograft TCV prediction Model 
 
The 3 previously mentioned datatypes, transformed from the healthy heart library data in step 1, 
were considered for prediction model development. In step 2, collinearity issues for each of the 3 
datatypes were addressed through a systematic elimination procedure using a VIF criterion 
threshold (≥ 10). The final predictors isolated for model consideration, from each of the datatypes, 
were as follows: original-value (Sex, Age, Ht, and BMI), log-log transform (Sex, Ht, and BMI), and 
cubed transform (Sex, Age, Ht, and BMI). Before the VIF procedural corrections were implemented, 
the initial maximum VIF values for each of the 3 datatypes were 820.60 (original-value; BSA), 
302260.70 (log-log transform; Wt), and 20740.54 (cubed transformed; BSA). After the VIF 
procedural corrections were completely implemented, the final maximum VIF value for each of the 
3 datatypes were 4.81 (original-value; Age), 1.32 (log-log transform; BMI), and 4.14 (cubed 
transformed; Age) - all other remaining predictors had VIF values less than the maximum VIF for 
their datatype. Interestingly, the VIF procedure for all 3 datatypes was constant in removing BSA 
and Wt in the first two iterations, i.e., if BSA was removed first then Wt was removed second. 
Clinical considerations early within this body of work considered excluding Age 
automatically (see discussion); therefore, the VIF process was repeated with Age removed. For all 
3 datatypes, with Age removed, the VIF procedure reduced the predictors to the same 3 final 
variables for consideration in the modeling process: Sex, Ht, and BMI. Regardless if Age was 
initially included or excluded in the modeling process, the log-log transform modeling process 
resulted in the VIF procedure isolating the same 3 predictors. This observation of the log-log 
transform modeling processes isolating the same 3 predictors was of particular importance 
because it helped contribute to a procedural simplification made after the completion of step 3. With 
Age excluded, the final maximum VIF values and their corresponding predictor for each of the 3 
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datatypes were 1.28 (original-value; Ht), 1.32 (log-log transform; BMI), and 1.16 (cubed 
transformed; Ht). 
The isolated predictor sets with their corresponding non-transformed or transformed 
datatypes underwent an exhaustive modeling search procedure, in step 3, to identify potential 
model structural frameworks for allograft TCV prediction. The R “glmulti” function was used to 
implement the exhaustive search. All 97 data points, for each of the 3 datatypes, were used to train 
each of the exhaustive search models and calculate their corresponding AICc values. Keeping the 
data set constant, i.e., keeping all 97 data points, eased interpretation of the AICc results. Using 
the different transformed data for AICc comparison was appropriate because it only manipulated 
the data points – it did not change the specific individual’s data points used. 
Considering Age within the modeling process, the lowest AICc values in the exhaustive 
search were 1160.4 (original-value), -85.3 (log-log transform), and 1145.1 (cubed transformed). 
Automatically excluding Age within the modeling process, the lowest AICc values in the exhaustive 
search were 1170.8 (original-value), -85.3 (log-log transform), and 1146.2 (cubed transformed). 
The AICc values were the same for both log-log transform modeling processes (with and without 
Age considered) because they ended up being the exact same exhaustive search executions, i.e., 
these two exhaustive search procedures considered the same 3 predictors, used the same training 
dataset, and used the same datatype. 
A reference exhaustive modeling search procedure, to demonstrate the importance of 
correcting for high collinearity issues, was also implemented with all 6 original predictors 
considered. The reference modeling process was achieved by skipping the VIF procedure. The 
lowest AICc values in the reference exhaustive search were 1141.9 (original-value), -88.2 (log-log 
transform), and 1133.8 (cubed transformed). 
A very important observation with the AICc results was all 3 log-log transform modeling 
processes, i.e., with and without Age included and the reference modeling process, had excessively 
lower-starting, lowest AICc values (reported above) compared to the original-value and cubed 
transformed datasets. These intermediate results supported the log-log transform modeling 
processes well outperformed the other processes and therefore the original-value and cubed 
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transformed modeling processes were immediately terminated. Although the reference modeling 
process had slightly lower-starting, lowest AICc values than the VIF corrected models there was 
concern the reference models were not robust due to collinearity related issues. The AICc results 
provide no information on model robustness issues and could be hiding overfitting issues. 
Furthermore, the difference between the lowest AICc values produced by the non-reference and 
reference log-log transform fitted models was minimal, i.e., < 3. Both the concerns that the 
reference model was not robust and the observation the AICc difference was minimal, i.e., provided 
evidence these models’ performances were nearly equivalent, justified a more in-depth analysis to 
tease out the “best”. 
As a consequence of both the VIF predictor reduction procedure results and the exhaustive 
search AICc results, the number of modeling processes needed to be considered was reduced to 
a single modeling process. This single modeling process needed to only consider log-log transform 
data with only 3 predictors, i.e., Sex, Ht, and BMI. As was previously shown, the inclusion or 
exclusion of Age had no effect on which predictors remained for consideration after the VIF 
procedure was implemented on the log-log transform data. Moving forward, due to the 
simplifications that could be made in the modeling process hereto, the allograft TCV prediction 
modeling process and reference modeling process were interchangeably referred to as the “VIF 
corrected” and the “non-VIF corrected” models, respectively. 
The VIF corrected, log-log transform modeling procedure had 64 model structural 
frameworks to investigate in the exhaustive search. The AICc difference threshold criterion (≤ 2) 
isolated 8 (out of 64) structural frameworks to be moved forward in the modeling process, i.e., move 
forward to the k-fold cross-validation procedure in step 4. The 64 AICc results were illustrated in 
Figure 5.2 by plotting the AICc values against their sequential AICc ranking. The 8 potential models 
that were moved forward in the modeling process were marked red in Figure 5.2 and their structural 
frameworks were presented in Table 5.3. Based on the sequential AICc ranking order, these 8 
models were referred to as potential Models 1, 2, …, and 8. A zoomed in view of the AICc ranking 
profile in Figure 5.2 illustrated a discontinuity between potential Models 6 and 7. Although a further 
investigation was needed to determine if Models 7 or 8 would have performance limitations, the 
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AICc profile discontinuity suggested neither models 7 or 8 would likely be selected as the final 
“best” model. For comparison, the reference modeling process isolated 74 (out of approximately 
4096) structural frameworks that were moved forward by using the same AICc difference criterion 
(≤ 2). The number of reference model structural frameworks analyzed in the exhaustive search was 
approximated using the provided equation 2𝑝
2
 by the “glmulti” author – where “𝑝”  was 6, i.e., was 
the number of predictors [122]. The VIF corrected modeling process did not need to approximate 
the number of structure frameworks analyzed because the “glmulti” reports up to the lowest 100 
AICc models and therefore the exact number was known. 
 
AICc Profiles from Initial Modeling Process’s Exhaustive Search 
 
Figure 5.2: The 64 AICc profiles sequential order rankings were illustrated with the 8 potential 
models (marked red) below the AICc difference threshold (blue, horizontal line). Although image 
(A) suggested minimal patterns of AICc profile discontinuity in the first 32 models, image (B), 
zoomed in, illustrated several discontinuities. One discontinuity of particular interest was between 
potential Models 6 and 7. The AICc values are from the VIF corrected exhaustive search modeling 
procedure in which both the ML method and all healthy heart data points (N = 97) were used. 
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Potential Models Identified by AICc Difference Criteria 
Model Structural Framework (R software notation) AICc 
1 TCV ~ 1 + Ht + BMI + BMI:Sex -85.35 
2 TCV ~ 1 + Ht + BMI:Sex + BMI:Ht -85.32 
3 TCV ~ 1 + Ht + Ht:Sex + BMI:Ht -85.20 
4 TCV ~ 1 + Ht + BMI + Ht:Sex -85.19 
5 TCV ~ 1 + Sex + Ht + BMI:Ht -84.96 
6 TCV ~ 1 + Sex + Ht + BMI -84.94 
7 TCV ~ 1 + Sex + Ht + BMI + Ht:Sex -83.36 
8 TCV ~ 1 + Sex + Ht + Ht:Sex + BMI:Ht -83.35 
 
Table 5.3: The 8 potential structural frameworks, that were moved forward in the modeling process, 
were presented in AICc sequential order. These frameworks were identified in an exhaustive 
search in which only Sex, Ht, and BMI were considered in the modeling process. As suggested by 
the VIF correction process, Age, BSA, and Wt were excluded to prevent high multicollinearity within 
the independent variables. The AICc values were produced from a modeling procedure in which 
both the ML method and all healthy heart data points (N = 97) were used. 
 
Before moving on to the cross-validation of these 8 potential models in step 4, an important 
clarification needs to be made on what AICc results were presented hereto and the AICc results 
presented henceforth. The “glmulti” function used the maximum likelihood (ML) to calculate the 
AICc values for model comparison [123]. However, the restricted ML (REML) is a more robust and 
preferred method of the ML technique for final model coefficient estimation [129]. When it comes 
to comparing the performance between two or more structural frameworks, by using their AICc 
values, there are well-established statistical reasons the ML, not the REML, needs to be used 
[129,132]. The concerns for using the REML method for model comparison very likely explain why 
the “glmulti” function did not have the REML as an option. Given these listed factors, the REML 
method was used herein for coefficient estimates analysis and final model reporting while the ML 
method was only used for comparisons made between two distinct structural frameworks. 
Nevertheless, REML derived AICc values were still reported herein as an easy method to suggest 
slight performance improvements gained for a specific structural framework through the 
implementation of heteroscedasticity corrections in step 5; however, these REML derived AICc 
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values were not used to make comparisons between distinctly different structural frameworks. In 
summary, the previous exhaustive search modeling AICc values (e.g., Figure 5.2 and Table 5.3), 
using ML, and the REML derived AICc values (to be presented shortly) were not comparable. 
The 8 potential VIF corrected models were k-fold cross-validated in step 4 and their testing 
statistical model metric results were summarized in Tables 5.4-15. The reported results were a 
summarization for each of the testing statistical model metrics by determining each metric’s 
minimum, 1st-quartile, mean, 2nd-quartile (i.e., median), 3rd-quartile, maximum, and standard 
deviation for the 1000 folds. For example, Model 1’s reported mean in Table 5.4, i.e., 65.6mL, was 
calculated by taking the mean of the 1000 MAE values determined for each of the 1000 folds. For 
Tables 5.4-15, the even tables specifically presented the results of the 8 potential models and the 
odd tables focused on making comparisons between the 8 potential modeling and the reference 
modeling results. 
Tables 5.4, 5.6, 5.8, 5.10, 5.12, and 5.14 presented testing statistical model metric result 
summaries for each of the 8 potential models. In-depth cross-validation analysis for each of the 8 
potential models did not identify any major testing error deviations between any of the model 
structural frameworks. The results suggested all 8 models were generally equivalent in prediction 
performance and robustness. The near-equivalent percentage errors, i.e., averaged MAPE (~ 12%) 
and MPE (~ -1%), and their standard deviations for all 8 models were perceived to be reasonable 
for the final model’s intended application – even though these specific percentage metrics have a 
well-established asymmetrical, bias (see discussion). The slight negative MPE values indicated a 
slight over-prediction bias for all 8 potential models. These percentage errors were important to 
consider because, for example, a 50mL allograft prediction error was perceived to be less of a 
concern for a teenager (e.g., a native 800mL TCV heart) then it was for an infant (e.g., a native 
75mL TCV heart). Nevertheless, there was a negligible but detectable trend that Model 2 might 
have performed “best” because it generally had the lowest (or near lowest) testing statistical model 
metric means, medians, and standard deviations. Model 2 specifically had the lowest means, 
medians, and standard deviations for the MSE and RMSE metrics – these two metrics are of 
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particular importance because they penalize larger errors (discussed later). Furthermore, analyze 
of the testing statistical model metrics suggested Model 3 was a close second in performance. 
Tables 5.5, 5.7, 5.9, 5.11, 5.13, and 5.15 compared the performances of the VIF corrected 
and the reference modeling processes though a series of testing statistical model metric 
summaries. The VIF corrected and reference testing metric summaries were derived from the 8 
and 74 potential models, respectively. In general, the lowest AICc reference model testing statistical 
model metric means and medians, for the 1000 folds, were closer to zero then for Model 1 (all 
metrics going to zero would indicate perfect predictions). Although the lowest AICc reference model 
produced better testing statistical model metric results, its corresponding testing statistical model 
metric variances were larger than Model 1’s variances and therefore indicated the reference model 
was less robust. Furthermore, averaging the 8 VIF corrected and 74 reference testing statistical 
model metric means, medians, and standard deviations further suggested (1) the VIF corrected 
models were more robust (had lower variances) and (2) the VIF corrected models, on average, had 
equal or slightly better prediction performances. This reduced robustness of the models produced 
during the reference modeling process was likely a consequence of high collinearity in the data that 
was not corrected. These testing statistical model metric result variations were dependent on the 
developed models’ robustness because the robustness determined how sensitive the results were 
to a specific testing and training dataset combination during a given fold. 
No large deviations between the 8 VIF corrected potential models’ prediction performance 
averages, i.e., testing statistical model metric results, in Tables 5.4-15, were observed in the cross-
validation process. The minimal differences in these 8 models’ performance averages could not 
justify preferential treatment or immediate termination of any models at this point in the modeling 
process. Model 2 and, to lesser extents, Models 3 and 5 did have slight trends suggesting they 
outperformed the other 5 models in prediction capability. However, trends indicated the variance of 
the VIF corrected models increased as the model number, i.e., Model 1, 2, …, 8, increased. Models 
3 and 5, with respect to Model 2, did have larger variances in their prediction performances. The 
averaged performance ranking trends for Models 2, 3 and 5 held with respect to their MSE and 
RMSE metrics. Hereto, cross-validation results suggested Model 2 might be the final structural 
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framework used to predict allograft TCV but given (1) the minimal performance deviations between 
the models and (2) there were less than 10 models to consider, all 8 VIF corrected models were 
moved forward in the modeling process. Henceforth, these 8 models were further considered as 
top potential models in the modeling process. 
 
Potential Models’ Cross-Validated Mean Absolute Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 29.6mL 51.1mL 64.3mL 65.6mL 78.8mL 101.4mL 18.1mL 
2 30.4mL 50.9mL 63.9mL 65.5mL 78.8mL 100.9mL 18.1mL 
3 29.4mL 49.5mL 63.9mL 65.2mL 79.4mL 101.0mL 18.3mL 
4 28.6mL 49.8mL 64.3mL 64.6mL 80.2mL 101.5mL 18.3mL 
5 29.8mL 49.6mL 64.0mL 64.9mL 79.8mL 100.8mL 18.3mL 
6 28.9mL 49.8mL 64.5mL 64.5mL 80.1mL 101.3mL 18.4mL 
7 28.0mL 49.4mL 64.5mL 65.0mL 79.5mL 101.8mL 18.3mL 
8 28.8mL 49.2mL 64.0mL 66.5mL 79.1mL 101.2mL 18.2mL 
Mean 29.2mL 49.9mL 64.2mL 65.2mL 79.5mL 101.2mL 18.2mL 
St. Dev. 0.8mL 0.7mL 0.3mL 0.7mL 0.6mL 0.3mL 0.1mL 
 
Table 5.4: Cross-validation results suggested all 8 models have an averaged testing MAE of 64mL 
and an averaged standard deviation of 18mL. The low standard deviations between the 8 structural 
frameworks’ testing MAE metric means, medians, and individual model standard deviations 
suggested the models were of similar performance and robustness. There were no strong indicates 
that any of the 8 structural frameworks were either far superior or inferior in allograft TCV prediction. 
 
 
 
 
 
 
 
 
 
 
 
  72 
 Mean Absolute Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
re
d
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to
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n
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id
e
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d
 b
y
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IF
 Lowest 
AICc 
Model 
29.6mL 51.1mL 64.3mL 65.6mL 78.8mL 101.4mL 18.1mL 
Mean of 
All 
Potential 
Models 
29.2mL 49.9mL 64.2mL 65.2mL 79.5mL 101.2mL 18.2mL 
St. Dev. 
of All 
Potential 
Models 
0.8mL 0.7mL 0.3mL 0.7mL 0.6mL 0.3mL 0.1mL 
A
ll
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 Lowest 
AICc 
Model 
29.4mL 50.0mL 63.7mL 64.9mL 75.6mL 107.6mL 19.6mL 
Mean of 
All 
Potential 
Models 
30.7mL 49.8mL 64.9mL 66.4mL 77.9mL 107.7mL 19.5mL 
St. Dev. 
of All 
Potential 
Models 
2.4mL 2.2mL 1.5mL 2.3mL 1.8mL 5.3mL 1.0mL 
 
Table 5.5: The lowest AICc VIF corrected and reference models’ cross-validation testing MAE 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
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Potential Models’ Cross-Validated Mean Absolute Percentage Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 5.88% 10.24% 12.07% 12.09% 13.69% 17.14% 2.45% 
2 5.98% 10.27% 12.01% 12.00% 13.58% 17.13% 2.41% 
3 5.82% 10.27% 12.00% 11.90% 13.70% 17.15% 2.46% 
4 5.71% 10.24% 12.06% 12.01% 13.77% 17.16% 2.51% 
5 5.83% 10.37% 12.03% 12.10% 13.70% 17.15% 2.46% 
6 5.73% 10.35% 12.09% 12.15% 13.82% 17.16% 2.51% 
7 5.83% 10.19% 12.17% 11.89% 14.66% 17.04% 2.57% 
8 5.93% 10.13% 12.08% 11.77% 14.23% 17.03% 2.51% 
Mean 5.84% 10.26% 12.06% 11.99% 13.89% 17.12% 2.48% 
St. Dev. 0.09% 0.08% 0.05% 0.13% 0.37% 0.05% 0.05% 
 
Table 5.6: Cross-validation results suggested all 8 models have an averaged testing MAPE of 12% 
and an averaged standard deviation of 2%. The low standard deviations between the 8 structural 
frameworks’ testing MAPE metric means, medians, and individual model standard deviations 
suggested the models were of similar performance and robustness. There were no strong indicates 
that any of the 8 structural frameworks were either far superior or inferior in allograft TCV prediction. 
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 Mean Absolute Percentage Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
re
d
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to
rs
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re
d
 b
y
 V
IF
 Lowest 
AICc 
Model 
5.88% 10.24% 12.07% 12.09% 13.69% 17.14% 2.45% 
Mean of 
All 
Potential 
Models 
5.84% 10.26% 12.06% 11.99% 13.89% 17.12% 2.48% 
St. Dev. 
of All 
Potential 
Models 
0.09% 0.08% 0.05% 0.13% 0.37% 0.05% 0.05% 
A
ll
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rs
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o
n
s
id
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d
 Lowest 
AICc 
Model 
6.81% 9.87% 11.91% 10.86% 13.25% 18.45% 2.90% 
Mean of 
All 
Potential 
Models 
6.73% 10.03% 12.12% 11.38% 13.72% 18.81% 2.88% 
St. Dev. 
of All 
Potential 
Models 
0.77% 0.30% 0.22% 0.38% 0.39% 1.30% 0.37% 
 
Table 5.7: The lowest AICc VIF corrected and reference models’ cross-validation testing MAPE 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
 
 
 
 
 
 
 
 
 
  75 
Potential Models’ Cross-Validated Mean Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 -41.1mL -10.6mL 8.2mL 3.6mL 33.8mL 57.3mL 26.3mL 
2 -40.6mL -10.7mL 8.0mL 4.7mL 32.7mL 58.0mL 26.0mL 
3 -39.8mL -11.0mL 8.0mL 5.8mL 32.0mL 57.4mL 25.5mL 
4 -40.2mL -10.9mL 8.3mL 4.7mL 33.3mL 56.6mL 25.8mL 
5 -39.9mL -10.6mL 8.1mL 5.6mL 31.9mL 57.5mL 25.5mL 
6 -40.4mL -10.5mL 8.3mL 4.6mL 33.2mL 56.7mL 25.7mL 
7 -39.6mL -12.1mL 8.2mL 5.7mL 33.7mL 56.9mL 26.1mL 
8 -39.2mL -12.1mL 7.9mL 6.8mL 32.3mL 57.6mL 25.8mL 
Mean -40.1mL -11.1mL 8.1mL 5.2mL 32.9mL 57.2mL 25.8mL 
St. Dev. 0.6mL 0.7mL 0.2mL 1.0mL 0.8mL 0.5mL 0.3mL 
 
Table 5.8: Cross-validation results suggested all 8 models have an averaged testing ME of 8mL 
and an averaged standard deviation of 26mL. The low standard deviations between the 8 structural 
frameworks’ testing ME metric means, medians, and individual model standard deviations 
suggested the models were of similar performance and robustness. There were no strong indicates 
that any of the 8 structural frameworks were either far superior or inferior in allograft TCV prediction. 
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 Mean Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
re
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y
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IF
 Lowest 
AICc 
Model 
-41.1mL -10.6mL 8.2mL 3.6mL 33.8mL 57.3mL 26.3mL 
Mean of 
All 
Potential 
Models 
-40.1mL -11.1mL 8.1mL 5.2mL 32.9mL 57.2mL 25.8mL 
St. Dev. 
of All 
Potential 
Models 
0.6mL 0.7mL 0.2mL 1.0mL 0.8mL 0.5mL 0.3mL 
A
ll
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 P
re
d
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rs
 C
o
n
s
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e
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d
 Lowest 
AICc 
Model 
-38.6mL -21.4mL 7.1mL 7.2mL 35.3mL 56.7mL 27.0mL 
Mean of 
All 
Potential 
Models 
-41.3mL -15.3mL 7.2mL 6.5mL 32.7mL 58.0mL 26.8mL 
St. Dev. 
of All 
Potential 
Models 
3.0mL 5.7mL 0.8mL 1.6mL 2.9mL 3.9mL 1.0mL 
 
Table 5.9: The lowest AICc VIF corrected and reference models’ cross-validation testing ME 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
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Potential Models’ Cross-Validated Mean Percentage Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 -10.42% -6.61% -1.06% -0.99% 2.31% 8.41% 4.92% 
2 -10.32% -6.55% -1.06% -0.70% 2.19% 8.49% 4.88% 
3 -10.48% -6.45% -1.07% -0.61% 2.06% 8.41% 4.83% 
4 -10.60% -6.49% -1.06% -0.79% 2.19% 8.32% 4.87% 
5 -10.45% -6.53% -1.07% -0.65% 2.04% 8.38% 4.84% 
6 -10.56% -6.59% -1.06% -0.82% 2.17% 8.28% 4.88% 
7 -10.87% -6.19% -0.94% -0.78% 2.85% 8.57% 4.93% 
8 -10.72% -6.20% -0.96% -0.48% 2.34% 8.66% 4.88% 
Mean -10.55% -6.45% -1.04% -0.73% 2.27% 8.44% 4.88% 
St. Dev. 0.18% 0.17% 0.05% 0.15% 0.26% 0.13% 0.03% 
 
Table 5.10: Cross-validation results suggested all 8 models have an averaged testing MPE of -1% 
and an averaged standard deviation of 5%. The low standard deviations between the 8 structural 
frameworks’ testing MPE metric means, medians, and individual model standard deviations 
suggested the models were of similar performance and robustness. There were no strong indicates 
that any of the 8 structural frameworks were either far superior or inferior in allograft TCV prediction. 
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 Mean Percentage Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
re
d
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y
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IF
 Lowest 
AICc 
Model 
-10.42% -6.61% -1.06% -0.99% 2.31% 8.41% 4.925 
Mean of 
All 
Potential 
Models 
-10.55% -6.45% -1.04% -0.73% 2.27% 8.44% 4.88% 
St. Dev. 
of All 
Potential 
Models 
0.18% 0.17% 0.05% 0.15% 0.26% 0.13% 0.03% 
A
ll
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d
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rs
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o
n
s
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d
 Lowest 
AICc 
Model 
-12.48% -5.67% -1.05% -0.31% 2.56% 9.33% 5.09% 
Mean of 
All 
Potential 
Models 
-12.14% -5.60% -1.07% -0.41% 2.49% 9.12% 5.02% 
St. Dev. 
of All 
Potential 
Models 
1.47% 0.80% 0.09% 0.35% 0.39% 0.65% 0.15% 
 
Table 5.11: The lowest AICc VIF corrected and reference models’ cross-validation testing MPE 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
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Potential Models’ Cross-Validated Mean Square Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 1317mL2 3231mL2 8715mL2 10270mL2 12280mL2 16380mL2 4609mL2 
2 1374mL2 3195mL2 8634mL2 10280mL2 12550mL2 15850mL2 4555mL2 
3 1322mL2 3052mL2 8646mL2 10120mL2 12360mL2 16320mL2 4601mL2 
4 1264mL2 3086mL2 8736mL2 10560mL2 12350mL2 16900mL2 4668mL2 
5 1336mL2 3070mL2 8651mL2 10190mL2 12330mL2 16470mL2 4605mL2 
6 1277mL2 3105mL2 8743mL2 10630mL2 12290mL2 17050mL2 4675mL2 
7 1265mL2 3031mL2 8781mL2 10650mL2 12690mL2 16560mL2 4685mL2 
8 1317mL2 3001mL2 8691mL2 10660mL2 12690mL2 15990mL2 4627mL2 
Mean 1309mL2 3096mL2 8700mL2 10420mL2 12443mL2 16440mL2 4628mL2 
St. Dev. 38mL2 79mL2 53mL2 227mL2 174mL2 408mL2 45mL2 
 
Table 5.12: Cross-validation results suggested all 8 models have an averaged testing MSE of 
8700mL2 and an averaged standard deviation of 4628mL2. The low standard deviations between 
the 8 structural frameworks’ testing MSE metric means, medians, and individual model standard 
deviations suggested the models were of similar performance and robustness. There were no 
strong indicates that any of the 8 structural frameworks were either far superior or inferior in allograft 
TCV prediction. 
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 Mean Square Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
re
d
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s
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IF
 Lowest 
AICc 
Model 
1317 
mL2 
3231 
mL2 
8715 
mL2 
10270 
mL2 
12280 
mL2 
16380 
mL2 
4609 
mL2 
Mean of 
All 
Potential 
Models 
1309 
mL2 
3096 
mL2 
8700 
mL2 
10420 
mL2 
12443 
mL2 
16440 
mL2 
4628 
mL2 
St. Dev. 
of All 
Potential 
Models 
38 
mL2 
79 
mL2 
53 
mL2 
227 
mL2 
174 
mL2 
408 
mL2 
45 
mL2 
A
ll
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d
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rs
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d
 Lowest 
AICc 
Model 
1337 
mL2 
3112 
mL2 
8646 
mL2 
9311 
mL2 
11830 
mL2 
17130 
mL2 
4840 
mL2 
Mean of 
All 
Potential 
Models 
1460 
mL2 
3260 
mL2 
8862 
mL2 
10208 
mL2 
12374 
mL2 
17618 
mL2 
4945 
mL2 
St. Dev. 
of All 
Potential 
Models 
247 
mL2 
374 
mL2 
226 
mL2 
680 
mL2 
635 
mL2 
1727 
mL2 
301 
mL2 
 
Table 5.13: The lowest AICc VIF corrected and reference models’ cross-validation testing MSE 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
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Potential Models’ Cross-Validated Root Mean Square Errors 
Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. Dev. 
1 36.3mL 56.8mL 89.1mL 101.3mL 110.8mL 128.0mL 27.9mL 
2 37.1mL 56.5mL 88.7mL 101.4mL 112.0mL 125.9mL 27.8mL 
3 36.4mL 55.2mL 88.7mL 100.6mL 111.2mL 127.8mL 28.0mL 
4 35.6mL 55.6mL 89.2mL 102.7mL 111.1mL 130.0mL 28.1mL 
5 36.6mL 55.4mL 88.7mL 101.0mL 111.0mL 128.3mL 28.0mL 
6 35.7mL 55.7mL 89.2mL 103.1mL 110.8mL 130.6mL 28.1mL 
7 35.6mL 55.1mL 89.3mL 103.2mL 112.6mL 128.7mL 28.3mL 
8 36.3mL 54.8mL 88.9mL 103.2mL 112.7mL 126.5mL 28.2mL 
Mean 36.2mL 55.6mL 89.0mL 102.1mL 111.5mL 128.2mL 28.0mL 
St. Dev. 0.5mL 0.7mL 0.3mL 1.1mL 0.8mL 1.6mL 0.2mL 
 
Table 5.14: Cross-validation results suggested all 8 models have an averaged testing RMSE of 
89mL and an averaged standard deviation of 28mL. The low standard deviations between the 8 
structural frameworks’ testing RMSE metric means, medians, and individual model standard 
deviations suggested the models were of similar performance and robustness. There were no 
strong indicates that any of the 8 structural frameworks were either far superior or inferior in allograft 
TCV prediction. 
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 Root Mean Square Errors: Summary and Comparison 
 Model Minimum 1st-Qt Mean 2nd-Qt 
(Median) 
3rd-Qt Maximum St. 
Dev. 
P
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IF
 Lowest 
AICc 
Model 
36.3mL 56.8mL 89.1mL 101.3mL 110.8mL 128.0mL 27.9mL 
Mean of 
All 
Potential 
Models 
36.2mL 55.6mL 89.0mL 102.1mL 111.5mL 128.2mL 28.0mL 
St. Dev. 
of All 
Potential 
Models 
0.5mL 0.7mL 0.3mL 1.1mL 0 .8mL 1.6mL 0.2mL 
A
ll
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o
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s
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d
 Lowest 
AICc 
Model 
36.6mL 55.8mL 88.5mL 96.5mL 108.7mL 130.9mL 28.7mL 
Mean of 
All 
Potential 
Models 
38.1mL 57.0mL 89.6mL 101.0mL 111.2mL 132.6mL 29.0mL 
St. Dev. 
of All 
Potential 
Models 
3.2mL 3.2mL 1.2mL 3.4mL 2.9mL 6.4mL 1.0mL 
 
Table 5.15: The lowest AICc VIF corrected and reference models’ cross-validation testing MAE 
means, medians, and standard deviations might have suggested the reference modeling process 
produced the “best” prediction model. However, the improved performance of the reference 
modeling process, with respect to the VIF correction process, was generally minimal, was not 
consistent for all models, and came at the cost of increased error variance. 
 
The 8 top potential models were investigated to determine if the specifications needed to 
be refined to account for heteroscedasticity. The Breusch-Pagan test results rejected the null 
hypothesis of homoscedasticity, i.e., heteroscedasticity was suggested, for all 8 models (p-values 
<< 0.05) and the results were presented in Table 5.16. The reported Table 5.16 results were 
determined using the REML to estimate the coefficients and therefore the reported AICc values 
were neither comparable to the earlier “glmulti” AICc values nor between the models within Table 
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5.16 due to the varied structural frameworks. However, the AICc values were presented in Tables 
5.16 and 5.17 to allow for a simple investigate in determining if heteroscedasticity corrections 
improved the overall prediction performances of a specific structural framework. 
 
Testing for Heteroscedasticity 
Model N Breusch-Pagan test 
P-Value 
AICc 
1 97 0.01 -63.82 
2 97 0.01 -60.56 
3 97 0.01 -59.49 
4 97 0.01 -62.71 
5 97 0.01 -62.47 
6 97 0.01 -65.69 
7 97 0.01 -61.98 
8 97 0.01 -58.74 
 
Table 5.16: The Breusch-Pagan test suggested strong heteroscedasticity for all 8 models (p-values 
<< .05) that very likely needed to be addressed to improve model performance. The presented p-
values were not exactly equal to 0.01 but rather this reflects a round off error in the precision. The 
results were determined using the REML. 
 
Two methods to correct for heteroscedasticity were considered in step 5. The Breusch-
Pagan test and AICc value results, reflecting after the heteroscedasticity corrections were 
implemented, were included in Tables 5.17.  
The first correction method used the R “varClass” functions to correct heteroscedasticity 
by applying weights to re-estimate the coefficients. The coefficients were re-estimated such that 
the models were made more robust to heteroscedasticity. The “varClass” functions results in Table 
5.17 did generally show negligible p-value improvements for the Breusch-Pagan test, howver, they 
were outside the reported precision in Tables 5.16 and 5.17. The slight decrease in the AICc values 
between the same structural frameworks in Tables 5.16 and 5.17 did support the implementation 
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of the “varClass” functions did improve the overall models’ performances. Although improvements 
were observed, the Breusch-Pagan test still detected heteroscedasticity in all 8 models.  
The second correction method used a Cook’s distance correction method to identify and 
remove influential outliers that might have caused the measurable heteroscedasticity presented in 
the models. The Cook’s distance method results in Table 5.17 showed large increases in the 
Breusch-Pagan test p-values and large decreases in the AICc values. These large changes in the 
p-values and AICc values strongly suggested the Cook’s distance method was a much more 
effective method at addressing the heteroscedasticity in the data and the models’ overall 
performances. In fact, Cook’s distance method performed so well at addressing heteroscedasticity 
that the Breusch-Pagan test failed to reject the null hypothesis of homoscedasticity for all 8 models. 
These superior, intermediate results justified the use of the Cook’s distance method to correct the 
heteroscedasticity issues for all 8 top models. 
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Heteroscedasticity Correction Results 
 “varClass” Weight Corrected Cook’s Distance Corrected 
Model N Breusch-Pagan test 
P-value 
AICc N Breusch-Pagan test 
P-value 
AICc 
1 97 0.01 -66.16 92 0.73 -85.08 
2 97 0.01 -62.96 92 0.69 -83.14 
3 97 0.01 -61.86 92 0.71 -82.32 
4 97 0.01 -64.91 92 0.74 -84.13 
5 97 0.01 -64.69 92 0.72 -85.42 
6 97 0.01 -68.06 92 0.75 -87.25 
7 97 0.01 -64.51 91 0.49 -86.13 
8 97 0.01 -61.43 91 0.49 -84.40 
 
Table 5.17: Breusch-Pagan test and AICc values demonstrated, when compared to the Table 5.16 
results, the “varClass” and Cook’s distance methods helped to correct the heteroscedasticity and 
improve the overall models’ performances. The “varClass” Breusch-Pagan test p-values did 
generally improve but the quantitative change was outside the reported precision. The Cook’s 
distance method performed superiorly in correcting the heteroscedasticity issues and improving 
overall model’s performances. The results were determined using the REML. 
 
 After Cook’s distance was shown to improve heteroscedasticity detected in the data, the 8 
top potential models had their coefficients re-estimated using REML and Cook’s distance. In 
addition to addressing heteroscedasticity in the data, the Cook’s distance method also helped to 
remove influential outliers that could negatively impact the final model. The 8 top potential model 
structural frameworks and coefficient estimates were presented in Tables 5.18 to 5.25. As Table 
5.17 indicates, these 8 models estimated coefficients were trained with either 92 or 91 data points, 
i.e., Cook’s distance identified 5 or 6 influential outliers to remove in the modeling process. Once 
the models’ coefficients were re-estimated, the coefficients were investigated to determine if they 
were statistically-significant in step 6. 
All estimated coefficients for Models 1 to 6, i.e., Tables 5.18 to 5.23, were statistically-
significant (p-values << 0.025). There were estimated coefficients in Models 7 and 8, i.e., Tables 
5.24 and 5.25, that were statistically non-significant (p-values >> 0.025) and therefore could 
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negatively affect the models’ robustness. The non-significant estimated coefficients in Models 7 
and 8 were terms containing the Sex variable. The larger reported estimated coefficient SEs and 
smaller t-value magnitudes for Models 7 and 8 supported these models were less robust than for 
Models 1 to 6 and therefore justified the insignificant terms should be considered for removal. 
Iteratively removing the largest p-values ≥ 0.025 demonstrated Models 7 and 8 were 
permutations of Models 4 and 3, respectively. As was expected, removing the non-significant 
estimated coefficients improved the remaining estimated coefficient SEs and t-value magnitudes 
of Model 7 and 8 because their structural frameworks became that of Models 4 and 3, respectively. 
The ln(Ht) estimated coefficients, SEs, and t-value magnitudes for the 8 top VIF corrected models 
were compiled in Table 5.27 (the table will be further discussed shortly) to help investigate the 
robustness of the models. The larger ln(Ht) estimated coefficient SEs and smaller t-value 
magnitudes for Models 7 and 8 further demonstrated that these models were less robust than 
Models 1 to 6. As was expected, the SEs and t-value magnitudes for ln(Ht) in Models 7 and 8 were 
seen to improve in Table 5.27 when their structural frameworks reduced to Models 4 and 3, 
respectively. Given the removal of the insignificant coefficient terms reduced the structural 
frameworks of Models 7 and 8 to Models 4 and 3, respectively, there were only 6 final models of 
interest and no need to re-estimate the coefficients a final time. Although the results suggested 
Models 7 and 8 were no longer models of interest to predict allograft TCV, they continued to be 
analyzed herein to confirm the intermediate finding. 
The lowest “glmulti” AICc reference model’s structural framework and estimate coefficients 
was presented in Table 5.26 such that it could be compared to Tables 5.18 to 5.25. Given the 
lowest AICc reference model had large estimate coefficient SEs, low t-value magnitudes, and 
statistically-insignificant p-values (> 0.05) suggest the reference model was not robust. For a closer 
comparison of model robustness between the 8 top VIF and the 8 top non-VIF corrected models, 
Table 5.27 (briefly mentioned) was created in which the ln(Ht) estimated coefficients, SEs, and t-
value magnitudes were isolated because they were present in all 16 models. The table shows the 
ln(Ht) estimated coefficients, SEs and t-value magnitudes for the 8 top models were relatively stable 
and did not show signs of classical multicollinearity issues. However, the ln(Ht) estimated 
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coefficients, SEs, and t-value magnitudes for the reference set were unstable – this was a classical 
sign of strong multicollinearity [108,109]. This finding appeared to confirm the earlier indication that 
failing to account for multicollinearity in the reference modeling process reduced these models’ 
robustness. 
 Before moving on to identify the final, “best” allograft TCV prediction model in this initial 
modeling process, instructions on how to use these models are warranted. To predict TCV from 
any of these 9 models, i.e., Tables 5.18 to 5.26, the user is to use the appropriate “Modeled log-
log Transform Equation”. The inputted units for Age, Ht, Wt, BSA, and BMI are required to be 
months, cm, kg, m2, and kg/m2, respectively. Sex is a dummy variable in which male is numerically 
code as “1” and female is “0”. The model outputs the predicted allograft TCV in mL. The ln( ) and 
exp( ) functions forward transform the predictors and backward transform the TCV, respectively. 
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Final Results for Initial Modeling Process: Model 1 
Structural Framework (R software notation) 
TCV ~ 1 + Ht + BMI + BMI:Sex 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) + 𝛂𝟒 ∗ ln(BMI) ∗ Sex 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) + 𝛂𝟒 ∗ ln(BMI) ∗ Sex) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -5.509098 0.26960075 -20.43428 0.00E+00 
𝜶𝟐 2.072416 0.06270071 33.05252 0.00E+00 
𝜶𝟑 0.41489 0.05708467 7.26798 0.00E+00 
𝜶𝟒 0.038364 0.00914381 4.19566 1.00E-04 
     
     
 
Table 5.18: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (<< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht and BMI increases with TCV. 
The interaction term of BMI with Sex suggested BMI had an additional, positive effect on the TCVs 
of males. 
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Final Results for Initial Modeling Process: Model 2 
Structural Framework (R software notation) 
TCV ~ 1 + Ht + BMI:Sex + Ht:BMI 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -4.325414 0.30333033 -14.259746 0.00E+00 
𝜶𝟐 1.834874 0.08288294 22.138135 0.00E+00 
𝜶𝟑 0.037606 0.00908287 4.140354 1.00E-04 
𝜶𝟒 0.083182 0.01122548 7.410076 0.00E+00 
     
     
 
Table 5.19: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (<< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht increases with TCV. The 
interaction term of BMI with Sex suggested BMI had an additional, positive effect on the TCVs of 
males. The interaction term of BMI with Ht suggested BMI had a larger, positive effect on the TCVs 
of taller individuals. 
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Final Results for Initial Modeling Process: Model 3 
Structural Framework (R software notation) 
TCV ~ 1 + Ht + Ht:Sex + Ht:BMI 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(Ht) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(Ht) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -4.25571 0.30258291 -14.064608 0.00E+00 
𝜶𝟐 1.806543 0.08290397 21.790791 0.00E+00 
𝜶𝟑 0.023339 0.0056087 4.161122 1.00E-04 
𝜶𝟒 0.087798 0.01119582 7.841997 0.00E+00 
     
     
 
Table 5.20: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (<< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht increases with TCV. The 
interaction term of Ht with Sex suggested Ht had an additional, positive effect on the TCVs of males. 
The interaction term of BMI with Ht suggested BMI had a larger, positive effect on the TCVs of taller 
individuals. 
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Final Results for Initial Modeling Process: Model 4 
Structural Framework (R software notation) 
TCV ~ 1 + Ht + BMI + Ht:Sex 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) + 𝛂𝟒 ∗ ln(Ht) ∗ Sex 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(BMI) + 𝛂𝟒 ∗ ln(Ht) ∗ Sex) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -5.504916 0.26956228 -20.42169 0.00E+00 
𝜶𝟐 2.056973 0.0628142 32.74695 0.00E+00 
𝜶𝟑 0.438429 0.05703488 7.68704 0.00E+00 
𝜶𝟒 0.02374 0.00565636 4.19708 1.00E-04 
     
     
 
Table 5.21: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (<< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht and BMI increases with TCV. 
The interaction term of Ht with Sex suggested Ht has an additional, positive effect on the TCVs of 
males. 
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Final Results for Initial Modeling Process: Model 5 
Structural Framework (R software notation) 
TCV ~ 1 + Sex + Ht + Ht:BMI 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(Ht) ∗ ln(BMI)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -4.352287 0.30370611 -14.330586 0.00E+00 
𝜶𝟐 0.115883 0.02795277 4.145687 1.00E-04 
𝜶𝟑 1.826155 0.08283307 22.046205 0.00E+00 
𝜶𝟒 0.087737 0.01120223 7.832095 0.00E+00 
     
     
 
Table 5.22: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (<< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht increases with TCV. The 
model also suggested TCVs were larger in males. The interaction term of BMI with Ht suggested 
BMI had a larger, positive effect on the TCVs of taller individuals. 
 
 
 
 
 
 
 
 
 
 
  93 
Final Results for Initial Modeling Process: Model 6 
Structural Framework (R software notation) 
TCV ~ 1 + Sex + Ht + BMI 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(BMI) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(BMI)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -5.602321 0.27121305 -20.65653 0.00E+00 
𝜶𝟐 0.117915 0.0281886 4.18306 1.00E-04 
𝜶𝟑 2.076736 0.06273797 33.10174 0.00E+00 
𝜶𝟒 0.438145 0.05706414 7.67811 0.00E+00 
     
     
 
Table 5.23: The model’s final estimated coefficients were trained with N = 92 healthy heart data 
points. All estimated coefficient p-values were statistically-significant (< 0.025) and suggested the 
model estimates were robust. The model suggested an individual’s Ht and BMI increases with TCV. 
The model also suggested TCVs were larger in males. 
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Final Results for Initial Modeling Process: Model 7 
Structural Framework (R software notation) 
TCV ~ 1 + Sex + Ht + BMI + Sex:Ht 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(BMI) + 𝛂𝟓 ∗ Sex ∗ ln(Ht) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ ln(BMI) + 𝛂𝟓 ∗ Sex ∗ ln(Ht)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -5.138692 0.6436249 -7.983985 0 
𝜶𝟐 -0.387835 0.7059376 -0.54939 0.5842 
𝜶𝟑 1.993095 0.1330423 14.980915 0 
𝜶𝟒 0.4258 0.0562411 7.570971 0 
𝜶𝟓 0.09972 0.14162 0.704141 0.4832 
     
 
Table 5.24: The model’s final estimated coefficients were trained with N = 91 healthy heart data 
points. Two of the estimated coefficient p-values were not statistically-significant (> 0.05) and 
suggested not all model estimates were robust. Setting the coefficient with the largest p-value, i.e., 
𝜶𝟐, to zero effectively removed that corresponding term from the model. Removing the  𝜶𝟐 related 
term converted Model 7 to Model 4. This result suggested Model 7 was a less robust permutation 
of Model 4. The model had insignificant terms and therefore the coefficients were not interpreted.  
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Final Results for Initial Modeling Process: Model 8 
Structural Framework (R software notation) 
TCV ~ 1 + Sex + Ht + Sex:Ht + Ht:BMI 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ Sex ∗ ln(Ht) + 𝛂𝟓 ∗ ln(Ht) ∗ ln(BMI) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ Sex + 𝛂𝟑 ∗ ln(Ht) + 𝛂𝟒 ∗ Sex ∗ ln(Ht) + 𝛂𝟓 ∗ ln(Ht) ∗ ln(BMI)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 -3.906945 0.6547818 -5.966788 0 
𝜶𝟐 -0.408828 0.6997865 -0.584219 0.5606 
𝜶𝟑 1.745897 0.1428938 12.218146 0 
𝜶𝟒 0.103541 0.1403862 0.737544 0.4628 
𝜶𝟓 0.085355 0.0110317 7.737252 0 
     
 
Table 5.25: The model’s final estimated coefficients were trained with N = 91 healthy heart data 
points. Two of the estimated coefficient p-values were not statistically-significant (> 0.05) and 
suggested not all model estimates were robust. Setting the coefficient with the largest p-value, i.e., 
𝜶𝟐, to zero effectively removed that corresponding term from the model. Removing the  𝜶𝟐 related 
term converted Model 8 to Model 3. This result suggested Model 8 was a less robust permutation 
of Model 3. The model had insignificant terms and therefore the coefficients were not interpreted. 
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Final Results for Reference Model with Lowest AICc Rank 
Structural Framework (R software notation) 
TCV ~ 1 + Ht + Age:Sex + Ht:Sex + Ht:Wt 
Modeled log-log Transform Equation 
ln(TCV) = 𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(Age) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ Sex + 𝛂𝟓 ∗ ln(Ht) ∗ ln(Wt) 
or 
TCV = exp(𝛂𝟏 + 𝛂𝟐 ∗ ln(Ht) + 𝛂𝟑 ∗ ln(Age) ∗ Sex + 𝛂𝟒 ∗ ln(Ht) ∗ Sex + 𝛂𝟓 ∗ ln(Ht) ∗ ln(Wt)) 
Coefficients Value SE t-value p-value 
𝜶𝟏 0.2576417 0.7809469 0.329909 0.7423 
𝜶𝟐 0.8502569 0.192942 4.4068 0 
𝜶𝟑 0.0771641 0.0399931 1.929435 0.057 
𝜶𝟒 -0.0549694 0.0389858 -1.409984 0.1622 
𝜶𝟓 0.0840404 0.0107574 7.812332 0 
     
 
Table 5.26: The model’s final estimated coefficients were trained with N = 91 healthy heart data 
points. Three of the estimated coefficient p-values were not statistically-significant (> 0.05) and 
suggested the model estimates were not robust. The fact that this model (1) had the lowest AICc 
value, (2) had statistically-insignificant estimate coefficients, and (3) did not undergo VIF correction, 
suggested that failing to account for multicollinearity might have affected the robustness of the 
models derived in the reference modeling procedure. The model had insignificant terms and 
therefore the coefficients were not interpreted. 
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  Final ln(Ht) Coefficient Comparison for the 8 Top AICc Models   
 VIF Corrected Reference (non-VIF Corrected) 
Model Coefficient 
Value 
SE t-value Coefficient Value SE t-value 
1 2.072 0.063 33.053 0.850 0.193 4.407 
2 1.835 0.083 22.138 0.740 0.203 3.646 
3 1.807 0.083 21.791 1.388 0.422 3.289 
4 2.057 0.063 32.747 1.262 0.422 2.991 
5 1.826 0.083 22.046 2.635 0.324 8.135 
6 2.077 0.063 33.102 0.844 0.194 4.342 
7 1.993 0.133 14.981 0.760 0.234 3.247 
8 1.746 0.143 12.218 1. 338 0. 346 3.868 
Mean 1.927 0.089 24.010 1.211 0.285 4.241 
St. Dev. 0.137 0.032 8.226 0.677 0.104 1.654 
 
Table 5.27: The 8 lowest AICc value models for both the VIF corrected and reference modeling 
procedures were presented with their estimated coefficients, SEs, and t-value magnitudes. A one-
way ANOVA confirmed the ln(Ht) estimated coefficients (p-value = 0.0082, effect size = 1.46) and 
SEs (p-value ≤ 0.0001, effect size = 2.54) were statistically different between the modeling 
procedures. The statistical difference between the two modeling procedure estimate coefficients 
and the reference procedure’s larger SEs and smaller t-value magnitudes suggested there is a 
large, classical multicollinearity issue in the reference models. Finding that the reference models 
suffer from multicollinearity was expected given the VIF procedure was intentionally skipped. 
 
Hereto multicollinearity, heteroscedasticity, and influential outlier issues were tested and 
corrected for in the modeling process. The 8 models’ coefficients were already re-estimated using 
the REML method with all 97 data points (excluding the influential outliers identified by Cook’s 
distance) and presented in Tables 5.18 to 5.25. The 8 models’ final testing statistical modeling 
metrics were re-estimated with a second, final cross-validation in which the modeling corrections 
were included. The final testing metric results were presented in Table 5.28. The need to cross-
validate the final testing statistical model metric results derived from the limited data available to 
formally set aside for testing with the recognition that training errors do not represent testing errors. 
The final analysis of the testing statistical modeling metric results was needed to (1) determine if 
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the decreased robustness of Models 7 and 8 had an effect on the Models’ predictive capabilities 
and (2) identify a final model for predicting allograft TCVs from donor parameters. It is worth 
explicitly stating that the second, final cross-validation procedure did not use the estimate 
coefficients in Tables 5.18 to 5.25 to estimate the final testing statistical model metric results.  
The initial inspection of the 48-individual testing statistical model metric results in Table 
5.28 demonstrated a challenge in identifying the “best” model. The challenge in identifying the 
“best” model was there were minor differences in the models’ errors and the models’ ranking order 
fluctuated, based on which specific metric was being analyzed. Therefore, the results in Table 5.28 
were reported in Table 5.29 as a numeric ranking based on the sequential order for each model 
within a given metric. A value of 1 was given to the model with the most preferable metric value for 
that given metric. For all statistical modeling metrics, values approaching zero were preferable. 
Table 5.29 presents the final, model sequential ranks for each metric (numeric, color-coded) and 
the overall model performance (row, color-coded). Red, green, and blue indicate 1st, 2nd, and 3rd 
place rankings. To simplify the model ranking assessments, the ranking means, medians, and 
totals for each of the statistical models were reported such that each metric was given an equal 
weighting of consideration. 
Models 2 and 5 dominated 1st and 2nd places in Table 5.29. Models 3 and 8 fluctuated 
between 3rd and 4th place, this was an interesting find because Model 8 is a permutation of Model 3. 
Model 8 had a lower mean and total ranking while Model 3 had a lower “glmulti” AICc and better 
median, MSE, and RMSE rankings. In fact, Model 3 outperformed Model 8 in ranking for all test 
statistical metrics except for the testing ME and MPE results. The MSE and RMSE are a special 
set of metrics are special set metrics are often used or recommended for use to analysis model 
errors because they increase the penalty for larger errors [108,118,133]. Furthermore, the MAPE 
and MPE are asymmetric error metrics that have an under-prediction penalty bias (discussed later). 
To address the under-prediction penalty bias, Table 5.30 presents the symmetrically corrected 
MAPE and MPE values, i.e. sMAPE and sMPE values. Although Model 3 and 8’s MAPE ranking 
showed no major change, there was a large change between the MPE and sMPE rankings. In 
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replacing the MAPE and MPE values for the sMAPE and sMPE values, the ranking means, 
medians, and totals strengthened Models’ 2, 5, and 3’s rankings. Given: 
 
1) Model 8 was a permutation of Model 3 with insignificant coefficients, 
2) Model 8 had larger testing metric error variances (as demonstrated in step 4), 
3) Model 3’s ranking was greatly reduced when MPE was replaced with sMPE, and 
4) Model 3 outperformed in MSE and RMSE rankings, 
 
it was concluded that Model 3 outperformed Model 8. Therefore, Model 3 took a ranking of 3rd place 
in the modeling process. To appreciate the final model selection process, an overview of what error 
attributes were being highlighted by each of the metrics will be discussed in the next section.  
 Model 2 was ranked 1st in the selection process and therefore it was ultimately determined 
to be the final, i.e., “best”, allograft TCV prediction model derived from the initial modeling process. 
Model 2 was interchangeable referred to as Model A because it was the final model in the initial 
modeling process. The Model 2 terminology was generally reserved henceforth when comparisons 
of Model A to the other 7 initial, potential models were made, otherwise the Model A terminology 
was preferential. The term “A” was used because after a preliminary assessment of the initial 
modeling procedural results a few modeling procedural changes were made to try and improve the 
final allograft TCV prediction model in an upcoming section. 
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Final Testing Statistical Model Metric Results 
Model MAE MAPE ME MPE MSE RMSE 
1 64.220mL 12.253% 5.801mL -1.037% 8578mL2 92.620mL 
2 63.795mL 12.190% 5.431mL -1.079% 8497mL2 92.180mL 
3 63.956mL 12.211% 5.732mL -1.088% 8552mL2 92.478mL 
4 64.411mL 12.279% 6.112mL -1.035% 8646mL2 92.983mL 
5 63.870mL 12.187% 5.643mL -1.075% 8536mL2 92.389mL 
6 64.416mL 12.275% 6.065mL -1.036% 8647mL2 92.991mL 
7 64.799mL 12.487% 5.894mL -0.956% 8694mL2 93.243mL 
8 64.107mL 12.356% 5.484mL -1.012% 8566mL2 92.552mL 
 
Table 5.28: The presented results were the final testing statistical model metric results used to 
identify the final prediction model in the initial modeling protocol. Starting with N = 97 data points, 
results were determined with 10-fold cross-validation, REML, and Cook’s distance. 
 
Final Ranked Testing Statistical Model Metric Results 
Model MAE MAPE ME MPE MSE RMSE Mean Median Total 
1 5 4 5 5 5 5 4.8 5.0 29.0 
2 1 2 1 7 1 1 2.2 1.0 13.0 
3 3 3 4 8 3 3 4.0 3.0 24.0 
4 6 6 8 3 6 6 5.8 6.0 35.0 
5 2 1 3 6 2 2 2.7 2.0 16.0 
6 7 5 7 4 7 7 6.2 7.0 37.0 
7 8 8 6 1 8 8 6.5 8.0 39.0 
8 4 7 2 2 4 4 3.8 4.0 23.0 
 
Table 5.29: To ease interpretation of the final testing statistical model metric results, models were 
given a ranking of 1 to 8 for each individual metric in which 1 was considered “best”. Colored 
numbers and rows indicated 1st (red), 2nd (green), and 3rd (blue) placed models in performance by 
specific metric and overall model, respectively. Metric ranking means, medians, and totals were 
taken to summarize model performance rankings. Model 2 generally outperformed all other models; 
this finding suggests Model 2 was the “best” allograft TCV prediction model within the initial 
modeling process. Model 2’s MSE and RMSE were ranked 1stl, this result further supports Model 
2 was the “best” model. 
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Final Ranked Testing Statistical Model Metric Results with sMAPE and sMPE 
Model sMAPE sMAPE MAPE sMPE sMPE MPE Mean Median Total 
 Value Rank Rank Value Rank Rank Rank Rank Rank 
1 12.08% 4 4 0.16% 4 5 4.7 5.0 28.0 
2 12.01% 1 2 0.12% 2 7 1.2 1.0 7.0 
3 12.03% 3 3 0.11% 1 8 2.8 3.0 17.0 
4 12.11% 5 6 0.16% 5 3 6.0 6.0 36.0 
5 12.02% 2 1 0.12% 3 6 2.3 2.0 14.0 
6 12.11% 6 5 0.16% 6 4 6.7 7.0 40.0 
7 12.35% 8 8 0.29% 8 1 7.7 8.0 46.0 
8 12.21% 7 7 0.22% 7 2 4.7 4.0 28.0 
 
Table 5.30: The asymmetrical MAPE and MPE results were replaced in the current table with the 
sMAPE and sMPE metrics. The sMAPE and sMPE metrics address a well-established under-
prediction penalty bias in the MAPE and MPE metrics. The ranking means, medians, and totals 
were recalculated after the MAPE and MPE metrics were replaced. The testing statistical model 
metric symmetry corrections increased support for Models 2, 5, and 3 to be ranked 1st, 2nd, and 3rd, 
respectively. Interestingly, by making the symmetric testing statistical model metric corrections, the 
MPE related metric rankings for Models 2, 5, and 3 (i.e., 1st, 2nd, and 3rd place models) went from 
7th, 6th, and 8th place to 2nd, 3rd, and 1st place. 
 
 Graphical representations of the final 10-fold cross-validated prediction results for Model A 
were presented with respect to the mTCVs in Figures 5.3 and 5.4. The pTCV values were 
determined by averaging the 100 10-fold cross-validation prediction results. Visual inspection of 
these figures generally suggested the errors fluctuate about the slope (line) of unity, i.e., the solid, 
black line. Model A’s residual distribution was presented in Figures 5.5 and 5.6 with both a quantile-
quantile plot and histogram plot, respectively. Although visual inspection of the histogram in Figure 
5.6 might be interrupted as being normal distributed; the normal quantile-quantile map presents 
“tails” suggested the residuals were not normality distributed. The null hypothesis of normality was 
rejected (p-value = 0.0002) with a Shapiro-Wilk test and therefore generally confirmed the errors 
were not normally distributed. The visual inspection of these residual plots suggested only mild 
deviation from normality, as is typically expected in real world empirical data. There was no 
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perceived indication this discrepancy from the normality assumption harmed the overall prediction 
capability of Model A and the overall initial modeling process. 
 
Model A’s pTCV vs. the mTCV 
 
Figure 5.3: The 10-fold cross-validated pTCV values (N = 97) for Model A were plotted against their 
corresponding mTCV values in a “predicted vs. actual” graph. Allograft TCV data points above or 
below the diagonal line indicated over- or under-predictions, respectively. Visual inspection of the 
graph suggested (1) Model A’s absolute error increased as the TCV increased and (2) Model A has 
a specific bias for under predicting in the largest of TCVs. 
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Relative Error between Model A’s pTCV and the mTCV 
 
Figure 5.4: Model A pTCV values (N = 97) were represented in a “relative error” graph to visualize 
how the prediction errors propagated as the allograft mTCVs increased. Visual inspection 
suggested no relative error bias until the mTCVs had reached a volume of approximately 750mL 
or greater – was also seen in Figure 5.3. Although the errors of Model A increased, as was shown 
in Figure 5.3, visual inspection of the current Figure suggested the relative errors held relatively 
constant. Dashed lines show ±25% relative error bandwidth. 
 
Normal Q-Q Plot for Model A’s pTCV Residuals 
 
Figure 5.5: A normal Quantiles-Quantiles plot was presented to investigate the normality 
assumption of the Model A pTCV residuals. These plots suggest the increased likelihood of 
normality as the residuals better fit a single, linear line. The residuals herein generally fitted a linear 
line with the exception of visually appearing mild “tails” to suggested a near-normal distribution was 
present. A Shapiro-Wilk test rejected the null hypothesis of normality (p-value = 0.0002) to further 
confirm the lack of normality. 
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Histogram for Model A’s pTCV Residuals 
 
Figure 5.6: A frequency plot was created with the Model A pTCV residuals placed in one of 14 
histogram containers. Visual inspection of the plot suggested either the residuals had a normal or 
near-normal distribution. The continuous curve (blue) was included to present an actual normal 
distribution with a mean (5.4mL) and standard deviation (92.5mL) matching the residual data. A 
Shapiro-Wilk test rejected the null hypothesis of normality (p-value = 0.0002). 
 
5.3 Discussion of the Allograft TCV prediction Model 
 
Important topics related to the development and validation of the initial allograft TCV prediction 
model, i.e., Model A, were discussed in the current section. The topics of interest included the 
exhaustive search, cross-validation, multicollinearity, heteroscedasticity, metric analysis, and the 
overall model development process. In later sections of the current chapter, the development and 
validation of Model B were covered and compared to Model A. 
 Model A’s modeling process used the “glmulti” function to implement a so called 
“exhaustive search”. The “glmulti” function searched for possible allograft TCV prediction model 
structural frameworks to be considered during model develop and had their corresponding AICc 
values calculated. A true exhaustive search would have considered all structural frameworks, 
however, the “glmulti” function’s algorithm included 2 simplifications that made the process a 
“pseudo” exhaustive search. The simplifications were likely included to cut down on the algorithm’s 
computational cost - a limitation that was highlighted in the function’s documentation [122]. 
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First, the algorithm only considered models with an intercept in the structural framework. 
The algorithm did not consider models with a forced non-intercept condition, i.e., a condition that 
automatically set the intercept’s coefficient to zero. Although the algorithm did not prevent the 
function from estimating the intercept’s coefficient to be exactly zero, nuisance factors in the real-
world made this an unlikely scenario. Near-zero intercept estimates could have set to zero by the 
author but this post-processing procedure would have been a subjective judgement call. 
Second, the algorithm only considered structural frameworks with no greater than pairwise, 
i.e., 2-way, interactions terms. Pairwise and higher interaction terms could have been pre-
processed in theory, e.g., 𝑥1𝑥2 = 𝑥12, and then included as additional “main effect” terms, e.g., 𝑥12. 
Including these pre-processed, interaction terms as “main effects” would have allowed the function 
to consider higher-level interactions in the modeling process. However, there were several issues 
in how the proposed method would have forced the higher-level interactions: (1) higher-order 
predictor powers would have been included, e.g., 𝑥12𝑥1 = 𝑥1𝑥1𝑥2 = 𝑥1
2𝑥2, (2) computational cost 
would have increased, and (3) “spurious” multicollinearity could have been introduced into the 
model. The “spurious” multicollinearity refers to higher-level interaction terms having strong linear 
relationships with other terms – it is “spurious” because the main effects, having undergone the VIF 
procedure, did not have linear relationships until the higher interactions were included [134]. 
Furthermore, introducing higher-order predictor powers would, at a minimum, have complicated 
the field of allometry concepts. 
The discussion on the “glmulti” function has demonstrated the function implemented in this 
body of work was not a true exhaustive search algorithm. The simplifications helped to reduce 
computational cost and resulted in the prevention of an end-user developing “spurious” 
multicollinearity in their modeling process. Even with the two well-needed simplifications included, 
the “glmulti” function, for all intents and purposes, was an exhaustive search – especially when 
compared to the “forward”, “backward”, and “stepwise” model selection methodologies. Given a 
careful consideration of these facts, the author decided to continue referring to the “glmulti” 
procedure as an “exhaustive search” for this body of work. 
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 A cross-validation procedure was implemented in this work to directly estimate the true 
testing error of the models being considered during the modeling process and of the final allograft 
TCV prediction model. The implemented cross-validation procedure allowed the testing errors to 
be estimated even though the healthy heart library was of moderate size (N=97). The testing error 
is the error of a dataset that contains no data points that were used to train the model. The 
importance of the testing error is it is an estimate of the model’s true prediction error – as long as 
the testing sample is a large, realistic distribution of prediction cases. The training error is the error 
of a dataset that was also used to train the model but it does not necessarily represent the true 
prediction error. The basic issues in using the training error to assess a model’s prediction 
capabilities are (1) it is biased to underestimate the true testing error and (2) the training error 
rankings do not necessarily represent the testing error rankings [118]. In particular, more flexible 
models, e.g., less robust models that are highly overfitted, can easily pass close to or even through 
many of the training data points and therefore greatly reduce, i.e., bias, the training error. This 
training error bias is specific to the training dataset and therefore explains the preference in using 
the testing error to analyze a model’s performance. 
Cross-validation procedures allow testing errors of relatively small datasets to be estimated 
by systematically separating the data into a series of training and testing datasets. The particular 
strengths of the cross-validation procedures when the only data available is of limited size are (1) 
the process reduces overestimation of the testing error and (2) the testing error variability can be 
averaged [118]. Overestimated testing errors can be caused by using a small training dataset, 
however, cross-validation allows for most of the data to be used in model training for any single 
fold [118]. Allowing most of the available data to train the model in a single fold helps to prevent 
the testing error from being overestimated. The testing error variability is a consequence of the 
training and testing datasets being highly variable, especially when the testing datasets is small. 
Cross-validation addresses the testing error variability of a small testing dataset by averaging the 
error of multiple folds, i.e., fits [118]. Without cross-validation techniques, appropriately large 
training and testing datasets are typically needed to reduce testing error overestimations and to 
reduce testing variability, respectively [118]. 
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Model A was developed using a k-fold cross-validation procedure. In general, a k-fold uses 
100% (
1
𝑘
) of the data for testing and 100% (1 −
1
𝑘
) of the data for training at any one time in the “k” 
individual folds. Implementing a 10-fold procedure, i.e., k = 10, would result in 90% and 10% of the 
data being used for training and testing the model for each of the folds, respectively. Reducing the 
value of “k” results in a lower error metric variance (preferential) but at an increased testing error 
estimated bias (undesired) – this is known as the bias-variance trade-off [118]. A reduction in “k” 
biases the model because the training dataset becomes smaller [118]. Model B, in the next section, 
was developed using leave-one-out cross-validation (LOOCV). For all intents and proposes, 
LOOCV is a k-fold situation in which k = N, i.e., k equals the sampling size. The LOOCV process 
generates the lowest bias for any of the k-fold methods but at the cost of increased error variance. 
The reason for the higher error variance in LOOCV is a direct consequence of averaging highly 
correlated quantities [118]. To address the bias-variance trade-off in the initial allograft TCV 
prediction model, a 10-fold cross-validation process was initially chosen to focus on not biasing the 
modeling process while being able to estimate the testing error with a low variance.  
The initial modeling process, which derived Model A, implemented k-fold cross-validation 
procedures in steps 4 and 7 to estimate the testing errors. The testing errors were then used to 
calculate the testing statistical model metric errors. As the methods, result, and discussion indicated 
hereto, the author took special care in selecting structural frameworks based on their testing 
statistical model metric errors. Testing error metrics were used herein to help ensure model 
selection was based on error metrics that were more reliable than the training error metrics. 
Furthermore, the cross-validation procedure of choice was chosen to address model error bias and 
variance. Step 4 presented intermediate testing statistical modeling metric error results in Tables 
5.4 to 5.15 for the 8 top models to (1) help ensure error bias and variance was minimal between 
the top models for consideration and (2) to ensure the modeling process was appropriately on track 
to develop a final allograft TCV prediction model. Analysis of the cross-validation testing statistical 
modeling metric errors and error ranking summaries in step 7, i.e., Tables 5.28 to 5.30, were used 
to help select the final allograft TCV prediction model, i.e. Model A. 
  108 
One important limitation of k-fold cross-validation procedures, especially for large values 
of “k”, is the increased computational cost required to estimate the direct testing error. Averaging 
several k-fold runs helps to remove the bias of a single run further increases the computational 
cost, e.g., as was the case herein in which each cross-validation procedure was run 100 times. 
Given these facts, it was not generally reasonable to use the k-fold procedure for the exhaustive 
search analysis. Instead of directly estimating the testing errors from the exhaustive search 
procedure, there were other means available to indirectly estimate testing errors and reduced the 
computational cost. 
The AICc metric, when calculated using the ML method, can be used as an indirect testing 
error metric to quickly compare the structural frameworks of interest – as was performed in step 3’s 
exhaustive search. The various indirect testing error estimation methods, including the AICc metric, 
make adjustments to the training error (based on theoretical assumptions) to estimate the testing 
error [118]. Although it may not be readily apparent, the adjusted-R2 is another indirect testing error 
measure while the R2 does not include theoretical adjustments to the training error [118]. The key 
issue with the R2 value is the value artificially improves as more terms, e.g., predictors, are added 
to the model – this is similar to how overfitting a model reduces the training error but does not 
correctly estimate the true testing error [118]. Ultimately, the AICc value and AICc difference 
threshold were used herein to (1) reduce computational cost and (2) quickly select a subset of 
models to focus on during allograft TCV prediction model development. It should be noted that 
because the AICc metric is an indirect estimate of the testing error the author decided this metric 
is not ideal for final model selection, especially because the AICc differences are less than 2 and 
therefore minimal. In other words, directly estimating the testing error was preferential in the 
modeling process when the computational cost of performing a k-fold cross-validation at a particular 
modeling step was reasonable, otherwise, the AICc metric was used herein. 
Multicollinearity was addressed in the modeling process, via a VIF procedure, to help 
ensure the final allograft TCV prediction model was robust. Although mild multicollinearity will have 
limited effect on the model performance, high collinearity increases the estimate coefficients SEs 
and reduces the overall model robustness [108,109]. Relationships between the dependent and 
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independent variables can become unstable to the point they are no longer interpretable or even 
to the point that the coefficient values change signs when high multicollinearity is an issue 
[108,109]. Similar to overfitting a model, high multicollinearity can lower training errors without 
improving the testing errors [108,109]. Extrapolated predictions, i.e., predictions made outside 
training dataset domain, are particularly problematic for models with high multicollinearity and even 
those that are overfitted because of the associated decreased robustness [108]. Interpolating a 
prediction, i.e., making a prediction within the training dataset domain, will generally perform better 
– this explains in part why extrapolated prediction should be avoid.   
Asking clinicians and other users of the allograft TCV prediction model, or any model, in 
general, to not extrapolate future predictions is advisable. Expecting model end-users to never 
extrapolate future predictions is unrealistic nonetheless for several reasons. First, there are 
perceivable clinical scenarios in which a clinical team might thing a slight extrapolation (a best-case 
scenario) would only increase the error of the TCV prediction only slightly and therefore be worth 
the clinical risk. The clinical team would likely be mistaken if multicollinearity and even overfitting 
issues were not addressed, i.e., if the developed model was allowed to remain unstable, because 
unrealistic predictions could be made. Second, even when experienced end-users avoid 
extrapolating predictions, there are so called “mild” extrapolations, i.e., hidden or hard to detect 
extrapolations, that can result in unrealistic predictions [108]. A mild extrapolation happens when a 
predictor is within the minimum and maximum range of two or more variables but still outside of the 
model’s actual training population. A generic example showing standard and mild extrapolations 
are illustrated in Figure 5.7. Multicollinearity was addressed herein for system redundancy, i.e., for 
a system safeguard, to help prevent unrealistic extrapolated allograft TCV predictions being made 
when an end-user performs an extrapolation intentionally or unintentionally. Future versions of the 
virtual HTx fit assessment tool could go a step further and include an algorithm that flags 
unintentional allograft TCV prediction extrapolations. 
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Examples of Interpolation and Extrapolation Predictions 
 
Figure 5.7: An example training data set (dark gray) was plotted against its “A” and “B” independent 
variables. The box (light gray) illustrated the minimum (e.g., lower left corner) and maximum (e.g., 
upper right corner) range of the training data. The red, green, and blue data points illustrated testing 
data points that would have corresponded to interpolated, mildly extrapolated, and extrapolated 
predictions. Notice mild extrapolations are still within the minimum and maximum ranges for the 
independent variables “A” and “B” but are not within the example training dataset. 
 
Heteroscedasticity was illustrated previously in Figures 4.2 and 4.3 and confirmed with the 
Breusch-Pagan test in Table 5.16. The issue with heteroscedasticity in the modeling data is it 
increases the estimated coefficient SEs and therefore can negatively impact the model’s 
robustness [108]. Herein, two methods to correct for heteroscedasticity were considered: (1) 
weighting the estimated coefficients and (2) removing influential outliers. First, coefficient weighting 
used “varClass” functions with little effect on improving the models’ prediction performances or 
Breusch-Pagan test p-values for heteroscedasticity, as was presented in Tables 5.16 and 5.17. 
Second, using Cook’s distance to remove influential outliers resulted in increased model prediction 
performance and the Breusch-Pagan test indicated no sign of heteroscedasticity, as was presented 
in Tables 5.16 and 5.17. The need to address heteroscedasticity in the data was a to ensure the 
model was robust and help reduce unrealistic predictions, especially with mild or standard 
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prediction extrapolations – this is a similar reasoning to building in model redundancies/safeguards 
by addressing multicollinearity during model development. 
 During the modeling process, there were 6 statistical modeling metrics, i.e., MAE, MAPE, 
ME, MPE, MSE, and RMSE, and two additional metrics, i.e., sMAPE and sMPE, mainly used to 
assess model development and performance. These 8 metrics quantitatively highlighted unique 
attributes of the prediction errors, i.e., residuals, of the models being developed, validated, and 
considered for the final allograft TCV prediction model. In reviewing these metrics’ formulas, 
presented in Table 5.2, it becomes apparent the large variety of metrics highlight a wide range of 
error information on the models being considered. Metrics that take the residual absolutes, i.e., 
MAE and MAPE, provide information on the overall error without considering if the error was an 
over- or under-prediction and without penalizing larger errors. The ME and MPE metrics function 
similarly to their corresponding residual absolute metrics but with over- and under-predictions 
considered in the metric, e.g., provide the direction of the bias, without penalization of larger errors. 
The MAPE and MPE metrics report relative errors by decreasing the penalty of errors for larger 
predictions; e.g., a 50mL error could be considered reasonable for an 800mL TCV in a teenager 
but not for a 75mL TCV in an infant. The MSE and RMSE squared the residuals and therefore do 
not provide directional over- or under-prediction information but they did penalize larger errors, 
regardless of the relative error. Furthermore, the RMSE takes the square root of the MSE such that 
the metrics unit is no longer squared, i.e., the RMSE value magnitudes are easy to interpret. 
The MPE and MAPE are important metrics, in general, because they provide information 
on relative error, however, there is an important limitation that could even be considered a flaw with 
these 2 metrics [135–137]. Table 5.2 shows these two metrics’ formulas are divided by the 
predicted value and this results in these metrics applying larger penalties on over-predictions. For 
example, if the MAPE metric had an under-prediction of 50% (i.e., Actual = 2 and Predicted = 1) 
then switching the actual and predicted values would result in an over-prediction of 100% (i.e., 
Actual = 1 and Predicted = 2). This higher penalty for over-predictions could bias the developed 
model to under-predict. This asymmetric bias of the MAPE and MPE metrics can be corrected, i.e., 
made symmetrical, by replacing the denominator with an average of both the actual and predicted 
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values – these are known as the sMPE and sMAPE metrics in Table 5.2 [136]. Although the MPE 
and MAPE metrics were used throughout the modeling process the final model selection included 
the sMPE and sMAPE metrics, i.e., Table 5.30, to help identify the “best” model. 
The importance of reporting multiple performance metrics, in summary, is it helps to better 
illustrate how a prediction model performs overall. Not every metric shows directional bias of a 
model, e.g., MAE, MAPE, MSE, or RMSE. Other metrics can show directional bias, e.g., ME and 
MPE, but cannot differentiate a net-zero directional bias vs. a model that has perfect prediction. 
Some metrics penalize the relative error size, e.g., MPE, MAPE, sMPE, and sMAPE, while other 
metrics penalize larger errors, regardless of relative size, e.g., MSE and RMSE. Furthermore, there 
are metrics that provide insight into a model while sacrificing or biasing another attribute that may 
not be ideal or even problematic in interpreting another attribute of a model’s performance, e.g., 
MAPE and MPE. The modeling process herein considered a wide range of statistical modeling 
metrics to understand the top model performances so a “best” model could be identified in the final 
model selection process. 
The testing statistical model metric rankings demonstrated Model 2 outperformed with the 
MAE, ME, MSE and RMSE metrics in Table 5.29. The MAE and ME showed Model 2 had the 
lowest absolute testing error and the lowest over- or under-prediction bias, respectively. The MSE 
and RMSE showed Model 2 was less likely to produce larger errors relative to other models. The 
MAPE and MPE showed a slight and large decrease in the performance of Model 2, however, after 
addressing the asymmetric of these metrics in Table 5.30, the sMAPE and sMPE showed large 
improvements in Model 2. The final results in Tables 5.29 and 5.30, after the symmetry correction, 
demonstrated Model 2 was ranked 1st for MAE, sMAPE, ME, MSE, and RMSE and was ranked 2nd 
for sMPE. The MAPE and MPE metrics were disregarded in the final assessment due to the well-
established symmetry issues and given the sMAPE and sMPE helped to distinguish Model 3 for 3rd 
place in model performance when it was previously unclear if Model 3 outperformed Model 8. The 
testing statistical model metric results demonstrated Model 2 was the “best” model and therefore 
became Model A. 
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Final Model A TCV prediction results that were used to calculate the final statistical 
modeling metric results that were presented in Figures 5.3-6. These residual results generally 
fluctuate about the line of unity in Figures 5.3-4 with a slight bias of under-prediction for the largest 
of heart predictions. This suggest Model A biases under-predictions for the largest of hearts but the 
relative errors are still within the more generally visible ±25% bandwidth in Figure 5.4. The Shapiro-
Wilk test results (p-value ≤ 0.0001) and Figure 5.5 indicate the residuals were not normally 
distributed. However, visual inspection of Figure 5.6 appears to be suggesting the residuals are 
somewhat near normality, centered nearly at 0, and generally suggested Model A performed well. 
Figure 5.6 does suggest errors between 0 and 50mL was the most frequent error size. 
The development of Model A was driven by the AICc difference profiles in the initial 
exhaustive search, the final estimated coefficient p-values, and the comparison of the statistical 
modeling metrics throughout the modeling process. Age was also considered initially, however, 
from a practical point-of-view Age was excluded early in the modeling process. The practical issue 
was getting donor Age in months was difficult for older donors while Age in years was too large for 
infants. Fortunately, the inclusion or exclusion of Age had no effect on the final predictors, i.e., Sex, 
Ht, and BMI, used in the log-log transform modeling process which was the datatype used to 
develop Model A. It is worth noting that non-parametric techniques were not considered in the 
modeling process because (1) they do not generate an equation but, generally speaking, are a set 
of smoothing criteria that require access to the training data and (2) they would have required a 
much larger dataset to train the model [118,138]. Although the author developed Model A as 
presented herein, it was suggested the initial modeling process could be improved upon and 
therefore Model B was developed. The development and results of Model B were presented and 
compared to Model A in the remaining sections of chapter 5. 
 
5.4 Methods and Materials of the Improved Allograft TCV prediction Models 
 
The “improved” allograft TCV prediction model, i.e., Model B, was developed after reviewing the 
initial modeling process methods and preliminary results. Seven key modifications to the modeling 
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process were made. First, the VIF procedure was performed in an iterative process but the highest 
VIF predictor was not automatically excluded. Instead, predictors with large VIF values were kept 
in the modeling process if they were shown to have strong correlation with TCV, however, 
predictors with lesser VIF values were removed. The VIF procedure removed predictors until all 
remaining predictors had VIF values that dropped enough to meet the VIF threshold. Second, the 
VIF cutoff threshold was increased (i.e., < 20). Third, the AICc difference cutoff threshold was 
increased (i.e., ≤ 3) – models that meet this criterion lie somewhere between having some and 
substantial chance of having equivalent performance [124]. Fourth, the k-fold cross-validation was 
changed to a leave-one-out cross-validation (LOOCV) procedure. Although Model A originally used 
10-fold cross-validation to estimate the testing errors during model development and validation, 
Model A’s testing errors were recalculated using LOOCV in the next section to compare the initial 
model results to Model B. Fifth, the predictors were standardized for coefficient estimation. Sixth, 
the coefficients were estimated with an iteratively reweighted least squares method based on the 
Huber weight function to ensure the developed model was robust to heteroscedasticity and outliers 
[139]. Seventh, estimated coefficients and their corresponding bootstrap-derived confidence 
intervals were investigated to ensure statistical significance. 
Prediction errors are a reality for any statistical model even though care is taken to minimize 
these errors. A key intent of the virtual fit assessment tool was to help clinicians safely expand a 
patient’s donor pool by maximizing allograft TCVs that could be accepted, however, under-
predictions were clinically concerning when the oversized allograft limits are being pushed. This 
opinion that over-predictions were clinically preferable to under-predictions led to the development 
of a secondary 0.75 quantile regression model, i.e., Model B*. Model B* was developed from Model 
B’s structural framework with modifications that penalized under-predictions 3 times more. 
 
5.5 Results of the Improved Allograft TCV prediction Models 
 
Models B and B* were developed with Age automatically excluded in the modeling process with 
the logic used during the development of Model A. The final, improved allograft TCV models were 
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presented in Table 5.31 in which they predicted allograft TCVs in mL. All continuous healthy heart 
library variables, including Age, were standardized and included in Table 5.31. The inputs for the 
standardized TCV, Age, Ht, Wt, BSA, and BMI variables were in mL, months, cm, kg, m2, and 
kg/m2, respectively. The standardized TCV was not used in the modeling process but was included 
to provide the variable’s mean and standard deviation. The standardized Age was included 
because it was originally considered in the modeling process until it was realized that getting older 
donors’ ages in months was impractical for the virtual fit assessment tool. Sex was a dummy 
variable in which male was numerically code as “1” and female was coded as “0”. Sex was not 
standardized because it was a nominal, categorical variable. 
Models A and B were estimated using least squares regression techniques in which the 
model estimates the conditional mean [140]. Model B* was not a least squares regression because 
it aimed at predicting the conditional 0.75-quantile of the response variable [140]. The 0.75-quantile 
regression model was fitted such that 75% of the training set was below the expected fit. If the 
training data represented the real-world than this fit would represent 75% of predictions would be 
over-estimated. 
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The LOOCV modeling statistical test results for Models A, B, and B* were presented in 
Table 5.32 using all the health heart library data points, i.e., N = 97. The testing ME was the only 
metric Model B outperformed Model A, otherwise, Model A outperformed Model B. Model B*’s 
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testing statistical modeling metrics indicated it had the worst performance out of the 3 reported 
models; however, this was not surprising due to the over-prediction bias that was forced in the 0.75-
quantile regression process. The LOOCV pTCV results for Models A, B, and B* were presented in 
Figures 5.8 and 5.9 as actual vs. observed and relative error plots. The plots in Figures 5.8 and 5.9 
further supported the testing statistical model metric results in Table 5.32 that Model B did not 
outperform Model A, in general. Figure 5.9 might have further suggested that Model A outperformed 
Model B by having a lower absolute relative error for the smallest of TCVs. 
 
Testing Statistical Metric Results for Initial and Improved Models 
Model MAE MAPE ME MPE MSE RMSE sMAPE sMPE 
A 
63.5mL 12.1% 5.5mL -1.0% 8408mL2 91.7mL 12.0% 0.2% 
B 64.0mL 12.7% 1.2mL -2.3% 8707mL2 93.3mL 12.3% -1.0% 
B* 74.2mL 16.1% -46.4mL -11.8% 10606mL2 103.0mL 14.4% -9.8% 
Standard Deviation for Metrics’ Means 
A 66.5mL 10.0% 92.0mL 15.7% 18586mL2 136.3mL 2.4% 3.8% 
B 68.2mL 10.8% 93.8mL 16.6% 20377mL2 142.7mL 2.5% 4.0% 
 
Table 5.32: The LOOCV modeling statistical metric results between the initial and “improved” 
processes. Model A outperformed Model B in 7 of the 8 testing statistical model metrics – the ME 
result was the exception. Although the testing statistical model metrics indicated Model B* was the 
worst model, this decrease in metric performance was expected because of the model was made 
to bias over-predictions, i.e., set to offset 75% of the training data. Model A’s standard deviations 
were smaller for all 8 testing metrics. 
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Model A, B, and B*’s pTCV vs. the mTCV 
 
Figure 5.8: The pTCV vs. mTCV plot demonstrated Models’ A, B, and B* LOOCV pTCV fits about 
the slope of unity (black line). Data points above the slope of unity were over-predictions. Notice, 
B* has an offset that pushed every B result upwards; this was a result of the model’s over-prediction 
bias. Visual inspection of the current plot illustrated no obvious deviations between Models A and 
B. 
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Relative Error between Model A, B, and B*’s pTCV and the mTCV 
 
Figure 5.9: The pTCV vs. mTCV plot demonstrated Models’ A, B, and B* relative LOOCV pTCV fits 
to the horizontal fit of unity (black line). The dashed lines illustrate the 0.75 and 1.25 relative error 
levels. Notice, B* had an offset that pushed every B result upward due to the over-prediction bias. 
Visual inspection of the current plot illustrated no obvious deviations between Models A and B, in 
general, except for the smallest TCVs. 
 
Figures 5.10 and 5.11 presented plots to compare the LOOCV pTCVs and the relative 
LOOCV errors between Models A and B. A tight fit about unity was illustrated in Figure 5.10’s Model 
A vs. Model B plot. The tight fit suggested, in general, Models A and B were nearly consistent in 
prediction performance even though Model A outperformed Model B based on the LOOCV 
modeling statistical metric results. Furthermore, the relative error results illustrated in Figure 5.11 
suggested that for all but the smallest of TCVs the models were nearly consistent in prediction 
performance. An ANOVA test failed to reject the null hypothesis that the Models A and B’s relative 
error predictions were statistically the same (p-value = 0.5588, Cohen’s distance effect size = 
0.08412). The small effect size confirmed the p-value finding, i.e., failure to reject the null 
hypothesis, was also supported in a practical sense. In other words, the p-value and effect size 
findings indicate the models’ relative prediction performances were equivalent in the practical 
sense. Zoomed in views of Figures 5.8 and 5.9, focusing on the lower TCV range for Models A and 
B, were presented in Figures 5.12 and 5.13. Figures 5.11, 5.12, and 5.13 illustrated although 
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Models A and B fluctuated about the slope of unity, Model B consistently made larger predictions 
than Model A for mTCVs up to 150mL. 
 
pTCVs of Model A vs. B 
 
Figure 5.10: Plot illustratively comparing the pTCV results between Models A and B. The plot’s 
results illustrated a fit tightly around unity and therefore suggested the models’ predictive 
performances were similar even though the testing statistical modeling metrics indicated Model A 
outperformed Model B. Model B pTCV results were chosen to be the reference data along the x-
axis because it was the final model used in the virtual heart transplant fit assessment tool. 
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Relative Error between Model A and B’s pTCV 
 
Figure 5.11: Comparative plot showing relative errors between Models A and B. The generally tight 
fit of relative error around unity further supported both models make similar predictions for TCV – 
excluding the smallest of TCV predictions. For the smallest of pTCVs, Model B made larger 
predictions than Model A. Model B pTCV results were chosen to be the reference data along the 
x-axis because it was the final model used in the virtual heart transplant fit assessment tool. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  122 
Model A and B’s pTCV vs. the mTCV: Zoomed In 
 
Figure 5.12: Zoom in of the pTCV vs. mTCV graft in Figure 5.4 illustrated a subtle, systematic bias 
between Model A and B’s predictions for TCVs ≤ 150mL. However, for TCVs ≤ 150mL, both models 
still fitted about the slope of unity (black line). Although there was a systematic difference in the 
pTCVs between the models, the models did not suggest a bias between the pTCVs and the mTCVs. 
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Relative Error between Model A and B’s pTCV and the mTCV: Zoomed In 
 
Figure 5.13: Zoom in of the relative error plot illustrated a systematic difference between Models A 
and B’s predictive performances for TCVs ≤ 150mL. 
 
Model B’s pTCV residual distribution was presented in Figures 5.14 and 5.15 with both a 
quantile-quantile plot and histogram plot. Although visual inspection of the histogram might be 
interpreted as being a normal distribution, the normal quantile-quantile plot presented “tails” that 
appeared to be more than negligible. The null hypothesis of normality was rejected (p-value ≤ 
0.0001) with a Shapiro-Wilk test and therefore confirms the errors were not normally distributed. 
Visual inspection of the quantile-quantile plot and histogram suggested the deviation from normality 
was mild and therefore suggested the lack of normality was unlikely to negatively affect the overall 
Model B performance. 
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Normal Q-Q Plot for Model B’s pTCV Residuals 
 
Figure 5.14: A normal Quantiles-Quantiles plot was presented to investigate the normality 
assumption of the Model B pTCV residuals. These plots suggest the increased likelihood of 
normality as the residuals better fit a single, linear line. The residuals herein generally fitted a linear 
line with the exception of visually appearing mild “tails” to suggested a near-normal distribution was 
present. A Shapiro-Wilk test rejected the null hypothesis of normality (p-value ≤ 0.0001) to further 
confirm the lack of normality. 
 
Histogram for Model B’s pTCV Residuals 
 
Figure 5.15: A frequency plot was created with the Model B pTCV residuals placed in one of 14 
histogram containers. Visual inspection of the plot suggested either the residuals had a normal or 
near-normal distribution. The continuous curve (blue) was included to present an actual normal 
distribution with a mean (1.2mL) and standard deviation (93.8mL) matching the residual data. A 
Shapiro-Wilk test rejected the null hypothesis of normality (p-value ≤ 0.0001). 
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5.6 Discussion of the Improved Allograft TCV prediction Models 
 
Model B was developed with the intent to build upon and improve Model A’s modeling protocol. 
The predictors were standardized in Model B to ease coefficient comparison but did not improve 
the overall model’s predictive capability [108]. The LOOCV testing statistical modeling metrics in 
Table 5.32 suggested Model A generally outperformed Model B – the ME was the only metric in 
which Model B outperformed Model A. Furthermore, the St. Dev. values were smaller for Model A 
in Table 5.32. Visual analysis of Figures 5.8 to 5.13 suggested that, although Model A outperformed 
Model B, their prediction performances were generally similar in the practical sense – the only 
obvious but minor exception was for the smallest of infant TCVs. A closer visual inspection of Figure 
5.13 further indicated Model A was particularly successful at infant TCV predictions ≤ 100mL – 
relative to Model B. An ANOVA test comparing the models’ relative errors further supported the 
visual graph inspections that Models A and B’s prediction performances were similar for all practical 
purposes (p-value = 0.5588, Cohen’s distance effect size = 0.08412). 
The residual distributions for Models and A and B were not found to be normally distributed; 
i.e., the null hypothesizes of normality were rejected using the Shapiro-Wilk test (p-value = 0.0002 
and p-value ≤ 0.0001, respectively). The slightly larger p-value for Model A and the visual 
comparisons of Figures 5.5 and 5.6 to Figures 5.14 and 5.15, respectively, suggested Model A was 
relatively (but minimally) closer to being normally distributed. It is worth noting that although the p-
value difference for the Shapiro-Wilk tests was measureable, it was also practically negligible. 
Nevertheless, visual inspection of the histograms in Figures 5.6 and 5.15 suggested the models 
were near-normally distributed for all practical purposes and therefore were unlikely to negatively 
affect the models’ practical performances [108]. The previous observation that Model B had an ME 
metric result that outperformed Model A, i.e., that had an error mean that was closer to zero, was 
further illustrated when comparing the histograms. The residual histogram plots suggested the 
improved ME metric performance of Model B came at the cost of a slightly larger variance. 
 The comparison of Models A and B indicated Model A slightly - but constantly for the 
majority of testing statistical modeling metrics and secondary analysis methods - outperformed 
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Model B. However, visual inspection of Figures 5.8 to 5.13 and an ANOVA test of the relative errors 
suggested there was no obvious practical predictive performance differences between the models. 
Furthermore, there was no obvious practical predictive capability differences between the models 
for the smallest of TCVs, in general. The only concerning large relative prediction error in Figure 
5.13 (for Model B) was for the smallest heart in the healthy heart library, however, this prediction 
was an extrapolation due to how the LOOCV procedure is implemented. Large extrapolation errors, 
especially if the model is not perfectly robust, can produce wild predictions and therefore this large 
prediction discrepancy should not be overly concerning. 
The testing statistical modeling metrics indicated Model A was generally better at prediction 
performance. This better prediction performance of Model A might suggest the model should be 
used in the virtual heart transplant fit assessment tool – not Model B. However, the prediction 
performance of Model B was practically the same to Model A, i.e., the difference in performances 
were found to be statistically-insignificant. Ultimately, Model B was the final model used in this body 
of work for the virtual HTx fit assessment work. The reasons Model B was the final model used in 
this work was due to (1) a limitation in the preliminary Model A development and (2) the author 
originally thought the SEs between the models were comparable. The SE values were not 
comparable but the t-values were. The coefficient t-value magnitude sizes were inconsistent 
between the models, however, the St. Dev. metric values in Table 5.32 were consistently smaller 
for Model A to suggest it was a more robust model. 
Before, during, and after the development of Model B, the Model B results were compared 
to the preliminary Model A results. The completion of Model A had been put on hold while Model B 
was being developed – it was only during the finalization of Model A for being included in this thesis 
that a few issues were highlighted. The author was either not aware of these issues or not aware 
of the consequences of these issues would have on data interpretation at the time Model A was 
put on hold during the development of Model B. First, while the initial step 4 modeling process 
analyzed testing error data results (from a k-fold cross-validation process), the step 7 modeling 
process analyzed training error data results. At the time of Model B develop, the author though the 
testing error data from the initial k-fold procedure at step 4 was enough. Second, the initial model 
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process used k-fold cross-validation and then the “improved” method, i.e., Model B, used LOOCV 
– there is a well-known bias-variance trade-off between these validation methods that can have 
impact on the final results [118]. Third, the author did not originally implement a true k-fold cross-
validation in step 4. The issue with the original k-fold procedure not being a true k-fold was the 
author’s computer script did not consistently separate the healthy heart library, for each of the folds, 
into sets of 10% and 90% for the testing and training datasets. Failing to appropriately divide the 
dataset into training and testing subsets was a consequence of how the R “set.seed” function was 
implemented – examples using the seed function were presented in the textbook by James et al. 
[118]. In fact, there were scenarios in which the testing and training datasets contained 0% and 
100% of the testing dataset. 
The preliminary initial modeling process (i.e., the process that developed Model A) was 
corrected by (1) correctly using k-fold testing error results in step 7 (during model selection of the 
initial modeling process) and (2) fixing the R “set.seed” function implementation so a 10% and 90% 
data split was consistent. For the final analysis comparison of Models A and B the author used final 
LOOCV testing errors from step 7; again, Model A used k-fold during the final model selection 
before the models were compared. To get the LOOCV testing errors for Model A, the author had 
to re-calculated step 7’s testing errors – this explains the testing error differences between Tables 
5.28 and 5.32. This thesis contains the finalized, corrected Model A results herein and the flawed, 
preliminary Model A results were removed. 
The limitations in the preliminary initial modeling process helped to derive Model B. Once 
the issues in the preliminary modeling process were observe they were corrected for and 
demonstrated Model A generally outperformed Model B based on the testing statistical model 
metrics. However, the better performance of Model A was not statistically-significant (i.e., the 
ANOVA test comparing the models’ relative errors). Given: 
 
1. the performance between Model’s A and B were statistically similar, 
 
2. a more conservative Model B* was already developed, and 
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3. the virtual HTx fit assessments were already performed with surgeons by the time the 
issue with preliminary Model A process was discovered, 
 
the author continued to use Model B. 
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CHAPTER 6 
 
ANALYSIS OF THE VIRTUAL HEART TRANSPLANT FIT ASSESSMENT TOOL’S CLINICAL 
UTILITY 
 
The novel virtual HTx fit assessment tool was developed with the intent to help clinicians safely 
expand their patients’ donor pools. The clinical utility of the tool was investigated under 2 main 
retrospective simulated virtual HTx fit assessment studies. The studies were designed based on 
the historical data that was available to start answering the following 2 important questions: 
 
1. Can the tool help clinicians expand their patients’ donor pools? 
 
2. Can the tool help clinicians perceive fit-related complications? 
 
In the 1st simulation study, surgeons identified the maximum allograft they were willing to take using 
the virtual tool. In the 2nd simulation study, surgeons virtually HTxed analogue allografts that were 
identified with the actual donors’ parameters and assessed for perceive fit-related complications. 
Additionally, a unique case study in which actual donor images were available was also discussed. 
Chapter 6 covers the simulated virtual HTx studies and their corresponding findings. First, 
the chapter covers the generalized virtual HTx fit assessment procedure and the studies’ 
underlining methods. Second, the results were analyzed and conclusions on the tool’s clinical utility 
were presented. Third, a case study in which a virtual HTx was performed using donor images was 
discussed and related to the simulation studies’ results. For this body of work, the analysis of the 
novel tool’s clinical utility constituted as Aim 3. 
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6.1 Methods and Materials for Virtual Heart Transplant Fit Assessments 
 
Virtual HTx fit assessments were performed in Mimics software. The virtual assessments consisted 
of a surgeon strategically fusing an allograft geometry into a patient’s CT or MR image. Allograft 
placement was performed in real-time by translating and rotating the geometry into place while 
viewing the 3 orthogonal planes, i.e., axial, coronal, and sagittal. The surgeon assessed for 
perceived oversized allograft fit-related complications during and after the virtual fit procedure. The 
surgeon needed to consider the allograft’s potential effect on the local anatomy and physiology 
after final placement. Considerable allograft overlay onto critical structures (e.g., aorta, airway, and 
diaphragm) and/or rigid structures (e.g., ribs, sternum, and vertebral column) were perceived to be 
particularly indicative for a potential poor outcome. In general, healthy heart library reconstructions 
served as allograft analogues for the virtual assessments. Donor images were required for a virtual 
assessment to be performed using an actual donor’s reconstruction and not rely on a healthy 
allograft analogue – a unique case study using donor images was available and was included at 
the end of chapter 6. Surgeons were specifically blinded to patient and actual donor body weights 
and to clinical outcomes. Studies 1 and 2’s virtual fit assessments were retrospective, simulated 
procedures. 
 
6.2 Methods and Materials for Study 1: Expanding Upper Donor Pool Ranges 
 
Simulated maximum allograft virtual HTx fit assessments were performed on listed PCH HTx 
patients with pre-transplant CT or MR images. The study’s objective was to see if the tool resulted 
in clinicians accepting traditionally perceived oversized allografts, i.e., accepting donors with 
traditionally larger than normal body weights, during the virtual assessments. There were 45 PCH 
patients that were pulled, de-identified, and analyzed for research in a retrospective chart review 
that spanned 2010 to 2015. The patients in the current study were carefully selected so they could 
be reused in study 2. Additionally, all available national level patients spanning 2010 to 2015 were 
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pulled from the Pediatric Heart Transplant Society (PHTS) and the United Network of Organ 
Sharing (UNOS) datasets for comparison. 
 Listed patient TCVs were reconstructed from pre-operative CT or MR images, using 
Mimics, and then measured. Surgeons used the patient’s native mTCV to select an initial allograft 
reconstruction from the healthy heart library for simulated HTx consideration in a virtual heart 
transplant fit assessment. Surgeons assessed the fits and then, in an iterative fashion, selected 
another healthy heart reconstruction for review by intentionally increasing or decreasing the next 
allograft’s mTCV. The iterative process was repeated until the surgeon identified the maximum 
allograft TCV they were willing to accept based on perceived fit-related complications. Once the 
surgeon identified the maximum allograft TCV they were willing to accept, the iterative fit 
assessment was ended and the maximum mTCV value was recorded. In summary, the virtual 
transplant and assessment followed the general procedure (previously discussed) but with the 
objective to identify the maximum allograft size the surgeon would accept. In identifying the 
maximum allograft, surgeons were asked to choose the largest allograft within reason, e.g., no 
“last-ditch effort” scenario for fear this would be the last allograft the patient would likely be offered 
before succumbing to heart failure. The surgeon was blinded to the actual transplant cases. 
 The maximum DRBW ratio was calculated using the patient and maximum donor’s, i.e., 
using the selected healthy heart patient’s, measured Wt. Simulated and national database DRBW 
ratios were visually and statistically analyzed. The DRBW ratio analysis included comparisons of 
the virtual results with actual and upper listed DRBW ratios. Analysis included a series of ANOVA 
tests (Null hypotheses = 0, Alpha = 0.05) and Student T-test to compare the DRBW ratio results. 
The Student T-test were performed in JMP as a series of two mean ANOVA comparisons.  
 
6.3 Methods and Materials for Study 2: Perceiving Fit-Related Complications 
 
Simulated allograft virtual HTx fit assessments were performed on pre-transplant CT or MR images 
of PCH patients that did have HTxs with actual clinical outcomes. The study’s objective was to see 
if the tool resulted in clinicians perceiving both appropriate fits that were void of over-sized fit-related 
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complications and oversized fits that resulted in over-sized fit-related complications. The PCH 
patients in the current study were the same patients in study 1, i.e., the expanding donor pools 
study, because to undergo a HTx required these individuals to be listed such that they could acquire 
a donor offer. 
 Actual donor parameters and Model B were used to determine donor pTCVs. The donor’s 
pTCV was used to select an allograft reconstruction analogue from the healthy heart library for the 
virtual fit assessment. A virtual assessment was performed and the surgeon’s fit-related 
observations were recorded, e.g., concerns for or lack of concerns for fit-related complication. The 
surgeon was blinded to the actual transplant cases.  
 The surgeon’s perceived findings were than compared to actual patient fit-related 
outcomes. Outcomes known to or clinically perceived to be associated with allograft overfitting were 
analyzed – these outcomes included pathological symptoms, e.g., pulmonary vein stenosis, and 
post-operative complications, e.g., delayed sternal closure. Perceived and actual outcome 
frequencies were analyzed and presented. Analysis included a series of chi square test to 
determine if the frequencies were statistically-significant. 
 
6.4 Results for Study 1: Expanding Upper Donor Pool Ranges 
 
The virtual maximum DRBW ratios (from the maximum TCVs surgeons were willing to take using 
the virtual fit assessment tool) were compared to the accepted and upper listed DRBW ratios at 
both the local, i.e., PCH, and national levels. A preliminary series of ANOVA tests were performed 
and demonstrated there were statistically-significant differences between (1) the PCH and the tool’s 
DRBW ratio means and (2) the national level and the tool’s DRBW ratio means. The statistically-
significant ANOVA results justified the need to perform a series of 5 Student T-test that compared 
specific DRBW ratio population pairing means. The 5 Student T-test DRBW ratio mean 
comparisons were presented in Table 6.1 and were referred herein as C1, C2, …, and C5 in which 
“C” stands for “comparison”. The PCH and virtual maximum quantile distributions were presented 
pictorially and quantitatively in Figure 6.1 and in Table 6.2, respectively. The national level and 
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virtual maximum quantile distributions were presented pictorially and quantitatively in Figure 6.2 
and in Table 6.3, respectively.  
The PCH results found the hospital’s accepted allograft DRBW ratio mean was smaller 
than what surgeons took using the tool but it was not statistically-significant (C1; ratio mean of 1.68 
vs. 1.94; p-value = 0.0725; effect size = 0.39). The 0.39 effect size suggested there was between 
a 78.7% and 72.6% overlap between PCH’s accepted and the tool’s DRBW ratio sample population 
distributions [113,141]. The PCH results found the hospital’s upper DRBW ratio listing mean was 
statistically larger than what surgeons took using the tool (C2; ratio mean of 2.90 vs. 1.94; p-value 
< 0.0001; effect size = 1.05). The 1.05 effect size suggested there was between a 44.6% and 41.1% 
overlap between PCH’s upper listed and the tool’s DRBW ratio sample population distributions 
[113,141]. 
PHTS’s accepted allograft DRBW ratio mean was statistically smaller than what surgeons 
took using the tool (C3; ratio mean of 1.37 vs. 1.94; p-value < 0.0001; effect size = 1.20). The 1.20 
effect size suggested there was a 37.8% overlap between PHTS’s accepted and the tool’s DRBW 
ratio sample population distributions [113,141]. PHTS does not collect upper DRBW ratio listings 
and therefore could not be compared to the tool. 
UNOS’s accepted allograft DRBW ratio mean was statistically smaller than what surgeons 
took using the tool (C4; ratio mean of 1.33 vs. 1.94; p-value < 0.0001; effect size = 1.39). The 1.39 
effect size suggested there was between a 34.7% and 31.9% overlap between UNOS’s accepted 
and the tool’s DRBW ratio sample population distributions [113,141]. UNOS’s upper DRBW ratio 
listing mean was slightly larger than what surgeons took using the tool but it was not statistically-
significant (C5; ratio mean of 2.02 vs. 1.94; p-value < 0.4033; effect size = 0.13). The 0.13 effect 
size suggested there was between a 92.3% and 85.3% overlap between UNOS’s upper listed and 
the tool’s DRBW ratio sample population distributions [113,141]. 
The frequency demographics of the PCH, PHTS, UNOS accepting undersized allografts 
(DRBW ratio < 1.0), equal sized allografts (DRBW ratio = 1.0), and oversized allografts (DRBW 
ratio > 1.0) were presented in Table 6.4. 
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PHTS, UNOS, and Virtual Maximum DRBW Ratios 
Group 1 Virtual vs.: 
Group 2 PCH PHTS UNOS 
Accepted Upper Accepted Upper Accepted Upper 
Comparison C1 C2 C3 NA C4 C5 
Mean 1 1.94 1.94 1.94 NA 1.94 1.94 
Mean 2 1.68 2.90 1.37 NA 1.33 2.02 
St. Dev. 1 0.67 0.67 0.67 NA 0.67 0.67 
St. Dev. 2 0.68 1.11 0.47 NA 0.43 0.64 
Sample Size 1 44 44 44 NA 44 44 
Sample Size 2 44 45 1913 NA 2332 3008 
St. Dev. Pooled 0.68 0.92 0.48 NA 0.44 0.64 
Effect Size: 0.39 1.05 1.20 NA 1.39 0.13 
P-Value: 0.0725 < 0.0001 < 0.0001 NA < 0.0001 0.4033 
 
Table 6.1: A series of Student T-test compared the PCH and national level DRBW ratios to the 
maximum TCV surgeons were willing to take during the simulated fit assessments. The C2, C3, 
and C4 differences were found to be statistically-significant with effect sizes > 1 while sample sizes 
were N = 44. C1 was nearly found to be statistically-significant as it nearly met the classical p-value 
≤ 0.05 criterion. C5 had a relatively low effect size and therefore was not found to be statistically-
significant as was demonstrated by its p-value. C5 was particularly interesting because the mean 
difference between UNOS and the tool’s upper listing means was < 0.1 – the magnitude of this 
difference was perceived to have no clinical practical importance. 
 
 
 
 
 
 
 
 
 
 
 
  135 
Phoenix Children’s Hospital and Virtual Maximum DRBW Ratios 
 
Figure 6.1: Box-plots of the PCH and virtual maximum DRBW ratios illustrated PCH’s accepted 
and upper listed DRBW ratio population distributions were either similar or larger than the tool’s 
DRBW ratio population distribution, in general. The results indicated the tool would not increase 
PCH’s upper listing DRBW ratio distribution; however, pairwise comparisons were needed to 
determine if the tool could have expanded individual listing pools. 
 
PCH and Virtual Maximum DRBW Ratios 
 PCH Virtual 
 Accepted Upper Maximum 
Maximum 3.50 6.62 3.65 
3rd-Qt 2.15 3.90 2.34 
2nd-Qt 1.48 2.82 1.81 
Mean 1.68 2.90 1.94 
1st-Qt 1.16 2.00 1.50 
Minimum 0.79 1.31 0.74 
 
Table 6.2: Figure 6.1’s quintile results were presented quantitatively. In general, the tool’s DRBW 
ratio quantiles were larger and smaller than PCH’s accepted and upper listed ratio populations, 
respectively. 
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PHTS, UNOS, and Virtual Maximum DRBW Ratios 
 
Figure 6.2: Box-plots of the national level and virtual maximum DRBW ratios. The plot illustrated 
the tool’s DRBW ratio population distribution was generally similar to the UNOS upper listed DRBW 
ratio population distribution. The plot further illustrated the tool’s DRBW ratio population distribution 
was generally larger than the PHTS and UNOS accepted DRBW ratio population distributions. 
 
PHTS, UNOS, and Virtual Maximum DRBW Ratios 
 PHTS UNOS Virtual 
 Accepted Upper Accepted Upper Maximum 
Maximum 3.70 NA 3.32 13.02 3.65 
3rd-Qt 1.60 NA 1.54 2.37 2.34 
2nd-Qt 1.30 NA 1.23 1.96 1.81 
Mean 1.37 NA 1.33 2.02 1.94 
1st-Qt 1.00 NA 1.01 1.53 1.50 
Minimum 0.10 NA 0.48 0.60 0.74 
 
Table 6.3: Figure 6.2’s quintile results were presented quantitatively. The tool’s DRBW ratio 
population distribution was larger than PHTS’s accepted DRBW ratio population distribution. The 
tool’s DRBW ratio population distribution was larger and slightly smaller than UNOS’s accepted 
and upper listed ratio population distributions, respectively. 
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Accepted Allograft Size-Match Percentage by Classification 
DRBW ratio PCH PHTS UNOS 
> 1.0 95.5% (42) 78.0% (1493) 75.9% (1771) 
= 1.0 0.0% (0) 1.2% (22) 0.9% (22) 
< 1.0 4.5% (2) 20.8% (398) 23.1% (539) 
Sample Size 44 1913 2332 
Table 6.4: A percentage (frequency) breakdown of accepted oversized, equal sized, and 
undersized allografts for the PCH, PHTS, and UNOS pediatric populations were presented. The 
acceptance of oversized allografts was constantly the norm for pediatric transplants at both PCH 
and the national levels, i.e., oversized allografts accounted for > 75% of pediatric transplants in 
each of the populations. 
 
An investigation into the 5 comparison’s effect sizes and sample sizes was performed to 
better understand the p-value results. Equation B.3 (see appendix B) was used to estimate the 
needed sample sizes to detect the mean differences between the populations with statistical-
significance – this assumes the mean and variance estimates hold as the population size changes. 
The relationship between the needed sample size and mean difference to be detected (given the 
variances hold) were combined and presented in Table 6.5. To detect a DRBW ratio mean 
difference of 0.1 it was estimated C4 would require the fewest individuals with approximately 411 
individuals per population. Furthermore, it was approximated 1735 individuals per population would 
be required for a 0.1 difference to be detected in all 5 comparisons. A DRBW ratio mean difference 
of 0.1 was investigated because it is arguably the smallest difference of clinical interest, i.e., of 
practical importance. The virtual tool’s sample size (N = 44) falls extremely short of these 
population size approximations. Using 44 individuals per population – at a minimum – the analysis 
suggested the smallest DRBW ratio differences the 5 comparisons could detect (based on their 
estimated population variances) ranged between 0.31 (C4) and 0.66 (C2). Closer inspection of the 
statistically-significant p-values in Table 6.1 and the smallest detectable DRBW ratio differences 
(when N = 44) in Table 6.5 demonstrated C2, C3, and C4 were found to be significant because the 
differences they could detect were less than the mean differences between the sample populations. 
Although increasing sample size allows for smaller size differences to be detected it is important to 
recognize it does not necessarily change the populations’ variances or means (and in theory it 
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should not). Given the variances and/or means estimates should not change then the percentage 
that the populations’ distributions overlap should not change (see appendix B discussion) – only 
the difference needed to detect something with “statistical-significance” would change. 
 
Approximate Sample Sizes Needed to Detect DRBW Ratio Differences 
Group 1 Virtual vs.: 
Group 2 PCH PHTS UNOS 
Accepted Upper Accepted Upper Accepted Upper 
Comparison C1 C2 C3 NA C4 C5 
Mean 1 1.94 1.94 1.94 NA 1.94 1.94 
Mean 2 1.68 2.90 1.37 NA 1.33 2.02 
|Mean ∆| 0.26 0.96 0.57 NA 0.61 0.08 
Sample Size 1 44 44 44 NA 44 44 
Sample Size 2 44 45 1913 NA 2332 3008 
St. Dev. Pooled 0.68 0.92 0.48 NA 0.44 0.64 
 The Estimated Minimal Sample Size Per Population Group Needed to 
Detect a |DRBW ∆| ≥: 
 0.1: 962 1735 488 NA 411 854 
0.3: 113 204 58 NA 49 101 
 0.5: 42 75 22 NA 18 37 
 |Mean ∆| 149 21 17 NA 13 1321 
 The Estimated Minimal Detectable |DRBW ∆| Given A Sample Size of 
N: 
 N = 44: 0.49 0.66 0.34 NA 0.31 0.46 
 
Table 6.5: An investigation into the relationship between sample size (per population) and the 
smallest DRBW ratio differences that can be detected were presented in three main blocks 
(separated by rows). The first block was a compilation of the key data needed for the investigation 
of all 5 comparisons. The second block investigated the sample sizes needed to detect various 
DRBW ratio differences. The row investigating the |Mean ∆| differences was investigating the 
sample size needed to detect the measured mean difference between the DRBW ratio populations. 
The third block investigated the smallest DRBW ratio difference that could be detected given the 
small population for all 5 comparisons (N = 44) and the previously estimated variances. 
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The PCH and national level DRBW ratios’ localized averages by Wt were visualized in 
Figure 6.3. In general, the localized DRBW ratio averages for the accepted HTxs were less than 
the maximum DRBW ratio averages the tool suggest clinicians could take. The localized PCH upper 
listings DRBW ratio averages were larger than the maximum DRBW ratio average the tool suggest 
clinicians could take. 
 A pairwise comparison of the maximum DRBW ratios surgeons were willing to take in the 
virtual fit assessments suggested that 9 of the 44 PCH upper listings, i.e., > 20%, could have 
accepted larger donors then what they were listed for as an upper range. To have a true pairwise 
comparison, 1 of the 45 patients did not have images to perform a virtual fit assessment and 
therefore they were removed from the upper listed DRBW ratio population –  hence the N = 44. 
The removed case was a heavily weighted outlier (DRBW ratio: 6.6) and therefore resulted in the 
previously presented PCH C2 DRBW ratio mean to drop from 2.900 to 2.820. PCH’s upper listing 
DRBW ratios for the patients the tool suggested their donor pools could have been expanded were 
then replaced with the virtual maximum DRBW ratios surgeons took. Replacing the PCH upper 
listings for the patients the tool suggested their donor pools could have been expanded to the tool’s 
suggested maximum DRBW ratio increased the mean from 2.820 to 2.899, however, this was not 
statistically-significant (p-value = 0.6991, Cohen’s distance effect size = 0.0827). Comparing the 
PCH upper listed and the tool’s maximum DRBW ratios for only the 9 patients that the tool 
suggested their donor pools could be expanded were presented in Figure 6.4 and had an upper 
listed DRBW ratio mean increase from 2.08 to 2.46 but it was not statistically-significant (p-value = 
0.2204, Cohen’s distance effect size = 0.6012). The moderately sized effect size, i.e., 0.6012, and 
failure to detect a difference with statistical-significance indicated the sample size, i.e., 9 per group, 
was too small – it was estimated a sample size of 62 per group (124 in total) was needed to detect 
a difference with significance (see appendix B).  
An important observation in this study was PCH’s upper DRBW ratio listings were 
statistically larger then UNOS’s reported upper listings, i.e., p-value < 0.001. The Cohen’s distance 
effect size between PCH’s upper DRBW ratio listings and UNOS’s reported upper listings was 
1.1232, respectively. There were 2727 (out of 3008; > 90%) cases in which UNOS had DRBW ratio 
  140 
listings smaller than the PCH 2.899 mean, i.e., the PCH mean after the upper listings for the 
patients the tool suggested could have their donor pools expanded were replaced with the tool’s 
suggested maximum DRBW ratio.  
 
Figure 6.3: Localized spline smoothing DRBW ratio averages plotted by recipient Wt. In general, 
the PCH and UNOS listed localized DRBW ratio averages were equal or larger than the maximum 
hearts the tool identified on a localized average. In general, the actual HTx localized DRBW ratio 
averages were less than the maximum hearts the tool identified on a localized average. 
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Cases Tool Suggested PCH’s Upper Listing could be Expanded 
 
Figure 6.4: Box plot of pairwise comparison for the 9 cases (out of 44) the tool suggested PCH’s 
upper listed DRBW ratio could be expanded. The virtual maximum DRBW ratio values were the 
maximum allografts surgeons were willing when using the tool. 
 
6.5 Results for Study 2: Perceiving Fit-Related Complications 
 
Actual donor predictors were inputted into Model B and surgeons assessed the analogue allograft’s 
virtual fit. Out of 45 cases, 43 cases were virtually transplanted and had their outcomes analyzed, 
i.e., 2 cases were excluded due to unavailable data. The list of perceived fit-related complication 
types surgeons perceived during the virtual fit assessments and their frequencies were presented 
in Table 6.6. Table 6.7 compared the frequencies between actual delayed closure and any 
perceived fit-related complication. Delayed sternal closures were analyzed because they are a 
measureable outcome that can be contributed to oversized allograft complications. Delayed sternal 
closure and surgeon perceived complication variables had a statistically-significant association 
(𝒳2 = 18.6484; degrees of freedom = 1; p-value = 0.000016). Of the 11 cases surgeons had 
perceived fit-related complications, 9 cases had delayed closures (𝒳2 = 4.4545; degrees of 
freedom = 1; p-value = 0.034809) – this was statistically-significant. Of the 32 cases surgeons had 
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perceived no fit-related complications, 28 cases had no delayed closures (𝒳2 = 18.0000; degrees 
of freedom = 1; p-value = 0.000022) – this was statistically-significant. An 𝛼 = 0.05 was the criterion 
used for the chi square test results to be declared as statistical-significant. 
There were 4 delayed closure cases (see Table 6.7) in which surgeons did not perceive fit-
related completions. Case 1 had low blood pressure and excessive bleeding. Case 2 had some 
ventricular dysfunction and concern for potential bleeding. Case 3 had concern for potential 
bleeding. Case 4 had pre-operative history of sever pulmonary hypertension. Interestingly, 2 of the 
4 cases, i.e., cases 3 and 4, that surgeons did not perceive fit-related complications had a delay in 
sternal closure only as a precaution – not due to complications that manifested. 
  
Frequency and Type of Surgeon Perceived Fit-Related Complications 
Concern Type 
Description of Surgeon’s Perceived Fit-Related 
Compression Concern(s) 
Frequency 
A Anterior-Posterior, Sternum, and Rib 4 
B Lung(s) with allograft overlap of main bronchi 1 
C Pulmonary, Pulmonary Vein 4 
A and B Concerns for A and B 0 
A and C Concerns for A and C 2 
B and C Concerns for B and C 0 
A, B, and C Concerns for A, B, and C 0 
 
Table 6.6: Out of 43 patients there were concerns for fit-related complications in 11 patients. 9 of 
the 11 patients had delayed sternal closures while 2 did not have delayed closure. Chest wall (i.e., 
concern A) and respiratory related (i.e., concerns B and C) concerns were the 2 fundamental 
concern types identified by surgeons in this simulated exercise. There were 2 additional cases of 
perceived lung compression, however, the compressions were not perceived to affect the main 
bronchi (i.e., the fused allograft did not appear to overlap the main bronchi structures). Lung 
compression with the lack of bronchi compression to both the left and right branches was not 
considered a fit-related complication, e.g., it was not perceived to cause a delayed sternal closure. 
The 1 lung case with main bronchi compression – listed in the table – had allograft overlap on both 
the left and right main bronchi branches and therefore was perceived to cause delayed closure. 
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Delayed Sternal Closure vs. Surgeon Perceived Fit-Related Complication Matrix 
 
Table 6.7: There were 9 cases in which surgeons perceived fit-related complications in which the 
patient had delayed sternal closure. 
 
6.6 Discussion of Tool’s Clinical Utility 
 
Study 1 and 2 results were designed to assess if the tool could be used to help expand patient 
donor pools safely. The results demonstrated the tool could (1) expand patient donor pools and (2) 
there was a significant correlation between perceived fit-related complications and delayed sternal 
closures. 
Starting with study 1, the PHTS (C3) and UNOS (C4) accepted allograft population DRBW 
ratio means, in Table 6.1, were statistically smaller than the upper DRBW ratio maximum the tool 
suggested could be transplanted. Furthermore, the PCH (C1) accepted allograft p-value nearly met 
the 𝛼 = 0.05 criterion to state the PCH accepted DRBW ratio mean was statistically smaller than 
the upper DRBW ratio maximum the tool suggested could be transplanted. The tool’s suggested 
maximum DRBW ratio mean being statistically larger, in general, than the accepted HTx means 
suggested clinicians were not constantly accepting the maximum allograft they could take for their 
patient as suggested by the tool. Figure 6.3 further demonstrated the localized (moving average) 
DRBW ratio means by Wt for the accepted allografts were generally less than what the tool 
suggested. Although accepting allografts smaller than what the tool suggested was the upper safe 
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limit was based on what allografts were available, the results could include cases clinicians 
unnecessarily passed up offers due to fear of allograft size. Future work would need to know what 
allograft offers were passed up to determine if clinicians were passing on allografts the tool 
suggested would fit during offer.  
The UNOS (C5) upper listed allograft population DRBW ratio mean, in Table 6.1, was not 
found to be statistically smaller than the upper maximum the tool suggested could be transplanted. 
The UNOS upper DRBW ratio and the tool’s DRBW ratio mean difference was < 0.1, suggesting 
there would be no clinically practical difference between the ratios – even if a p-value < 0.05 was 
found.  
The PCH (C2) upper listed allograft population DRBW ratio mean was statistically larger 
than the upper maximum the tool suggested could be transplanted. Interestingly, > 95% of PCH’s 
accepted allografts were oversized (see Table 6.4) with an accepted DRBW ratio mean of 1.68 
even though PCH’s upper listed DRBW ratio mean was 2.90. Furthermore, PCH’s accepted DRBW 
ratio mean was between the PHTS and UNOS accepted DRBW ratio means and the tool’s 
suggested upper DRBW ratio mean. Future work would need to know what allograft offers were 
passed up but these current findings could be explained with the new hypothesis that even though 
PCH list high they might be passing on allografts during offer that the tool would have suggested 
would fit. 
A pairwise comparison of maximum DRBW ratios surgeons were willing to take in the 
virtual fit assessments suggested > 20% of PCH’s listed patients, i.e., 9 of 44, could have accepted 
larger hearts than what they were listed for. The result of this pairwise comparison suggested there 
was a subset of the PCH population that the tool could have expanded their listed donor pools. It 
was an interesting find that there was a subset in PCH’s listed population that the tool suggested 
their donor pool listing range could have been expanded even though this institute is aware they 
are aggressive in their listing. PCH’s originally listed DRBW ratio mean difference, when compared 
to the national level, was > 0.85 with statistical-significance – this supported the fact that PCH is 
aggressive in its upper DRBW ratio listing. In fact, results showed > 90% of the patients in UNOS 
database had listed DRBW ratios less than the average of the tool’s listed DRBW ratio for PCH 
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(i.e., the 2.899 listed DRBW ratio average after replacing the PCH listed DRBW ratios with the 
maximum virtual DRBW ratio for the cases the tool suggested PCH listings could be expanded). 
Given:  
 
1) the tool would expand a subset of the PCH listing population, 
 
2) the PCH listing population DRBW ratio mean was statistically larger than that of the 
national level, and 
 
3)  > 90% of the cases in the national database population had listed DRBW ratios less than 
PCH’s listed DRBW ratio when the tool was used,  
 
the results might imply the tool would have potential to expand national donor pools; however, 
future work needs to investigate this. 
In analyzing the p-value results of the 5 comparisons in Table 6.1, it was suggested that 
increasing the sample size would allow for population mean differences to be found statistically-
significant. Sample size controlling if a mean difference was found to be statistically-significant 
assumed the population means and variances were held constant – this was further covered in 
appendix B. However, it is important to note that increasing sample population sizes, in theory, 
does not generally change the populations’ means or reduce the populations’ variances and 
therefore would not change the overlap of the two distributions.  In other words, increasing the 
sample size would not improve one’s chances, i.e., probability, of correctly guessing which 
population a new measurement belongs to even though one increases the chances that a p-value 
< 0.05 will be calculated. The consequence is increasing the sample size increases the chances 
the mean difference of 2 or more populations is found to be of statistical-significance. 
Study 2 virtual fit assessments results in Table 6.6 demonstrated chest wall, lung (with 
allograft overlap of main bronchi), and pulmonary compression were the types of fit-related 
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complication concerns surgeons perceived during the virtual HTx fit assessment. Although a wide 
range of post-operative complications (e.g., mechanical support and pulmonary vein stenosis) were 
originally considered for indications of allograft oversized complications, it was advised the study 
should focus on delayed sternal closures. Many of the original post-operative complications 
considered as metrics for fit-related complications (including delayed sternal closure) could be 
caused by non-fit-related complications. However, delayed sternal closure was perceived to be the 
measure that most likely corresponded to oversized allograft fit-related complications (relative to 
other metrics) and therefore was the only outcome metric analyzed herein. Furthermore, there were 
2 cases of perceived lung compression but the fused allograft did not appear to overlap the main 
bronchi – these cases were not perceived to cause delayed chest closures and therefore they were 
not included in Table 6.6. Results in Table 6.7 demonstrated there was a statistically-significant 
association between the perceived fit-related complications and delayed sternal closure variables, 
i.e., p-value = 0.000016. Of the cases surgeons perceived there would be fit-related complications, 
the frequency of delayed sternal closures was statistically-significant, i.e., p-value = 0.034809. Of 
the cases surgeons perceived there would be no fit-related complications, the frequency of not 
having a delayed sternal closure was statistically-significant, i.e., p-value = 0.000022.  
Out of the 9 cases that (1) surgeons perceived fit-related complications and (2) had 
outcomes with delayed closure, as shown in Table 6.7, only 1 of these closures had actual fit-
related complications (or indications of fit-related complications) reported in the surgical notes. 
Bleeding and hemodynamic concerns were the causes for the other 8 cases to have delayed 
closures. Although, there were no clinical indications available to suggest the bleeding or 
hemodynamic issues for the 8 cases were related to allograft oversizing, this might be a multi-
factorial problem. This might be a multi-factorial problem because there might be unknown 
nuisance factors, related to oversized allograft complications, that caused the bleeding and 
hemodynamic issues. What was observed when surgeons perceived or did not perceive fit-related 
complications was their perception corresponded with statistical-significance to patients having or 
not having delayed closures, respectively. Future work would need to identify what, if any, 
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oversized allograft nuisance factors related the bleeding and hemodynamic complication trends to 
delayed sternal closure. 
 
6.7 Discussion on Virtual Transplant Case Study Using Donor Images and the Tool 
 
The virtual HTx fit assessment tool was developed to utilize a healthy heart library and an allograft 
TCV prediction model developed in chapters 4 and 5, respectively. The need to identify a healthy 
heart reconstruction (of similar TCV) to serve as an allograft analogue was to overcome the 
technical challenges in performing a virtual fit assessment with donor images. The technical 
challenges include having donor images readily available for a fit assessment. The assessment 
would need to be performed within the typical 1-hour time-window clinicians have available to make 
a provisional acceptance or refusal of an offer. Furthermore, once a donor is deceased, i.e., 
available for offer, the financial cost of sustaining the donor for procurement falls to the donor’s 
center. The current system does not financially support donor centers to acquire CT or MR images 
for a fit assessment as this is an atypical request. Nevertheless, there was one unique case in 
which donor images became available and used in supplemental patient care (previously presented 
as a case study [142]). 
 The case was of a hypoplastic left heart patient (female, 10 years old, 140cm, 28kg) that 
was offered a larger donor (female, 16 years old, 163cm, 60kg). Given the complex anatomical 
nature of the hypoplastic left heart patient’s cardiothoracic space, the clinical team was leaning 
towards declining the donor offer due to a 2.1 DRBW ratio. A virtual HTx fit assessment using donor 
images, illustrated in Figure 6.5, and the corresponding donor-recipient TCV ratio, i.e., 0.6, were 
used during supplemental patient care. The additional information augmented the clinical team’s 
available information. The clinical team accepted the allograft offer with no observed post-operative 
fit-related complications. The patient was discharged 15 days post-transplant and is currently 
thriving well over a year. To achieve this case’s virtual assessment, a provisional yes was made 
such that time was allowed for the electronic data transfer of the donor images and virtual 
assessment to be performed before a final allograft acceptance was made. 
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Virtual Fit Assessment for Case Study 
 
Figure 6.5: The case study virtual HTx fit assessment in which the allograft (green) was 
reconstructed from donor images. The allograft is fused onto the recipient’s pre-transplant CT 
images with the native heart (red). The allograft was found to be undersized and therefore 
augmented the clinical team’s perception to accept the offer. The image was previously presented 
but did not require permissions to reproduce (see appendix D) [142]. 
 
Retrospectively inputting donor’s predictors into Model B resulted in a -45% error, i.e., over-
prediction. This large over-prediction error was unsurprising because the largest over-prediction 
error measured in Model B’s training dataset was -56%. These large errors are still present even 
though Model B had training MAPE and sMAPE values of 12.7% and 12.3%, respectively. 
Interestingly, the large over-prediction of Model B still resulted in a 0.85 donor-recipient TCV ratio 
and therefore suggested the allograft was still undersized. Even if the allograft over-prediction did 
not deem the transplant permissive, declining an offer due to excessively oversized concerns is 
preferable to accepting an allograft that was larger than expected. 
There are two key messages from this unique case study. First, the case study suggested 
there might be scenarios in which virtual HTx fit assessments can help clinicians perceive 
acceptable fits that they would otherwise not take. In this case the clinical team was originally 
  149 
concerned for fit-related complications (possibly including delayed closure) based on (1) pathology 
and (2) the DRBW ratio. However, the reconstructed allograft was very undersized and therefore 
the virtual fit assessment did not suggest the offered allograft would have trouble fitting the native 
heart’s space. It is important to point out that this case study did not perceive fit-related 
complications and therefore does not indicate if the tool could perceive fit-related complications. 
The case study did support study 1 and 2’s findings that the tool can be used to identify a subset 
of cases in which the donor pool can be safely expanded. Second, although using a prediction 
model might be clinically preferable to the alterative, it is a model that will not work perfectly in every 
scenario. A push to acquire donor images for virtual HTx fit assessments might lead to better patient 
outcomes as clinicians might be able to better perceive fit-related complications before transplant.  
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CHAPTER 7 
 
LIMITATIONS, FUTURE WORK, AND CONCLUSIONS 
 
There were two hypotheses laid out in chapter 1 for this thesis. The first hypothesis was a tool 
leveraging medical images could be developed to allow clinicians to virtually assess donor allograft 
fits with qualitative information. The second hypothesis was the tool would help clinicians expand 
patient donor pools and perceive fit-related complications. It was found the tool (1) could have 
expanded the upper DRBW ratio listing range for > 20% of PCH’s patients in the study and (2) a 
statistically-significant trend between delay sternal closures and surgeon perceived fit-related 
complications (using the tool) was observed. The results demonstrated a novel tool could be 
developed to leverage medical images and help clinicians assess allograft fits, i.e., the first 
hypothesis was achieved. The results further supported the tool could be used to expand patient 
donor pools, i.e., the first part of the second hypothesis was achieved. Lastly, the results found a 
trend between surgeon perceived fit-related complications and delayed sternal closure, however, 
future work needs to investigate this multi-factorial relationship to confirm causality, i.e., the second 
part of the second hypothesis looks promising but future work is needed to fully answer this 
question. 
Chapter 7 covers the limitations, future work, and final conclusions of the author’s thesis 
work herein. The limitations will cover the healthy heart library and its possible effects on allograft 
reconstructions and the allograft TCV prediction model. Furthermore, the limitations section will 
cover clinical limitations and their possible effects on the analysis of the tool’s clinical utility. Next, 
future work will look at (1) improving the clinical utility study, (2) improving the novel virtual fit 
assessment tool for HTx and other areas of solid-organ transplant, and (3) investigate new 
areas/questions that arose from this work. The chapter and therefore the thesis will conclude with 
a discussion on what has been achieved from the engineering and/or scientific points-of-view. 
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7.1 Limitations of the Healthy Heart Library and Allograft TCV Prediction Model 
 
The healthy heart library and the allograft TCV prediction model relied on 97 “healthy” heart patients 
identified to develop the novel virtual HTx fit assessment tool. The limited sample size and source 
of population were key limitations in this body of work. The type of available data for a retrospective 
study further limited the modeling process. 
For logistical reasons, the work herein was designed for a retrospective, single center even 
though it was recognized there would be a limited number of “healthy” heart patients available in a 
chart review. K-fold cross-validation and parametric modeling techniques were intentionally 
deployed to develop and validate an allograft TCV prediction model with a limited data sample size. 
The 97 patients identified were above the 50 minimum typically suggested by statisticians when 
building a linear, parametric regression model [105]. Although steps were taken to minimize the 
limitations of working with a small but realistic sample size, future work might want to further expand 
upon the size of the healthy heart library in a multicenter study. Increasing the library size would 
allow for more complex modeling techniques to be implemented. 
The inclusion criteria for “healthy” was another limitation of the healthy heart library. In this 
retrospective study, patients with CT or MR images were included into the library. Given these 
subjects were patients, it indicates (1) they are not truly healthy or (2) there was a concern they 
may not be healthy. Careful chart evaluation from radiology interpretation summaries were 
reviewed to help ensure included individuals had normal, well-functioning, healthy hearts with 
normal anatomical volumes pertaining to the chambers and overall TCV. Pathologies and/or 
treatments known to affect heart anatomy and/or physiology were automatically excluded. Mild 
aberrations of the greater vessels and coronaries were generally considered healthy unless 
indicated otherwise. The careful chart review helped prevent the inclusion of unhealthy hearts, 
however, future work may want to develop a prospective study to acquire truly heart healthy 
individuals. 
The retrospective study and the tool were limited on what data was available to be used 
as predictors in the allograft TCV prediction model. The limitations arose from both the chart review 
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and what data is typically available from donors during offer. For example, donor echocardiograph 
data is available at offer and includes the acquisition of a measured left ventricular volume. 
However, it was known during study development that this ventricular measurement would not be 
available in the majority of subjects in the healthy heart library as they were not necessarily likely 
to have received an ultrasound of the heart. The development of the allograft TCV prediction model 
was carefully crafted based on what donor parameters would be available from subjects in the 
healthy heart library and at donor offer. Unfortunately, due to the lack of echocardiograph and other 
cardiac based measurements, the model was not developed from direct cardiac measurements but 
rather relied on secondary, gross body metric parameters, e.g., Sex, Ht, Wt, etc. Future work might 
want to consider the prospective development of a healthy heart library in which subject-specific 
cardiac parameters can be included into the model develop - assuming the corresponding donor 
measurements are readily available as standard of care during offer. 
The library and model limitations were carefully considered during the development of the 
novel tool. The author made careful considerations, based on the data that would be available for 
this initial, retrospective project, to develop a novel virtual HTx fit assessment tool. Considerations 
included the fact that donor images may or may not be available at the time of donor offer for a 
virtual fit assessment. The author took several additional steps (e.g., careful healthy heart inclusion 
criteria, statistical model design, validation steps, etc.) to help ensure a sound, practical allograft 
TCV prediction model was developed (e.g., as the 12.3% sMAPE suggested) given the current 
limitations. 
 
7.2 Limitations of the Clinical Utility Assessment 
 
The initial evaluation of the tool’s clinical utility had 2 major sources of limitation. The first limitation 
was the sample size of the data that was available. The second limitation was what specific type of 
data was available based on current clinical practices (e.g., what data gets measured and/or 
recorded). Both of these limitations were ultimately due to working with historical data in a 
retrospective study. 
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 Sample size was largely driven by PCH’s HTxs that had pre-operative CT or MR image 
images of the cardiothoracic space. Between 45 and 43 PCH HTx individuals were used in the 
various studies (and sub-study comparisons) based on what data was available. This low PCH 
population size (along with low effect sizes < 0.5) resulted in many of the mean differences in Table 
6.1 to not be statistically-significant. However, increasing the sample size to get a statistically-
significant p-value would not have changed the probability of guessing which population a new 
measurement belonged to, in theory. Another issue with the small PCH sample size was whether 
the sample means and variances truly represent PCH’s population. Future work might need to 
either include more individuals, repeat the study with a new PCH cohort, or perform a cross-
validation to help confirm the true PCH means and variances within this study. 
 The listed, accepted, and virtual maximum DRBW ratios represented fundamentally 
different scenarios and therefore were not completely comparable. The listed DRBW ratio 
corresponded to a clinical scenario in which clinicians were preparing for a “last-ditch effort” wherein 
the probably of declining an offer could have resulted in a poorer outcome. However, if the patient 
isn’t sick enough to accept a “last-ditch effort” allograft then decision makers will often pass on 
offers approaching the upper DRBW ratio limit. Additionally, in conversations with a PCH clinician, 
it was explained that actively over-listing patients has no repercussions – other then maybe 
clinicians having to spend more time declining offers – and would only provide the institute with 
more opportunities to procure allografts for their patients. The upper listed DRBW ratio was further 
complicated because clinicians may go back and increase the upper listing range depending on 
how sick the patient has become. The accepted DRBW ratio represents allografts that were within 
the upper and lower listed ranges that were actually accepted – it states nothing on what offers 
were actually declined even though they were within the listing range. The “level of sickness” is one 
hidden factor contributing to why an allograft of given DRBW ratio gets accepted (or declined). 
Lastly, the virtual tool asked surgeons to push the upper allograft limits within reason, i.e., no “last-
ditch effort” scenarios. 
Comparing the listed and accepted DRBW ratio means to the tool’s suggested DRBW ratio 
means might provide some insight into the tool’s clinical utility, however, it would be limited. To 
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address the limitation of interpretation for these population mean comparisons, a pairwise 
comparison between PCH’s upper listed and the tool’s suggested DRBW ratios was performed to 
answer if the tool could expand patient donor pools. The pairwise comparison analyzed the 
frequency (and percentage) of PCH’s listed population that the tool suggested could have had their 
listed DRBW ratio expanded.  
 During virtual fit assessments with the surgeons it became clear that asking them to 
perceive fit-related complications was not as trivial as originally thought. There was uncertainty as 
to whether or not the level of compression the surgeon was perceiving would result in problematic 
outcomes. Surgeons were still asked to make a judgment call in this study without formal training. 
The interactions with surgeons suggested (1) a formal, pre-clinical prospective study on what 
oversized allografts look like in a virtual assessment might be warranted and (2) surgeons might 
benefit from using the pre-clinical results to train on how to assess the virtual fits. A future, pre-
clinical or clinical prospective study might find that the virtual maximum surgeons accepted in the 
simulated scenarios herein were not the true virtual maximum allografts that could be taken. 
Furthermore, the maximum allografts surgeons perceived they could take were based on perceived 
compression effects; it is likely some compression effects with post-operative complications are 
preferable to declining an offer. Clinicians will need to (1) better define what a poor outcome is and 
(2) better determine how to perceive these defined poor outcomes from medical images, for the full 
potential clinical utility of the proposed tool to be realized. 
 The use of measureable outcomes with known (or perceived) associations to oversized fit-
related complications was a technical challenge for this study. First, many of the complications 
associated with oversized allografts, i.e., respiratory related complications, were clinically 
perceived by PCH personal to be more likely indicate something other than oversized fit-related 
complications. Delayed sternal closures were the only outcome analyzed herein because it was 
perceived (before the analysis was performed) to be the outcome most likely to correspond with 
oversized fit-related complications. Second, of the 9 delayed closures that the surgeons had also 
perceived fit-related complications (while blinded to actual outcomes), only 1 case had surgical 
notes indicating oversized allograft complications. The other 8 cases indicated bleeding and 
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hemodynamic issues for the delayed closure – the complications may or may not have been part 
of a multi-factorial interaction caused by the oversized allograft. This study only states the cases 
that surgeons had perceived fit-related complications also had delayed closures with statistical-
significance – a prospective study would be needed to fully understand if the trend had causality 
as the retrospective surgical notes might be limited in information.  
 
7.3 Future Work 
 
There are 5 areas of future work that can be derived from this thesis. Areas of future work to 
improve the current work focus on expanding the healthy heart library pool, improving studies on 
the clinical utility of the tool, and applying more advanced modeling techniques to predict allograft 
TCV and clinically safe donor fits. The need to model pediatric, biological scaling relationships of 
cardiac structures from more advanced CT and MR images in future work also arose from this 
study 
First, as pointed out in the limitation sections, increasing the healthy heart’s library size and 
inclusion of cardiac and other closely related parameters is warranted in future work – this could 
be achieved in a prospective study that recruits healthy heart subjects. Increasing the library’s size 
will allow for more advanced statistical modeling techniques to be implemented and result in a 
larger training dataset that would likely help improve allograft prediction performance. Cardiac (e.g., 
left ventricular volume from echocardiograph) and anatomical measurements near the heart (e.g., 
chest circumference) could be acquired to help further predict TCV. The inclusion of 
echocardiograph measurements was originally thought of, but the perceived lack of these 
echocardiograph measurements for healthy heart individuals was a limitation for the retrospective 
study. Similarly, cardiothoracic related measurements – such as chest cavity circumference – could 
further help with TCV prediction but body type (from subcutaneous fat) and relative heart size 
(varied during development) would need to be carefully accounted for [143–145]. 
The developed tool herein focused on expanding donor pools based on geometric 
concerns, i.e., oversized allograft sizes, but did not focus on cardiac output needs. Both over- and 
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under-perfusion – due to inappropriate cardiac output needs – have warranted clinical concern in 
the literature [57,59,67]. Future work might consider inclusion of cardiac output in the virtual fit 
assessment process to help ensure a donor offer would provide the patient with an appropriate 
blood flow rate. Cardiac index might be a better metric to account for cardiac output as it is a 
clinically accepted metric that indexes cardiac output needs to patient size, i.e., BSA. 
Second, additional assessment of the tool’s clinical utility in a prospective study is 
warranted before it can be determined if the tool can help clinicians to safely expand patient donor 
pools by determining if they can actually perceive post-operative fit-related complications by using 
the tool. This thesis only demonstrated a statistically-significant trend between delayed closure and 
surgeon perceived fit-related complications using the tool – future work needs to investigate and 
confirm actual causality. A study into what an oversized allograft with complications looks like is 
warranted as perceiving safe fits does not appear to be trivial. A prospective study designed to 
record specific allograft HTx outcomes (including both size appropriate and mismatched) would 
help to determine if the tool does in fact help clinicians to perceive fit-related complications. The 
prospective study would need to better determine what outcomes would need to be measured and 
how to measure them to assess if surgeons could perceive fit-related complications. Metrics 
identified as indicators of poor outcome could be used to help predict poor outcomes in a support 
vector machine classifier and therefore determine if an offer should be accepted. The HTx 
performance metrics could be acquired from the virtual fit assessment or from other clinical metrics, 
e.g., cardiac index. Several support vector machine classifier models could be developed to 
determine if an offer should be accepted based on a patient’s degree of sickness, e.g., A1, B1, and 
B2 listings. It is likely that the classifier would more likely accept mismatched allografts in sicker 
patients as the risk of accepting the allograft is less than if the allograft was reject.  
Third, more advanced TCV prediction modeling process might be warranted in which small, 
clinically acceptable TCV prediction errors do not add to the cost function, i.e., only prediction errors 
that are unacceptably large would penalize the model. Support vector regression would allow for 
small errors (i.e., errors that have no importance in the practical sense) to not add to the cost 
function [146,147]. This regression technique allows for coefficient estimates to be approximated 
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in such a manner that reduces errors of practical importance and does not estimate coefficients to 
address errors that have no practical importance [118,147]. In other words, the method focuses on 
minimizing the chance of making large, problematic errors at the cost of not improving small errors 
that have no real practical consequence. To implement this regression technique, clinicians will 
need to identify an acceptable prediction error size – the size error could either be a constant or 
non-constant value. A benefit of support vector regression techniques is overall model robustness 
can potentially be improved as a consequence of the modeling process not caring about small 
errors that have no practical importance [146,148]. Furthermore, support vector regression models 
can easily model both linear and nonlinear relationships [146]. 
Segmented regression (also known as piecewise regression) is another modeling 
technique that may have benefits in TCV prediction. It is known that rapid developmental growth 
happens in (1) infant and early childhood and (2) during puberty. These periods of development 
may have different rates of growth that were not analyzed herein – in part because of the limited 
healthy heart library size. After a further increase in the healthy heart library’s population size, it 
would be advisable to use segmented regression to capture the unique differences between the 
different periods of human growth.  
Fourth, future work might want to consider if virtual fit assessments can be improved upon 
and/or expanded to other solid-organ transplant areas. It might be found that finite element analysis 
studies, using material property parameters, could help to improve fit assessments. Lung, liver, and 
kidney transplants are solid-organ transplant areas that could also benefit from a virtual fit 
assessment tool to help improve patient outcomes, particularly in the pediatric arena. 
Fifth, in chapter 4 a 0.8 scaling signal was observed several times in the healthy heart 
library data. Future work should determine if this previously discussed 0.8 signal was happenstance 
or if it has biological significance. Furthermore, future work should investigate pediatric cardiac 
signals from CT and or MR images. The author found most reported cardiac scaling relationships 
were limited in pediatrics, i.e., cardiac scaling relationships were typically available from adult 
studies, and that such signals were often acquired using echocardiograph data. However, the 
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clinical utility of CT and MR data is growing in the current era while the availability of scaling 
relationships derived from advanced cardiac CT or MR imaging is limited. 
The author proposes the immediate next sets for the further improvement and validation of 
the novel tool developed herein is a multicenter, prospective study. To improve TCV prediction, the 
prospective study should (1) recruit health individuals, e.g., no patients, and (2) include both cardiac 
and cardiothoracic measurements that could easily be made readily available at donor offer, e.g., 
from echocardiograph measurements. At the same time clinicians will need to identify, e.g., classify, 
poor and good outcomes based on patients’ categorical levels of sickness in a large HTx sample 
population – patients will need to have HTx outcomes. The classification of poor and good 
outcomes could then be used to develop a support vector machine classifier to guide the 
acceptance or decline of donor offers. The author suggest the future work should consider support 
vector machine classification techniques and not logistics regression techniques due the wide 
variety of nonlinear kernels having been previously developed for the former classification method 
[118]. The clinical utility can then be assessed to determine if (1) the classifier still allows clinicians 
to accept allografts they normally would not accept based on the DRBW ratio and (2) determine 
the tool’s sensitivity and specificity to predicting both poor and good outcomes. The next steps for 
both the regression model development and assessment of the tool’s clinical utility in HTx 
assessments will need large sample sizes due to effect sizes being either of “small” or of “moderate” 
size, in general. 
 
7.4 Conclusions 
 
A novel virtual heart transplant fit assessment tool was developed in this thesis. From this work, 
knowledge about pediatric cardiac biological signals was gained and a model to predict TCVs 
during human development was developed. In addition to human development, the TCV model 
also considers body type, e.g., overweight. 
Assessment of the tool’s clinical utility suggested the novel tool would have expanded the 
PCH listed DRBW ratios for > 20% of the PCH patients in this study. This demonstrated the tool 
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could have expanded the donor pool for a subset of PCH’s HTx population. Furthermore, an 
assessment of the tool’s utility found a trend between surgeon perceived fit-related complications 
and delayed sternal closure, i.e., a clinical outcome perceived to be associated with oversized 
allograft transplants, was observed with statistical-significance. The early retrospective findings 
suggest the novel tool developed herein can possibly help clinicians to safely expand their patient 
donor pools but future, prospective work is warranted to further assess the tool’s clinical utility. The 
DRBW ratio metric would still be a clinically important metric in the foreseeable future, however, 
the results suggest the virtual tool can be incorporated with the DRBW ratio metric to help expand 
patient donor pools. We expect that only after experience will clinicians begin to trust the tool 
developed herein; in the imminent future clinicians will likely use the tool conservatively in 
prospective research studies and supplemental patient care. 
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LIST OF ACRONYMS 
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Clinical Acronyms: 
 
BMI  Body Mass Index 
BSA  Body Surface Area 
CT  Computed Tomography  
DRBW  Donor-Recipient Body Weight 
HHT  Heterotopic Heart Transplant 
Ht  HeighT (i.e., body height) 
HTx  Heart Transplant 
IRB  Internal Review Board 
MR  Magnetic Resonance 
mTCV  measured Total Cardiac Volume 
OHT  Orthotopic Heart Transplant 
PCH  Phoenix Children’s Hospital 
PHTS  the Pediatric Heart Transplant Study (an organization) 
pTCV  predicted Total Cardiac Volume 
TCM  Total Cardiac Mass 
TCV  Total Cardiac Volume 
UNOS  the United Network of Organ Sharing (an organization) 
Wt  Weight (i.e., body weight or body mass)* 
 
 
 
 
 
 
 
 
* Wt, i.e., body weight, will be used interchangeably for body mass herein. The justification for 
terminology misuse is elaborated upon, in chapter 1. 
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Statistical Acronyms: 
 
AICc  corrected Akaike Information Criterion  
LOOCV Leave-One-Out Cross-Validation 
MAE  Mean Absolute Error 
MAPE  Mean Absolute Percent Error 
ME  Mean Error 
MPE  Mean Percentage Error 
MSE  Mean Square Error 
RMSE  Root Mean Square Error 
SE  Standard Error 
St. Dev. Standard Deviation 
VIF  Variance Inflation Factor 
1st-Qt  First Quartile 
2nd-Qt  Second Quartile 
3rd-Qt  Third Quartile 
 
 
Other Acronyms: 
 
USA  United States of America 
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EFFECT SIZE AND SAMPLE SIZE NEEDED FOR TWO MEAN COMPARISON 
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When determining if two or more sample populations are statistically different the p-value is 
referenced, however, the effect size is an equally important metric. The work herein used Cohen’s 
two-tail, non-directional d equation:  
 
𝑑 =  
|𝑀𝑒𝑎𝑛 𝐴−𝑀𝑒𝑎𝑛 𝐵|
𝜎
 (Equation B.1) 
 
to estimate the effect size between two populations in which 𝜎 is a standard deviation [141]. The 
standard deviation could be for population A, population B, or it could be the pooled standard 
deviation of both populations [141,149]. To estimate Cohen’s d herein, a pooled standard deviation 
was used to account for (1) population size and (2) variance differences between the populations 
[149,150]: 
 
𝜎𝑝𝑜𝑜𝑙𝑒𝑑 =  √
(𝑁𝐴−1)𝜎𝐴2+(𝑁𝐵−1)𝜎𝐵2
𝑁𝐴+𝑁𝐵−2
 (Equation B.2) 
 
The effect size scales the mean difference between populations relative to their variance 
and therefore quantifies the strength of the difference. Larger effect sizes indicate less overlap 
between the two populations’ normal distributions – the reduced overlap supports the population 
difference is of practically importance [113,141]. Without the effect size the p-value loses practical 
meaning in what is statistically-significant [113]. In particular, the weakness of reporting only the p-
value is any effect size > 0 can produce a p-value < 0.05, i.e., be found to be “statistically-
significant”, as long as the sample sizes are large enough [113]. It is important to recognize that it 
is the effect size and not the sample size that controls the overlap between the two populations – 
this highlights the danger of using the p-value as a standalone metric [113,141]. Providing both the 
effect size and p-value allows the reviewer to understand how strong a difference between two 
populations is and therefore determine if the difference is truly statistically-significant in the practical 
sense. 
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An additionally important use of effect size is approximating the sample size a study needs 
to determine if a difference between populations is statistically-significant in the practical sense. In 
determining the needed sample size, one would need to know (or guess) (1) the population 
variances and (2) either the effect size or population mean difference they would like to detect. 
Reworking the mathematical relationship between sample size and effect size could be used to 
analyze why a relationship was found or not found to be statistically-significant.  
The author used this mathematical relationship between sample size and effect size to 
analyze the results in chapter 6. For the analysis, the author derived a relationship between sample 
size and mean differences in two key steps. First, the relationship between sample size and effect 
size for a two mean comparison was approximated using Dr. Danial Soper’s online Student T-test 
sample size calculator [151]. The computed sample size results were then fitted to model the effect 
size needed to detect a given sample size, as shown in Figure B.1. Second, the fitted equation –
with Cohen’s d equation plugged in – was reworked to approximate the sample size to mean 
difference relationship. The final, reworked equation related the sample size to the populations’ 
mean difference in a Student T-test comparison; the final equation used was as follows: 
 
𝑀𝑒𝑎𝑛 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  𝜎 ∗ (
𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒
22.792
)
−1
1.952
  (Equation B.3) 
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Figure B.1: The sample sizes needed (per sample population, i.e., group) for detecting a given 
effect size were approximated with a set alpha and power of 0.05 and 0.90, respectively. The 
relationship between the approximated sample size (blue; dots) vs. effect size fitted a power law 
function (red; dashed line). 
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APPENDIX C 
 
DELEGATION OF TCV MODEL DEVELOPMENT AND VALIDATION 
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Jonathan Plasencia Model Contributions: 
Plasencia developed Model A under the mentorship of Dr. Kamarianakis. Plasencia pointed out the 
potential clinical needed to develop a more conservative model after Model B was developed. 
 
Yiannis Kamarianakis, Ph.D. Model Contributions: 
Dr. Kamarianakis developed Model B and B* after reviewing Plasencia’s preliminary Model A 
results. Model B* was developed in recognition that a more conservative model might be needed 
to prevent under-predictions. Furthermore, Dr. Kamarianakis helped mentor Plasencia as he 
developed Model A. 
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